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Tuberculosis (TB) infection has burdened mankind for centuries, and it remains a major 
and growing health problem throughout the world. In 2007, there were an estimated 
9.3 million people newly developing TB and 1.3 million people died from this infectious 
disease [1].  
The first anti-tuberculous drugs streptomycin and para-aminosalicylic acid (PAS) were 
developed in 1944. Afterwards, it took four decades to establish the current first-line 
regimen for TB that usually contains rifampicin (R), isoniazid (H), pyrazinamide (Z) 
and ethambutol (E) to be taken for at least six months. The second-line drugs are for 
drug-resistant TB and for patients who cannot tolerate the first-line drugs; they are less 
effective, more toxic and require longer use than the first-line drugs [2].
Cure rates are generally high, but there are several problems associated with current 
TB treatment. The long duration and complexity of available drug regimens result in 
non-adherence to treatment. This leads to suboptimal response (failure and relapse), the 
emergence of drug resistance, and continuous spread of the disease. According to the 
World Health Organization, in 2007 the overall success rate for tuberculosis treatment 
was 70%, with an estimated 510,545 cases of multi-drug resistant TB (MDR-TB) [1]. 
Specific-patient groups, like children, patients with HIV infection, diabetes mellitus (DM) 
or malnutrition may be at increased risk for a poor treatment outcome. 
Clinical pharmacological view of tuberculosis treatment
Of many factors associated with outcome of TB treatment, drug treatment is the one we 
can most easily modify. One of the major goals of clinical pharmacology is to identify 
(and provide a basis for) the optimum drug dosage regimen for a given type of patient 
and disease state [3]. A conceptual model of the treatment of TB is shown in figure 1. 
This concept shows the drug concentration as a connecting link between prescribed 
drug dose and response to anti-TB drugs. Non-adherence and variability in pharma-
cokinetics increase the risk of suboptimal (low or high) drug concentrations. Variation 
in pharmacodynamics determines the subsequent effects of low or high drug concen-
trations. Low drug concentrations may cause treatment failure and the emergence of 
resistance; high drug concentration may lead to more toxicity. We will now discuss 
some aspects from this model in more detail.
Introduction and outline of the thesis 1
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Adherence is a major determinant of outcome of TB treatment. By detecting patients 
who are non-adherent, appropriate interventions can be taken to enhance patient’s 
drug intake. Several methods for measuring adherence and detecting non-adherence 
are available, all with advantages and disadvantages, and they should be evaluated in 
the field setting. 
A higher dose of rifampicin is believed as one of the strategies that could shorten and 
thereby improve TB treatment. Rifampicin is considered a cornerstone for TB treatment. 
It exhibits a concentration-dependent or exposure-dependent killing activity against 
M. tuberculosis [4,5]. A higher dose of rifampicin will result in higher drug concentra-
tions, which in turn could result in more effective treatment (figure 1), or the possibility 
to shorten treatment duration. Of course, a higher dose may compromise safety and 
reduce tolerability of treatment as well. 
Chapter 1
Figure 1  Conceptual model for the treatment of TB
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Newer drugs may also help to improve the treatment outcome and to shorten the 
treatment duration. Moxifloxacin is a fluoroquinolone that has potent in-vitro activity 
against M. tuberculosis [6]. Studies in the murine model [7] and in TB patients [8] have 
shown the potential of moxifloxacin to shorten TB treatment by two months when used 
as a substitute for isoniazid or ethambutol. Little is known about possible pharmacoki-
netic interactions between moxifloxacin and current anti-TB drugs, which might affect 
the concentrations of moxifloxacin and eventually treatment response (figure 1). 
Specific-patient groups like HIV-patients and children have a lower response to 
TB-treatment. This is also the case for patients with diabetes mellitus [9-11], which is 
witnessing a global increase, especially in developing countries where TB is endemic 
[1,12]. A negative outcome to TB treatment in diabetes patients might possibly be due 
to an alteration of pharmacokinetics of TB drugs, as conceptually shown in figure 1. 
Diabetes patients have lower plasma concentrations of certain drugs [13], but 
information about the pharmacokinetics of rifampicin and other TB drugs in patients 
with diabetes is lacking.
Tuberculosis in Indonesia
Even though the incidence of TB is decreasing in Indonesia, this country still has the 
third highest TB caseload worldwide after India and China. In 2007, among a population 
of 232 million, there were an estimated 528,000 new TB cases (equivalent to 244 cases 
per 100,000 people) with 91,400 deaths (39 per 100,000 people). Among them, the 
estimated proportion of patients with MDR-TB was 2.0% or 12,209 cases. [1]
Treatment according to the National TB Program (NTP) is based on the WHO guideline 
and uses rifampicin (450 mg or 10 mg/kg), isoniazid (300 mg or 5 mg/kg), pyrazinamide 
(1500 mg or 30 mg/kg) and ethambutol (750 mg or 15 mg/kg). 
To our knowledge, there are few data about adherence to TB treatment in Indonesian 
TB patients, and even less about the pharmacokinetics of anti-TB drugs. Such data can 
help to improve the TB program.
Regarding specific-patient groups, the number of TB patients with co-morbidities like 
HIV and diabetes is rising. The HIV prevalence among TB patients in Indonesia is still 
low, at 0.3% [1]. On the other hand, Indonesia has the fourth highest number of diabetes 
patients worldwide. In 2000, there were an estimated 8.4 million cases of diabetes, and 
by the year of 2030 this is estimated to be 21.3 million [12]. 
Introduction and outline of the thesis 1
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Outline of the thesis 
This thesis consists of three parts: the first part focuses on adherence; the second part 
on optimization of TB treatment from a pharmacokinetic point of view; and the third part 
on a specific patient-group, patients with diabetes mellitus.
Adherence to drug treatment is an important determinant of outcome of TB treatment. 
Even though DOT (directly observed therapy) is very helpful in assuring patient’s 
adherence, it is not always feasible in every setting. There is no single accepted method 
to measure adherence. In chapter 2 we asked ourselves how to choose the most 
valid and feasible method or combination of methods to detect non-adherence to TB 
treatment in an Indonesian setting.
Suboptimal drug concentrations are associated with treatment failure and emergence 
of drug resistance. Chapter 3 – 5 focus on the optimization of TB treatment from 
a pharmacokinetic point of view. The effect of rifampicin in killing the bacteria is 
dependent on its maximum plasma concentration and/or the exposure to the drug 
(concentration-dependent and exposure-dependent killing activity). In chapter 3 we 
asked the question whether a higher dose of rifampicin leads to a significant increase 
of rifampicin maximum concentration (Cmax) and whether this exposure is still tolerable. 
In chapter 4, we examined this question in more detail by conducting a randomized 
double-blinded study measuring full pharmacokinetic curves of rifampicin. We also 
determined possible interactions of a higher dose of rifampicin with other anti-TB 
drugs (pyrazinamide and ethambutol) and a possible increase in toxicity and adverse 
events. Newer drugs might help to improve treatment outcome and shorten treatment 
duration; and moxifloxacin is one of the best candidates. In chapter 5 the question 
was addressed whether rifampicin, a strong inducer of metabolism and transport 
mechanisms of many drugs, affects moxifloxacin plasma concentrations.
The last 3 chapters (Chapter 6 – 8) highlight the clinical pharmacology of TB treatment 
in patients with diabetes. Diabetes is known as a risk factor for developing active TB and 
is associated with poorer treatment outcome. In chapter 6 we performed a literature 
review on current knowledge about TB and diabetes, assessing the implication of the 
global increase of diabetes for TB control and patient care. In chapter 7 we examined 
if the pharmacokinetics of rifampicin are altered in diabetic patients. In chapter 8 we 
addressed this question in more detail, also investigating the pharmacokinetics of 
other anti-TB drugs, the underlying mechanism for possible altered pharmacokinetics 
of anti-TB drugs in diabetes, and the possible effect of glucose control. 
Chapter 1
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The main findings of these studies are summarized and discussed in chapter 9, 
in which the framework for our ongoing and future research program is provided as 
well. I hope it will add to the understanding of the clinical pharmacology of anti-TB 
drugs, TB treatment and treatment outcome in Indonesia and beyond.
Introduction and outline of the thesis 1
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Abstract
A step-wise approach to identify valid and feasible methods to detect non-adherence 
to tuberculosis drugs was evaluated in a prospective study among pulmonary 
tuberculosis patients in an outpatient clinic in Indonesia. First, adherence was measured 
by self-reporting with the standardized Morisky questionnaire, physician assessment, 
pill-count, visit attendance, diary and an electronic medication event monitoring 
system (MEMS). Next, validity of single methods was assessed against MEMS as gold 
standard. Feasibility of methods was then judged by physicians in the field. Finally, 
when valid and feasible methods were combined, it appeared that self-reporting by 
a questionnaire plus physician assessment could identify all non-adherent patients. It 
is recommended to use a systematic approach to develop a valid and locally feasible 
combination of methods to detect non-adherence to TB drugs.  
Chapter 2
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Introduction
Non-adherence to tuberculosis (TB) treatment is a major problem for cure of TB. It may 
lead to treatment failure, relapse, acquired drug resistance and continuing transmission 
of TB [1-3]. The WHO has recommended DOT (Directly Observed Therapy) and this has 
been shown to increase patient adherence, decrease drug resistance and transmission 
of TB in the community [4]. However, daily witnessed drug intake is not always feasible 
in a high volume setting, such as our outpatient clinic in Indonesia, a country with 
the third highest TB caseload worldwide [5]. Patients in our clinic are also involved 
in clinical trials with TB drugs and this also requires good adherence. Therefore, valid 
and feasible method(s) to detect non-adherence are needed both for the clinical and 
research setting.
Numerous direct and indirect methods for measuring patient adherence are now 
available [6]. All these methods have specific advantages and disadvantages, for which 
reason a combination of methods is recommended for monitoring adherence [6] . As 
regards to the validity of these methods, many consider electronic monitoring using 
MEMS (Medication Event Monitoring System) as the reference or gold standard [6-8]. 
MEMS is a standard-sized medication container fitted with a special cap containing 
a microprocessor, which records each time the cap is opened as a presumptive time 
of drug intake [7]. Apart from being valid, a method for measuring adherence should 
also be feasible in the setting where it is to be used. Our study aimed to evaluate a 
step-wise approach to identify a combination of valid and feasible methods to detect 
non-adherence to TB treatment.
 
Materials and methods
We conducted a prospective study on consecutively selected pulmonary TB patients in 
the first two months of TB treatment, who were aged > 15 years and were treated in an 
out-patient urban pulmonary clinic (BP4) in Bandung, Indonesia, visited by more than 
12,000 patients per year. All patients received TB drugs and pyridoxine according to the 
Indonesian National TB Program. They could not join the study if they were unable to 
read and write, or could not attend the clinic every two weeks as appointed. 
Our step-wise approach to identify valid and feasible methods to detect non-adherence 
was started by measuring adherence with several methods. As a second step, the 
validity of each method was assessed among those patients who used MEMS by 
Adherence study in an Indonesian setting
2
Ruslami.1070-Proefschrift.indd   27 28-09-2009   06:40:05
28
calculating the sensitivity, specificity, positive and negative predictive value [9] for the 
detection of non-adherence, with MEMS as gold standard. Thirdly, the feasibility of each 
single method was assessed based on experience gained with monitoring all patients 
in the study. Finally, an optimal combination of two methods was defined based on 
previously assessed validity and feasibility of each of the single methods.
Available methods used in this study were self-assessment using a questionnaire, 
physician assessment, pill count, visit attendance, diary and MEMS. Due to the 
expense of MEMS, a subset of patients (the first 30 patients) received these devices. 
All patients were monitored for four weeks and adherence was assessed after two and 
four weeks.
For self-assessment, patients filled-in the standardized Morisky questionnaire, consisting 
of four questions related to the intake of medication [10]. In physician assessment, a 
physician with experience in counseling and treating TB patients estimated every patient’s 
adherence based on a short discussion about drug intake. Pill-count was performed by 
comparing the number of returned empty drug blisters to the number of blisters that was 
handed out at the previous visit. According to the visit attendance method, adherence 
was 100% if the patient attended the clinic according to the appointments, 0% if they did 
not. A diary was used by the patients to record any drug intake and time of intake. Finally, 
for 30 patients we put 28 pyridoxine tablets of the TB program into a MEMS bottle and 
asked patients to take these tablets from this device. 
The extent of adherence was expressed as a percentage, except for the Morisky 
questionnaire, which defines adherence as high, medium or low. As we wanted to 
be sure that we would detect all non-adherence, adherence values below 100%, or 
medium/low according to Morisky scale, were considered as non-adherence. 
Results
Seventy-nine patients were included; 30 were given MEMS bottles. The median age 
of the patients was 32 years (range: 16 – 84 years) and 49% were male.  Most of them 
(80%) had an income of two US dollars or less per day combined with a low educational 
level  (50% had only completed primary school). Three quarter (76%) of patients were 
in the first month of TB treatment, and had more than four symptoms of pulmonary TB 
(81%). There were no differences in baseline characteristics between patients who were 
given MEMS caps and those who were not. 
Chapter 2
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According to the various individual methods, 43% (self-reporting with the Morisky 
questionnaire), 50% (physician assessment), 47% (pill-count), 26% (visit attendance), 
23% (diary) and 43% (MEMS, applied in 30/79 patients) of patients were non-adherent 
to some extent. As assessed by the first three methods, there was no difference in the 
percent of non-adherent patients among those who used MEMS versus those who did 
not. 
All methods apart from visit attendance were considered to have an acceptable 
sensitivity and negative predictive value to detect non-adherence, compared to MEMS 
as gold standard (table 1).  
Adherence study in an Indonesian setting
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Methods Sensitivity Specificity Positive Negative
 (%) (%) predictive predictive
   value (%) value (%)
Single  methods
Morisky questionnaire  69 76 69 76
Physician assessment  85 71 69 86
Pill-count  60 87 75 76
Visit attendance  38 82 63 64
Diary  61 100 100 77
Combination of methods
Morisky questionnaire +  100 59 65 100
Physician assessment  
Morisky questionnaire +  77 53 56 75
Pill-count  
Physician assessment +  85 59 61 83
Pill-count  
Sensitivity: proportion of non-adherent cases detected 
Specificity: proportion of adherent cases detected
Positive predictive value: proportion of truly non-adherent cases among those which were  
detected as non-adherent
Negative predictive value: percentage of truly adherent cases among those which were  
detected as adherent
Table 1  Validity of methods for detecting non-adherence with MEMS  
as gold standard (n=30)
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From the experience with all patients, treating physicians assessed that the remaining 
methods of self-reporting with the standardized Morisky questionnaire, physician 
assessment and pill-count were simple and fast methods, easy to use and costless. 
Diary imposed to much burden on our patients, because they had to write down their 
drug intake every day and they were not used to this. MEMS is considered as the gold 
standard, but it is too expensive in our setting. 
In the final stage of our stepwise approach, we focused on three methods with 
higher sensitivity to detect non-adherence that were also feasible: self-reporting with 
the standardized Morisky questionnaire, physician assessment and pill-count. All 
non-adherent patients could be identified by combining physician assessment and 
self-reporting (100% sensitivity, table 1). Pill-count did not have any added value for 
detecting non-adherence. 
Discussion
In this study we applied a systematic, step-wise approach with MEMS as the gold 
standard to identify a combination of valid and locally feasible methods to detect 
non-adherence to TB treatment. We aimed to find a combination of methods, considering 
that every single method has its own disadvantages. A combination of methods may 
provide a better result in detecting non-adherence. 
The similar approach of comparing some methods with MEMS as a reference standard 
has been applied in similar studies focusing on adherence to other drugs [11-3]. Only 
few studies have evaluated MEMS in the prophylaxis of tuberculosis so far [14,15]. 
In our study, combining physician assessment and patients’ self-reporting using 
the standardized Morisky questionnaire gave the highest sensitivity to detect any 
non-adherence.  Use of these methods will allow an efficient focus on those patients 
with adherence problems. In these patients, a tailored approach could be performed to 
try and enhance adherence. This might include additional counseling or full or modified 
DOT for these particular patients.  
This study was limited by a small sample size and was conducted in a single clinic, 
so care should be taken to extrapolate the results to other settings. In addition, the 
period of follow-up was relatively short. Further studies with a larger sample size and 
conducted in multiple centers are warranted to evaluate our stepwise approach and the 
effectiveness of combinations of methods in detecting non-adherence to TB drugs. 
Chapter 2
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In summary, DOT is not always possible in every setting. We have presented and 
recommend a step-wise approach to select a combination of valid and locally feasible 
methods to detect non-adherence to TB drugs.
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We previously found peak plasma concentrations of rifampicin below 4 mg/L in 70% of 
Indonesian tuberculosis (TB) patients treated with 10 mg/kg rifampicin daily [1], much 
below the reference concentration of > 8 mg/L [2]. In addition, both murine models [3] 
and studies in TB patients [4] suggest that the typical 10 mg/kg dose of rifampicin may 
be too low and that a higher dose may reduce treatment duration [5]. Indeed a regimen 
incorporating a higher dose of 1200 mg rifampicin daily yielded much faster conversion 
of sputum culture [6]. Based on these findings, we decided to investigate the effect of 
increasing the dose of rifampicin in terms of pharmacokinetics and tolerability. 
In an open-label randomized phase II clinical trial in an urban clinic in Indonesia, 
consecutive patients with microbiologically proven pulmonary TB were randomized 
to a standard (450 mg, 10 mg/kg) or high (600 mg) dose of rifampicin. High and 
standard doses of rifampicin were administered every day in the intensive phase and 
three times weekly in the continuation phase of treatment. All other TB drugs were 
dosed according to the Indonesian National TB Program. All patients provided written 
informed consent and the study was approved by the local institutional review board. 
After 4 and 8 weeks of treatment, blood samples were collected at the Tmax (time to 
peak plasma concentration) of rifampicin, two hours (5) after witnessed intake of TB 
drugs on an empty stomach. Plasma was separated immediately and stored at -80°C 
until measurement of rifampicin concentrations with a validated high performance liquid 
chromatographic (HPLC) assay. Patients were questioned actively for possible adverse 
events and liver transaminases were monitored. The simultaneous effects of the dose 
of rifampicin and the week of treatment on the rifampicin peak plasma concentrations 
were evaluated with a two-way mixed analysis of variance.
Fifty patients were included and 46 completed the study (54 % male; median age 25; 
range 18 - 50). Patients from both groups had a similar body weight, and the median 
dose of rifampicin corresponded to 13.3 mg/kg in the 600 mg group and 10.3 mg/kg 
in the 450 mg group. The mean peak plasma concentration of rifampicin was higher 
in the 600 mg compared to the 400 mg group (11.1 vs 8.0 mg/L, F= 8.77, p = 0.005), 
mean plasma concentrations were similar in weeks 4 and 8, and there was no dose x 
week interaction. In week 4, the percentage of patients with rifampicin peak plasma 
concentrations > 8 mg/L was 78% vs. 48% (600 mg vs 450 mg group,  χ2, p=0.03; 
see Figure). One patient receiving 600 mg developed reversible elevation of liver 
transaminases > 5 times normal, while four patients (two in each study arm) showed 
mildly elevated transaminases. No differences were noted in terms of tolerability. 
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In conclusion, this trial in Indonesia shows that a higher dose of rifampicin significantly 
increases the proportion of patients with rifampicin peak plasma concentrations above 
the reference value of 8 mg/L. Blinded studies with more extensive pharmacokinetic 
assessments will provide more insight in the merits of high-dose rifampicin and may pave 
the road for studies evaluating high dose rifampicin in shorter treatment regimens. 
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Two-hour plasma rifampicin concentrations after 4 weeks of TB treatment in Indonesian patients 
randomized to standard 450 mg or high dose 600 mg rifampicin daily, combined with standard dose 
isoniazid, pyrazinamide and ethambutol. Depicted are individual patients (bullets) and median for  
both groups (horizontal bars).
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Abstract
Rifampicin is a key drug for tuberculosis treatment. Available data suggest that the 
currently applied 10 mg/kg dose of rifampicin may be too low, and that increasing 
the dose may shorten the treatment duration. 
A double blind randomized phase II clinical trial was performed to investigate the 
effect of a higher dose of rifampicin in terms of pharmacokinetics and tolerability. 
Fifty newly diagnosed adult Indonesian TB patients were randomized to receive a 
standard (450 mg; i.e. 10 mg/kg in Indonesian patients) or higher (600 mg) dose 
of rifampicin besides other TB drugs. A full pharmacokinetic curve for rifampicin, 
pyrazinamide and ethambutol was recorded after 6 weeks of daily TB treatment. 
Tolerability was assessed during the 6-month treatment period. 
Geometric means of exposure to rifampicin (AUC0-24) were increased by 65% 
(p<0.001) in the higher-dose group (79.7 mg.h/L) compared to the standard-dose 
group (48.5 mg.h/L). Maximum rifampicin concentrations (Cmax) were 15.6 mg/L vs. 
10.5 mg/L (49% increase, p<0.001). The percentage of patients with rifampicin Cmax 
> 8 mg/L was 96% vs. 79%, p=0.094. The pharmacokinetics of pyrazinamide and 
ethambutol were similar in both groups. Mild (grade I or II) hepatotoxicity was more 
common in the higher-dose group (46 vs. 20%, p=0.054), but no patient developed 
severe hepatotoxicity. 
Increasing the rifampicin dose is associated with a more than dose-proportional 
increase in the mean AUC0-24 and Cmax of rifampicin without affecting the incidence 
of serious adverse effects. Follow-up studies are warranted to assess whether high 
dose rifampicin may enable shortening of TB treatment. 
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Introduction
Each year eight million persons develop active tuberculosis (TB) and 2 to 3 million 
people die from this infectious disease. The treatment of TB is complicated by the 
length and complexicity of currently available drug regimens, which invites problems 
of nonadherence, inadequate response and resistance development. Therefore, a 
long-term goal for TB control has been to shorten the duration of treatment. This 
may possibly be achieved by increasing the dose of the pivotal TB drug rifampicin, 
considering that early bactericidal activity studies in TB patients [1] and recent work 
in the mouse model [2] suggest that the typical 10 mg/kg dose of rifampicin is rather 
low. A 50% increase in the rifampicin dose may reduce the duration of treatment 
by one-third [2]. Apart from these studies, we and others have found low two-hour 
(peak) plasma concentrations of rifampicin in TB patients treated with 10 mg/kg 
rifampicin daily [3-5], which also suggests that a higher dose of rifampicin merits 
further study. 
So far, only few clinical data have been available with regard to the pharmacokinetics, 
tolerability and effectiveness of drug regimens based on a higher dose of rifampicin 
[6,7].  Hence we performed a pilot study in Indonesian patients, in which we compared 
a higher (600 mg) and the standard dose (450 mg or 10 mg/kg, considering the body 
weight of Indonesian people) of rifampicin. It appeared that 78% of patients in the 
higher-dose arm versus 48% of those in the standard-dose arm achieved a rifampicin 
peak (two-hour) plasma concentration above a reference value of 8 mg/L [8]. As the 
pilot study evaluated only a single time point in the rifampicin pharmacokinetic curve 
and was non-blinded, we decided to conduct a double-blind randomized clinical trial 
with intensive pharmacokinetic sampling to compare the steady-state pharmacoki-
netics and tolerability of a higher and the standard dose of rifampicin. 
Materials and methods
Subjects
The study was conducted in an urban outpatient tuberculosis clinic in Bandung, 
Indonesia. Study subjects were patients with newly diagnosed, untreated pulmonary 
tuberculosis. The diagnosis of pulmonary tuberculosis was based on clinical symptoms 
and chest X-ray examination, confirmed by microscopic detection of acid-fast bacilli. 
Patients were excluded if they were below 18 years of age, had a body weight less 
than 33 kg, were pregnant or lactating, had a history of liver or kidney disease or any 
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other disease that might affect the pharmacokinetics of TB drugs, or if they had been 
treated for tuberculosis previously. HIV status was assessed anonymously at the end 
of the study. Informed consent was obtained from all subjects and the study was 
approved by the Independent Ethics Committee, Faculty of Medicine, University of 
Padjadjaran, Bandung, Indonesia and by the Ethical Review Board Region Arnhem/
Nijmegen, The Netherlands.
Study design
This was a double blind, randomized, two-arm, phase II clinical trial. Eligible patients 
were randomized to a standard dose (450 mg, corresponding to 10 mg/kg in 
Indonesian people) or a higher dose (600 mg) of rifampicin besides other TB drugs. 
In accordance with the Indonesian National TB Program, TB treatment consisted 
of daily isoniazide 300 mg, rifampicin (higher or standard dose), pyrazinamide 
1500 mg, and ethambutol 750 mg for two months, followed by isoniazid 600 mg 
and rifampicin (higher- or standard-dose) three times weekly for four months [9]. 
All patients received TB drugs from the same manufacturer, formulated in separate 
tablets. Bioequivalence of the rifampicin tablets and an international reference 
standard has been established before [10].
Double blinding for the dose of rifampicin was accomplished by inserting rifampicin 
tablets of 450 mg and 600 mg into blank capsule shells with the same colour and 
size. Five capsules were sealed into an aluminium blister. The encapsulation and 
sealing of tablets was performed by the manufacturer of the drugs. Information about 
the randomization of the participants was not available to anyone involved in the 
study until it was completed.  
A full pharmacokinetic curve was recorded at steady state after six weeks of treatment. 
Patients were followed every other week during the intensive phase and once monthly 
thereafter for evaluation of possible adverse events as well as microbiological tests 
(sputum microscopy and culture).
Based on available data from the previous pilot study [8], it was estimated that at 
least 24 participants were required in each arm to be able to demonstrate a change 
(two-sided test) of at least 40% in the peak plasma concentration of rifampicin at a 
5% significance level and with 80% statistical power. The study was not powered to 
detect differences in bacteriological outcome. 
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Pharmacokinetic assessment
Patients refrained from the intake of any food or any drugs (other than the study 
medication) from 11 p.m. on the day preceding the pharmacokinetic assessment 
until four hours after the intake of study medication. They took all antituberculosis 
drugs with 230 ml of still water. Serial venous blood samples were collected just prior 
to, and 1, 1.5, 2, 2.5, 3, 4, 6 and 12 hours after witnessed drug intake. Plasma was 
immediately separated and frozen at -20°C, transferred to -80°C within 72 h and 
transported on dry ice to the Netherlands for bioanalysis. 
Bioanalysis
The plasma concentrations of rifampicin, desacetylrifampicin, pyrazinamide and 
ethambutol were assessed with validated high performance liquid chromato-
graphic (HPLC) methods. Concentrations of isoniazid were not assessed, as undue 
degradation of this unstable drug was anticipated during storage and transport. 
Rifampicin and desacetylrifampicin were measured with protein precipitation followed 
by HPLC with ultraviolet (UV) detection.  Hundred microliters of acetonitrile and 10 
µL ascorbic acid solution (20 mg/ml) were added to 200 µL of plasma sample. The 
mixture was vortexed for 20 sec and centrifuged for five minutes. Then 200 µL of 
10 mM potassium dihydrogen phosphate buffer was added and the mixture was 
vortexed and centrifuged again. One hundred microliters of the clear supernatant 
was injected in the HPLC system, which consisted of an Omnispher 5 C18 column 
(250 by 4.6 mm, Varian, Middelburg, The Netherlands) protected with a Chromguard 
RP guard column (10 by 3 mm, Varian, Middelburg, the Netherlands). The mobile 
phase consisted of 10 mM potassium dihydrogen phosphate (pH 4.5) and acetonitrile 
(62:38 % v/v). The flow rate was set at 1 ml/min and the wavelength for UV detection 
was 334 nm. Accuracy for standard concentrations was between 99.8% and 100.4% 
for rifampicin and between 102.4 and 103.9% for desacetylrifampicin, dependent 
on the concentration level. The intra- and inter-assay coefficients of variation were 
less than 4% over the ranges of 0.28-30 mg/L and 0.15-3 mg/L for rifampicin and 
desacetylrifampicin, respectively. Lower limits of quantitation were 0.28 and 0.15 
mg/L respectively. Rifampicin containing plasma samples were stable (< 5% loss) 
for at least 16 months at -20°C and -80°C.   
Total plasma concentrations of pyrazinamide were measured by solid phase extraction 
followed by HPLC-UV. Briefly, Waters Oasis HLB 1 cc 30 mg extraction cartridges 
were washed sequentially with methanol and HPLC-grade water. A half ml of plasma 
sample and 0.5 ml of water were drawn slowly onto the column and allowed to 
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stand. The column was washed with water and elution was performed with methanol. 
The eluate was dried and after addition of 10 mM phosphate buffer pH 6.0/methanol 
(95/5% v/v), vortexing and centrifugation, the clear supernatant was injected into 
the HPLC apparatus. Chromatographic analysis was performed on an Atlantis dC18 
column (150 by 4.6 mm, Waters). The mobile phase consisted of 10 mM phosphate 
buffer pH 6.0 / acetonitrile (99/1% v/v) (fluid A) and acetonitril (fluid B), in which the 
percentage of acetonitril (fluid B) was changed linearly as follows: 0 min, 0%; 11.5 
min, 0 %; 12 min, 45 %; 17 min, 45%; 17.5 min, 0% and 25 min, 0%. The flow rate was 
set at 1.3 ml/min and the wavelength for UV detection was 266 nm. The accuracy 
for standard concentrations was between 96.0% and 109.2%, intra- and inter-assay 
coefficients of variation were less than 10% over the range of 0.1 to 66.8 mg/L and 
the lower limit of quantitation was 0.1 mg/L. Plasma samples with pyrazinamide were 
stable (< 5% loss) for at least 3 months at -20°C and -80°C.   
Ethambutol was quantitated with liquid-liquid extraction, followed by  derivatization 
and HPLC-UV. Plasma samples (100 µL) were spiked with internal standard 
(N,N-diisopropylethylendiamine 99%), alkalized and extracted with chloroform. 
The chloroform layer was poured into other tubes containing derivatization reagens 
(0.01% phenylethylthyocyanate), and evaporated to dryness. Samples were resolved 
in acetonitrile/0.05 M phosphate buffer (40:60 v/v). After vortexing and centrifugation 
the supernatant was injected in the HPLC apparatus. Chromatographic analysis was 
performed on an Omnispher 5 C18 column (100 by 4.6 mm, Varian, Middelburg, the 
Netherlands). The mobile phase was 0.05 M phosphate buffer (pH 5.6) – acetonitril 
gradient in which the percentage of phosphate buffer was changed linearly as 
follows: 0 min, 65%; 21 min, 46 %; 22 min, 65 %;  25 min, 65%. Flow rate was set at 
1.5 ml/min and the wavelength for UV detection was 215 nm. Accuracy was between 
101% and 105%, intra- and inter-assay coefficients of variation were less than 4% 
over the range of 0.05 to 10 mg/L, and the lower limit of quantitation was 0.05 mg/L. 
Plasma samples with ethambutol were stable (< 5% loss) for at least 8 months at 
-20°C and -80°C.
Pharmacokinetic analysis
A noncompartmental analysis with WinNonLin version 4.1 (Pharsight Corp., Mountain 
View, California) was performed to compute the pharmacokinetic parameters of 
rifampicin, desacetylrifampicin, pyrazinamide and ethambutol.
The maximum concentration of drug in plasma was defined as Cmax and the time 
to this maximum concentration as Tmax. Cmax and Tmax were determined directly 
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from the plasma concentration-time data. The value of the slope (-β/2.303, where 
β is the first-order elimination rate constant) was calculated by least-squares linear 
regression analysis. If the concentration at 12 h post dose (C12) was quantifiable, the 
concentration at 24 h (C24) was estimated using the equation C24 = C12 * e-β(t24-t12). 
The area under the concentration-time curve from 0 to 24 h post dose (AUC0-24) was 
assessed using the linear-log trapezoidal rule from 0 up to the last concentration. 
Half-life (t½) was calculated from the expression 0.693/β. Apparent clearance (CL/F, 
where F is bioavailability) was calculated by dividing dose by AUC0-24, and apparent 
volume of distribution (V/F) was obtained by dividing CL/F by β.
The relative exposure of metabolite desacetylrifampicin to rifampicin was expressed 
as the ratio of the metabolite and the parent drug.
Tolerability
Safety and tolerability were assessed by questioning patients actively (before the 
study and in weeks 2, 4, 6 and 8 in the intensive phase and weeks 12, 16, 20 and 
26 in the continuation phase, in total 8 times after inclusion), guided by a list of nine 
possible adverse events that could occur during treatment with TB drugs. Patients 
were questioned by a field investigator, who was a medical doctor at every time. 
Serum glutamine pyruvate transferase (SGPT) was measured to evaluate for hepa-
totoxicity in weeks 2, 4, 6 and 8 during the intensive phase, i.e. 4 times during the 
study. All possible adverse events were categorized according to an adverse event 
grading system [11]. For elevations of SGPT, grade 1 was 1.25 - 2.5 times upper limit 
of normal (ULN); grade 2 was 2.6 - 5 times ULN; grade 3 was 5 - 20 times ULN and 
grade 4 was > 20 times ULN. Patients were withdrawn if they experienced grade 
3 or 4 hepatotoxicity. After the reversal of hepatotoxicity, treatment was gradually 
resumed.  
Bacteriological examinations and treatment outcome
Microscopic examination of Ziehl-Neelsen stained sputum slides was done for 
acid-fast bacilli (AFB) and M. tuberculosis culture was performed on Ogawa 3%. 
Drug susceptibility testing for rifampicin, isoniazid, ethambutol and streptomycin 
was performed on cultured isolates, using an absolute concentration method with 
supranational control.
After 6 months of TB treatment a patient was cured (referring to an initially smear-
positive patient who was smear-negative in the last month of treatment and on at 
least one previous occasion), failed treatment (i.e. a smear-positive patient who 
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remained smear-positive at month 5 or later during treatment), completed treatment 
(a patient who completed treatment but did not meet the criteria for cure or failure 
because no sputum examination was possible during the last month of treatment, 
as the patient did not produce sputum), defaulted (treatment was interrupted for > 2 
consecutive months) or died (death from any cause during treatment) [12].
Statistical analysis
Pharmacokinetic parameters were log-transformed before statistical analysis. 
Differences in AUC0-24, Cmax, t½, CL/F and V/F in the higher- versus standard-dose 
group were tested with the independent-samples t-test and a geometric mean ratio 
plus 95% confidence interval was calculated for every comparison. Values for Tmax 
were not transformed and were compared using Wilcoxon rank sum test. Pearson 
Chi-square test was used to compare the proportions of patients who reached a 
reference peak plasma concentration of 8 mg/L for rifampicin [13], as well as the 
incidence of adverse events, as reported at least once in eight consecutive reporting 
times during the study.
Univariate analyses were performed in the higher-dose and standard-dose arms 
separately to assess the effects of gender, age, body weight and the occurrence 
of nausea or vomiting on the AUC0-24 and Cmax of rifampicin, pyrazinamide and 
ethambutol. A multivariate linear regression analysis was performed to assess the 
variation in AUC0-24 and Cmax attributable to the presence of those variables that 
emerged from the univariate analyses. 
All statistical evaluations were performed with SPSS for Windows, version 12.0.1 
(SPSS Inc., Chicago, IL, USA). P values less than 0.05 were considered statistically 
significant in all analyses.
Results
Patients
Fifty patients were included in the study. They presented with a history of cough 
(100%), shortness of breath (70%), fever (76%), night sweats (62%) and weight loss 
(84%). All patients showed chest X-ray abnormalities and M. tuberculosis culture was 
positive in 92% of them. Fifty-two percent of the patients was male, median age was 
28 years (range: 18 – 55 years), and mean body weight was 46.1 kg (range 35.6 – 
71.2 kg). One patient was HIV-positive and type-2 diabetes was found in four patients 
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(8%). One patient used glibenclamide as co-medication, a drug which is not known 
to affect the pharmacokinetics of TB drugs. Twenty-five patients were allocated to 
each of the two study arms. Both at baseline (data not shown) and at the time of the 
pharmacokinetic assessment (table 1), patient characteristics were similar in the two 
arms, except for rifampicin dose per kg. 
Pharmacokinetic data were available from 47 patients (of whom 23 in the higher- 
dose arm), tolerability data were available from 49 patients (24 in the higher-dose 
arm) and 47 patients were available for an evaluation of treatment response (23 in 
the higher-dose arm). 
Pharmacokinetics of tuberculosis drugs 
All pharmacokinetic assessments occurred as planned without any events (e.g. 
vomiting) that may affect the pharmacokinetic profiles that were recorded. 
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Table 1  Patient characteristics at the time of the pharmacokinetic 
assessment.
Rifampicin dose 600 mg 450 mg
N 23 24
Gender (%)
Male  12/23 (52%) 13/24 (54%)
Age (year)
Median (range) 27 (18 – 55) 34 (19 – 55)
Weight (kg)
Mean (s.d.) 47.3 (6.9) 48.4 (8.1)
Body Mass Index (kg/m2)  
Mean (s.d.) 18.4 (2.6) 18.8 (2.7)
Diabetes mellitus (%)
Yes 1/23 (4%) 2/24 (8%)
HIV status (%)
(+) 0 1 (4%)
Rifampicin dose (mg/kg)
Mean (s.d.) 12.9 (1.7) 9.5 (1.4)
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Marked inter-individual variability in AUC0-24 and Cmax values for rifampicin was 
observed both in the higher-dose and standard-dose arm (table 2). 
Exposure to rifampicin (AUC0-24) was 65% (or 1.65 fold) higher in the higher-dose 
group, which reflects a more than dose-proportional increase of the exposure upon 
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Table 2  Steady-state pharmacokinetics of rifampicin and desacetyl-
rifampicin after daily administration of a high (600 mg,  
13 mg/kg) or standard (450 mg, 10 mg/kg) dose of rifampicin 
(geometric mean plus range, unless stated otherwise)
Parametera Rifampicin  Rifampicin Ratio p-value
 600 mg 450 mg 600mg/450 mg
 (n=23) (n=24) (geometr. mean, 
    95 CI)
Rifampicin
AUC0-24 (mg⋅h/L) 79.7 (38.7-138.1) 48.5 (26.7-72.8)  1.65 [1.38 – 1.96] <0.001b
Cmax (mg/L) 15.6 (5.1-26.6) 10.5 (6.2-16.6) 1.49 [1.22 – 1.81] <0.001b
Cmax  > 8 mg/L (%) 22/23 (96%) 19/24 (79%)  0.090c
tmax (h; median, range) 1 (1 – 6) 2 (1 – 4)  0.428d
T½ (h) 2.2 (1.3-6.3) 1.9 (1.5-5.2) 1.13 [0.95 – 1.35] 0.176b
CL/F (L/h) 7.5 (4.3-15.5) 9.2 (6.1-16.8) 0.82 [0.69 – 0.97] 0.021b
V/F (L) 23.3 (12.3-96.1) 25.3 (12.9-55.7) 0.92 [0.72 – 1.18] 0.502b
Desacetylrifampicin
AUC0-24 (mg⋅h/L) 13.2 (7.2-25.6) 6.4 (2.3-13.3) 2.07 [1.61 – 2.65] <0.001b
Cmax (mg/L) 2.2 (0.6-3.9) 1.2 (0.5-2.6) 1.83 [1.40 – 2.41] <0.001b
tmax (h; median, range) 4 (1.5 – 6) 4 (1.5 – 4)  0.586d
T½ (h) 2.5 (1.7-9.9) 3.2 (2.0-18.9) 0.80 [0.63 – 1.03] 0.085b
Ratio desacetylrifampicin/rifampicin
AUC0-24 0.17 (0.10-0.25) 0.13 (0.08-0.20)  1.26 [1.09 – 1.45] 0.002b
Cmax 0.14 (0.07-0.22) 0.11 (0.05-0.19) 1.23 [1.03 – 1.48] 0.024b
a AUC0-24: area under the concentration-time curve from 0 to 24 h post-dose, Cmax: maximum  
concentration, tmax: time to maximum concentration, CL/F : total clearance, V/F: apparent volume of 
distribution, F: bio-availability, CI: confidence interval.  b Independent t-test on log transformed data.   
c Pearson Chi-square test.  d Wilcoxon rank sum test.
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increasing the dose (table 2 and figure 1). Likewise, rifampicin Cmax was significantly 
higher in the higher-dose group (table 2). The percent of patients who reached a 
reference value of at least 8 mg/L [16] was 96% in the higher-dose group and 79% 
in the standard-dose group (p=0.094). At two hours post dose, 87% of patients in 
the higher-dose group and 58% in the standard-dose group had a concentration of 
at least 8 mg/L (p= 0.01). 
With regard to metabolite desacetylrifampicin, it appeared that absolute values for 
AUC0-24 and Cmax were approximately two fold higher in the higher-dose group 
compared to the standard-dose group (table 2). In addition, desacetylrifampicin / 
rifampicin ratios for AUC0-24 and Cmax were significantly higher in the higher-dose 
group.   
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Figure 1
Mean steady-state plasma concentration - time profiles of rifampicin in tuberculosis  patients 
who received high dose (600 mg, 13 mg/kg, n=23) or standard dose (450 mg,  
10 mg/kg, n=24) of rifampicin, with standard deviations.
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The pharmacokinetics of pyrazinamide and ethambutol did not differ between the 
two study groups (table 3). Of note, there were strong correlations between AUC0-24 
values of rifampicin, pyrazinamide and ethambutol, and the same applied to Cmax 
values (data not shown). 
Tolerability and bacteriological examinations  
No significant differences were found between the high and standard dose group 
in the incidence of nausea (33% resp. 24%, p=0.47), vomiting (21% resp. 12%, 
p=0.40), abdominal pain (4% resp. 8%, p=0.58), itching (50% resp. 64%, p=0.32), 
arthralgia (21% resp. 28%, p=0.57), hyperuricemia (21% resp. 20%, p=0.94), 
dizziness (13% resp. 8%, p=0.60), fever (13% resp. 4%, p=0.28), paresthesia (8% 
resp. 8%, p=0.97), and hepatotoxicity grade 3 (4% resp. 12%, p=0.32).  
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Table 3  Steady-state pharmacokinetics of pyrazinamide and  
ethambutol after daily administration of 1500 mg  
(30 mg/kg) and 750 mg (15 mg/kg) (geometric mean plus 
range, unless stated otherwise).
Parametera Rifampicin  Rifampicin Ratio p-value
 600 mg 450 mg 600mg/450 mg
 (n=23) (n=24) (geometr. mean, 
    95 CI)
Pyrazinamide 
AUC0-24 (mg⋅h/L) 514.5 (266.4-775.3) 472.8 (258.9-705.1)  1.04 [0.93 – 1.27] 0.269b
Cmax (mg/L) 46.0 (23.3-71.8) 43.8 (19.2-62.1) 1.05 [0.91 – 1.21] 0.493b
tmax (h; median, range) 2.5 (2-6) 2.75 (1-6)  0.897c
t½ (h) 6.9 (4.1-11.7)  6.6 (3.9-12.7) 1.04 [0.89 – 1.22] 0.593b
Ethambutol 
AUC0-24 (mg⋅h/L) 14.7 (10.0-23.4) 14.4 (9.6-22.5) 1.02 [0.88 – 1.17] 0.830b
Cmax (mg/L) 2.3 (1.2-5.6) 2.4 (1.1-4.9) 0.98 [0.77 –1.24] 0.863b
tmax (h; median, range) 2.5 (1.5-4) 2.5 (1.5-6)  0.397c
t½ (h) 4.6 (1.8-6.8) 4.2 (2.6-5.5) 1.09 [0.95 – 1.24] 0.217b
a AUC0-24: area under the concentration-time curve from 0 to 24 h post-dose, Cmax: maximum 
concentration, tmax: time to maximum concentration, CI: confidence interval.  b Independent t-test 
on log transformed data. c Wilcoxon rank sum test.
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Hepatotoxicity grade 1 or 2 was more common in the higher dose group (46% vs. 
20%; p=0.054), but none of the patients developed serious hepatotoxicity and no 
action had to be taken. The grade 3 hepatotoxicity which developed in four of 49 
patients (8%, three from the standard-dose arm and one from the higher-dose arm) 
was reversible in all patients. The majority of adverse events (99%) occurred in 
the first weeks of the intensive phase. No ‘flu-like syndrome’ was reported during 
intermittent dosing of rifampicin in the continuation phase. 
Among 47 patients available for an evaluation of treatment response, nobody died, 
38 patients were cured (81%), four completed the treatment (9%), three (6%) showed 
bacteriological failure (one received rifampicin 600 mg) and two patients defaulted 
(4%, one from the higher-dose group). Drug susceptibility tests revealed isoniazid 
monoresistance in two patients (one from the higher-dose group), rifampicin monore-
sistance in one (from the standard-dose group), and multidrug-resistant TB in one 
patient (from the standard-dose group). There was no significant difference in the 
cumulative culture conversion rate between the higher- and standard-dose group, 
but it should be noted that the study was not powered to detect a difference in this 
respect. 
The low number of undesirable events precludes firm conclusions about relationships 
between pharmacokinetic data on the one hand and the occurrence of adverse effects 
or inadequate response on the other. Patients with rifampicin Cmax values above an 
upper reference value of 24 mg/L [13] did not report any serious adverse event and 
patients with grade 3 and 4 hepatotoxicity did not show unduly high exposure to 
rifampicin or pyrazinamide. Likewise, the few patients with bacteriological failure had 
rifampicin Cmax values within the reference range. 
Determinants of the pharmacokinetics of rifampicin, pyrazinamide 
and ethambutol
In univariate analyses, both in the higher- and in the standard-dose group, gender and 
age did not show a significant relationship with the AUC0-24 and Cmax of rifampicin, 
pyrazinamide and ethambutol. However, body weight correlated with the AUC0-24 of 
all three drugs in both study groups; for rifampicin, the Pearson correlation coefficient 
was -0.371 (p=0.081) in the higher-dose group and -0.445 (p=0.029) in the 
standard-dose group. Patients in the separate study arms who had reported nausea 
or vomiting at least once did not have lower exposures to rifampicin, pyrazinamide or 
ethambutol compared to those patients who never reported nausea or vomiting. For 
example, in the higher dose arm, the mean value for the AUC0-24 of rifampicin was 
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80.6 h*mg/L (geometric mean: 76.1 h*mg/L) among patients who once experienced 
nausea or vomiting compared to 85.1 h*mg/L (geometric mean 81.7 h*mg/L) who 
did not (p=0.62, independent-samples t-test on log-transformed data). Similarly, the 
occurrence of just vomiting was not associated with large or significant decreases 
in exposure to the TB drugs in each of the study arms. Rifampicin, pyrazinamide 
and ethambutol Cmax values for three patients with diabetes mellitus (one in the 
higher-dose group and two in the standard-dose group) and one HIV-infected patient 
were within reference ranges.   
Multivariate analysis in all study patients revealed that both the dose of rifampicin and 
body weight were independent predictors of the AUC0-24 of rifampicin, according to 
the formula ln AUC0-24 (in h.mg/L) = 3.288 + [0.003 × rifampicin dose (mg)] – [0.017 
× body weight (kg)].  
Discussion
This phase II clinical study shows that an increase in the rifampicin dose from 10 to 13 
mg/kg daily results in a more than dose-proportional increase in the mean AUC0-24 
(65% increase) and mean Cmax (49 % increase) of rifampicin without a significant 
increase in the incidence of serious adverse events. An increase in the AUC0-24 or 
Cmax of rifampicin predicts an increase in effectivity, as rifampicin exhibits exposure- 
[2] or concentration-dependent [14] activity against M. tuberculosis. Therefore 
increasing the dose of rifampicin appears to be effective (from a pharmacokinetic 
point of view) and feasible. This calls for follow-up phase II studies that evaluate an 
even higher (15 or 20 mg/kg) dose of rifampicin. In-vitro and murine data [6] and 
data in man [15] indicate that TB treatment duration could possibly be shortened to 
4 months by using higher doses of rifampicin. This should eventually be tested in 
larger numbers of patients, within the context of a phase III trial.   
 
The main problem of currently available TB treatment is its length and complexity. 
Strategies to shorten treatment include further optimization of the dosing of available 
TB drugs and the evaluation of new antituberculosis drugs (of which the quinolone 
moxifloxacin seems most promising [16]), or a combination of these [17]. Based on 
available data [1,2], increasing the dose of rifampicin seemed a promising means to 
optimize the response to this drug. This intervention is particularly attractive when it is 
acknowledged that rifampicin is widely available at low costs, and that the properties 
of this drug are well known to physicians all over the world. If increasing the dose 
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of rifampicin proves worthwhile, this intervention could be implemented broadly and 
quickly to the benefit of many patients.      
Only few clinical studies have addressed the concept of high-dose rifampicin in TB 
treatment so far [7]. In one study a short regimen that incorporated a high dose 
of rifampicin (1200 mg daily or every other day) yielded very high sputum culture 
negativity by two months [15]. On the other hand, another study demonstrated 
no difference in effectivity between patients who used 600 (10 mg/kg) or 750 mg 
rifampicin daily. In the latter study, 750 mg of rifampicin was well tolerated [17]. Past 
attempts to use large intermittent doses of rifampicin were met with a high incidence 
of a ‘flu-like syndrome’, but this was ascribed to the intermittency of dosing rather 
than the height of the dose [7,18]. 
In the current study, a moderate (one-third) increase in the dose of rifampicin 
was evaluated. We chose to be cautious, considering the paucity of clinical data 
regarding high-dose rifampicin in general, and taking into account that there are only 
scarce pharmacokinetic and tolerability data for even a standard dose of rifampicin 
in Asian populations. A high dose of rifampicin (20 mg/kg) is used in the treatment 
of brucellosis [7], but it should be considered that tolerability data for high dose 
rifampicin in brucellosis cannot be directly extrapolated to TB. In the treatment of 
brucellosis, high dose rifampicin is combined with just one other drug (doxycyclin) 
instead of several toxic TB drugs, and treatment of this infection takes only 45 days. 
The moderate increase in rifampicin dose, as applied in this study, resulted in a 
relatively strong, more than dose-proportional increase in rifampicin plasma concen-
trations, which is consistent with the non-linear pharmacokinetics of rifampicin 
[18-20]. Increasing the dose of rifampicin also caused a more than proportional 
(around 2-fold) increase in the AUC0-24 of active metabolite desacetylrifampicin 
and an increase in the desacetylrifampicin/rifampicin ratio, which is in agreement 
with previous data [11]. Considering the relatively small contribution of the active 
metabolite to the exposure and effectivity of rifampicin, these findings do not seem 
to be clinically relevant. Importantly, the increase in rifampicin dose did not affect 
the mean AUC0-24 and Cmax of pyrazinamide and ethambutol, despite the observed 
correlations between the pharmacokinetics of rifampicin on the one hand and those 
of pyrazinamide and ethambutol on the other.  
The toxicity of rifampicin is known to be related to dose and administration interval 
[18]. In this study, the incidence of adverse events was relatively high, both in the 
higher- and standard-dose group. This high incidence may be attributable in part to 
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the active and frequent questioning of patients that we applied to guarantee their 
safety. The large majority of adverse events were mild in severity. The incidence of 
grade 1-2 hepatotoxicity was higher in the higher-dose group, but this was transient 
and did not cause treatment interruption or alteration. More importantly, this study 
did not show evidence for an increase in the incidence of serious hepatotoxicity 
related to a higher dose of rifampicin, which is in agreement with previous data [6].  
Nausea and vomiting occurred some 10% more often in the higher dose arm, which 
reflects a (non-significant) difference of only 2-3 patients in this small phase II study. 
These adverse events should be monitored carefully in follow-up studies, as they 
may possibly affect adherence and the absorption of rifampicin, which may offset the 
advantages of high dose rifampicin. In the current study, nausea or vomiting was not 
associated with exposure to the TB drugs. This may not be surprising, considering 
that no vomiting occurred during the pharmacokinetic assessments.  
A limitation of this study, inherent to phase II studies in general, is the relatively 
small number of participants. This means that only large differences in the incidence 
of adverse events became statistically significant. Furthermore, the number of 
participants, in combination with a relatively short (6-month) follow-up, did not allow 
for a valid comparison of bacteriological response between the two treatment arms. 
As another limitation, it should be considered that all participants were Indonesian. 
Although rifampicin doses were based on body weight, it cannot be excluded that 
the pharmacokinetics and/or tolerability of high-dose rifampicin may be different in 
people with another race or genetic background. As a third limitation, the effect of 
high-dose rifampicin on the pharmacokinetics of isoniazid was not assessed in this 
study.
In conclusion, this study shows that an increase in the rifampicin dose from 10 to 13 
mg/kg daily causes a more than dose-proportional increase in the mean AUC0-24 and 
Cmax of rifampicin without causing an increase in severe adverse events to the TB 
treatment. Therefore increasing the dose of rifampicin is feasible and effective from 
a pharmacokinetic point of view. Follow-up phase II studies should be performed 
to evaluate an even higher dose of rifampicin. These studies should be carefully 
monitored, considering the non-linear pharmacokinetics of rifampicin. Eventually, 
high dose rifampicin is to be tested in larger phase IIII trials. For certain risk groups, 
e.g. patients with drug resistance or patients with HIV infection [4] or diabetes mellitus 
[21], a higher dose of rifampicin may be useful as part of the current 6-month TB 
treatment regimen. In the absence of such risk factors, a higher dose of rifampicin 
(possibly in conjunction with new TB drugs) may enable shortening of TB treatment. 
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Rifampicin reduces plasma concentrations 
of moxifloxacin in tuberculosis patients
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Abstract
Introduction
The long duration of the current tuberculosis treatment is demanding and warrants 
new drugs. Moxifloxacin shows promising results and may be combined with 
rifampicin for shortening of TB treatment. Rifampicin induces the phase II metabolic 
enzymes that are involved in the biotransformation of moxifloxacin. Therefore, the 
interaction between rifampicin and moxifloxacin should be investigated. 
Methods
Nineteen Indonesian pulmonary tuberculosis patients in the last month of their 
tuberculosis treatment completed this one-arm, two-period, fixed-order pharma-
cokinetic study. They received 400 mg of moxifloxacin q.d. for five days in addition to 
rifampicin 450 mg and isoniazid 600 mg thrice weekly (phase 1). After a one-month 
washout period, patients received moxifloxacin for another five days (without 
rifampicin and isoniazid; phase 2). A 24h-pharmacokinetic curve for moxifloxacin was 
recorded on the last day of both study periods and its pharmacokinetic parameters 
were evaluated for an interaction with rifampicin, using a bioequivalence approach. 
Results 
Co-administration of moxifloxacin with rifampicin and isoniazid resulted in an almost 
uniform decrease (18 out of 19) in moxifloxacin exposure. The geometric means 
[90% CI] for the ratio AUCphase1/AUCphase2 and Cmax,phase1/Cmax,phase2 were 0.69 
[0.65-0.74] and 0.68 [0.64-0.73]. Moxifloxacin tmax was prolonged from 1h to 2.5 h 
(median values) when combined with rifampicin and isoniazid (p=0.003).  
Discussion
Co-administration of moxifloxacin with intermittently administered rifampicin and 
isoniazid results in reduced moxifloxacin plasma concentrations, which is most 
likely due to induced glucuronidation or sulphation by rifampicin. Further studies are 
warranted to evaluate the impact of the interaction on the outcome of tuberculosis 
treatment. 
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Introduction 
Worldwide, tuberculosis (TB) claims approximately two million victims each year [1,2]. 
The main problem of TB treatment is its duration (6 months), which is very demanding 
in terms of adherence and tolerability. New TB drugs may help to shorten the treatment 
duration. The quinolone antibiotics have raised great interest for their possible ability 
to shorten TB treatment, following a study with the quinolone ofloxacin [3]. 
Newer generation quinolones possess even greater in-vitro activity against M. 
tuberculosis than ofloxacin. The quinolone moxifloxacin, currently recommended in 
multidrug resistant TB [4], shows the highest in vitro activity against M. tuberculosis 
[5]. Moxifloxacin has shown the potential to shorten TB treatment with two months 
when used as a substitute for isoniazid in a murine model [6,7]. Studies in humans 
show that the early bactericidal activity (EBA) of moxifloxacin is comparable to that of 
isoniazid [8,9]. Furthermore, it has been shown that moxifloxacin is safe in long-term 
use in TB patients [10]. A recent study evaluated the effect of moxifloxacin versus 
ethambutol, both in combination with other TB drugs, on sputum conversion at 2 
months [11], and similar studies are underway.
Rifampicin is the strongest known inducer of cytochrome P450 isoenzymes. No pharma-
cokinetic interaction between moxifloxacin and rifampicin is anticipated at the level 
of phase I metabolism, since moxifloxacin is entirely metabolized by the phase II 
metabolizing processes of glucuronidation and sulphation. However, rifampicin also 
induces the phase II enzymes uridine diphoshate glucuronosyltransferase (UGT) and 
sulphotransferase, which may possibly affect the area under the curve (AUC) and 
peak plasma concentrations (Cmax) of moxifloxacin. This interaction could also be of 
relevance in western countries when moxifloxacin and rifampicin are combined in TB 
treatment, for example in case of intolerability of first-line TB drugs or in patients with 
isoniazid monoresistance and extensive disease [12]. The objective of this pharma-
cokinetic study was to assess the interaction between rifampicin and moxifloxacin. 
Methods
Subjects
Study subjects were Indonesian pulmonary TB patients in the last month of the 
continuation phase of TB treatment. They had a body weight above 35 kg, were 
between 18 and 55 years of age and had a normal ECG. All patients had a satisfactory 
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response to treatment, and none had been sputum smear-positive after two months 
of treatment. Subjects were excluded in case of pregnancy or lactation; a relevant 
history or condition that might interfere with drug absorption, distribution, metabolism 
or excretion; heart rhythm disturbances; a history of seizures or epilepsy; G-6PD 
deficiency; hypersensitivity to quinolones; experience of tendon disorders related to 
fluoroquinolone treatment; hypokalaemia or use of any drug that might interact with 
moxifloxacin.
Study design
This study was an open-label, multiple dose, one-arm, two-period, fixed-order phar-
macokinetic interaction study and was performed in an outpatient clinic in Bandung, 
Indonesia. According to the National Tuberculosis Program (NTP) of Indonesia, the 
continuation phase of TB treatment consists of 600 mg of isoniazid and 450 mg of 
rifampicin, both dosed three times weekly. The dose of rifampicin is lower than the 
usual 600 mg dose, considering the low mean body weight of Indonesian people. 
Since all patients were in the last month of TB treatment, steady state for rifampicin 
and isoniazid was already achieved at the start of the study. Next to regular TB 
treatment, subjects were given 400 mg of moxifloxacin QD during five days to attain 
steady state of this drug ([13], figure 1). After finishing TB treatment and a washout 
period of one month, patients received moxifloxacin 400 mg QD for another five 
days. A full pharmacokinetic curve was recorded at day 5 in both phases. Intake of 
study medication was observed on days 1, 3, and 5 in each phase. Furthermore, 
adherence with study medication was evaluated by counting capsules and by the 
use of Medication Event Monitoring System (MEMS) vials. These vials contain micro-
processors that register the date and time of each opening of the vial. All patients 
gave written informed consent and both the Ethical Review Board of Hasan Sadikin 
Hospital / Padjadjaran University in Bandung, Indonesia and the Advisory Board 
of Radboud University Nijmegen Medical Centre, The Netherlands approved the 
study.
Experimental procedures
Steady state pharmacokinetic parameters were assessed on the last day in both 
phases.  Patients were asked to refrain from any food intake from 11 p.m. the 
preceding night until standardized lunch was provided, four hours after intake of 
study medication. Study drugs (moxifloxacin in phase 1 and 2 plus rifampicin and 
isoniazid in phase 1 only) were taken together on an empty stomach. In order to 
assess plasma concentrations of moxifloxacin and rifampicin, serial blood sampling 
was performed before intake and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 hours after 
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intake of the drugs. All blood samples were centrifuged immediately and placed in 
–20ºC within 20 minutes. Afterwards, all samples were transferred to – 80ºC. Samples 
were shipped on dry ice to the Netherlands for bio-analysis. 
Plasma concentrations
Moxifloxacin plasma concentrations were measured by means of a validated high 
performance liquid chromatography (HPLC) method with fluorescence detection. 
Accuracy was > 95% for the moxifloxacin standard concentrations of 0.074 
mg/L, 0.15 mg/L, 0.74 mg/L and 7.4 mg/L, respectively. Intraday precision and 
between-day precision (in %, coefficient of variation) ranged from 1.4% to 5.4% and 
from 0.2% to 3.9%, dependent on the concentration. Ninety-eight drugs were tested 
for interference. The lower and upper limits of quantitation were 0.03 mg/L and 10.0 
mg/L. Moxifloxacin in plasma is stable at –20°C and –80°C for at least 12 months. 
The plasma concentrations of rifampicin and desacetylrifampicin were analyzed 
by a previously described validated HPLC-UV method [14]. Accuracy was 99.8%, 
100.4%, and 100.4% for the rifampicin standard concentrations of 2.9 mg/L, 9.5 
mg/L and 23.7 mg/L respectively. The accuracy of the desacetylrifampicin standard 
concentrations of 0.09 mg/L, 2.25 mg/L and 27.0 mg/L was 103.9%, 102.4% and 
102.6% respectively. Intraday precision and between-day precision ranged from 
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Figure 1  Study design
S: Screening; MXF: moxifloxacin 400 mg once daily; INH: isoniazid 600 mg thrice weekly; 
RIF: rifampicin 450 mg thrice weekly. The washout phase had a duration of one month. 
PK: Pharmacokinetic assessment. Phase 1 took place in the last month of TB treatment; 
therefore steady state was already achieved for rifampicin and isoniazid at the start of the 
study. Phase 2 took place after TB treatment had finished for one month.
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0.7% to 1.1% and from 0.1% to 0.6% for rifampicin, and from 0.9% to 2.9% and from 
0.5 to 3.6% for desacetylrifampicin, respectively. Rifampicin in plasma is stable for at 
least 16 months in –20°C and –80°C. 
Concentrations of isoniazid were not assessed, as measurement of this drug was 
not relevant to the study. 
Tolerability and safety
Tolerability and safety were assessed on days 1, 3, and 5 in both study phases. 
Patients were actively questioned about the occurrence of the known adverse effects 
of moxifloxacin. Clinical chemistry and hematological tests and evaluations of vital 
signs (heart rate, blood pressure) and ECGs were performed on the same days. 
All possible adverse events were graded according to the Common Toxicity Criteria 
(CTC), version 2.0 [15]. 
Pharmacokinetic and statistical analysis
All pharmacokinetic evaluations for rifampicin and moxifloxacin were performed 
using non-compartmental methods using WinNonLin version 4.1 (Pharsight Corp., 
Mountain View, California). The highest observed plasma concentration was defined 
as Cmax, with the corresponding time as tmax. Cmin was the plasma concentration at 
24 hours after intake of study medication. The area under the curve (AUC0-24h) was 
calculated using the log-linear trapezoidal rule from zero up to the last concentration. 
The terminal log-linear period (log C versus t) was based on the last data points 
(n ≥ 3). The absolute value of the slope was calculated by least squares linear 
regression analysis. β is the first order elimination rate constant. Terminal half-life 
was obtained by the equation: 0.693/β. The apparent clearance of the drug (Cl/F) 
was calculated by (dose/ AUC0-24h). The volume of distribution (Vd/F) was calculated 
by the equation (Cl/F / [β]).
The sample size of the study was derived from the main pharmacokinetic parameter, 
the AUC0-24h of moxifloxacin, and determined for a data-analysis that is similar 
to a within-subject two-period bioequivalence study [16], as recommended for 
interaction studies. The desired power of the study was 90% and the within-subject 
coefficient of variation for the logarithmically transformed AUC0-24h of moxifloxacin 
was  conservatively estimated at 15%.  Based on these data, at least 12 subjects 
were required. Since this was estimation and dropouts were expected, 22 patients 
were enrolled in the study.  
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The MIC of moxifloxacin on M. tuberculosis (0.5 mg/L, [17]) was used to calculate 
the pharmacodynamic (PD) parameters AUC0-24h/MIC and Cmax/MIC. The number 
of patients that reached the targets of AUC24h/MIC and Cmax/MIC ratios of 100 
and 10 [18-23], respectively, was compared using the Chi square test. The mutant 
prevention concentration (MPC) for moxifloxacin in TB treatment was set at 2.5 mg/L 
[24], uncorrected for protein binding. Time > MPC was the time when moxifloxacin 
concentration was above the MPC. 
All statistical evaluations were performed with SPSS for Windows, version 12.0.1. 
Pharmacokinetic parameters were log-transformed before statistical analysis. 
The values for tmax were not transformed and were compared using Wilcoxon signed 
rank test. Using a bio-equivalence approach for the evaluation of the interaction, the 
90% confidence interval of the geometric mean ratios AUCphase 1/ AUCphase 2 and 
Cmax,phase 1/Cmax,phase 2 should lie between 80 and 125% to conclude the absence 
of an interaction. P-values < 0.05 were considered statistically significant in all other 
analyses. 
Results
Patients
Twenty-two subjects were included in the study. Two of them dropped out during the 
second phase of the study: the first for medical reasons unrelated to the study and 
the second for personal reasons. A third subject was excluded from all analyses after 
the study, since this subject missed one dose on the day preceding the pharma-
cokinetic assessment in phase 2. 
The diagnosis of TB in the study subjects was based on the following clinical 
symptoms; history of cough (100%), shortness of breath (50%), fever (60%), night 
sweats (65%) and weight loss (65%). All patients showed X-ray abnormalities and 
had cultures positive for M. tuberculosis at initiation of TB treatment. The mean age 
of the nineteen study subjects who completed the study (of whom 6 females) was 30 
years (range: 20-55) and their mean weight was 55 kg (range: 38-80 kg) at the first 
day of pharmacokinetic assessment. Type 2 diabetes was present in one patient, 
but the patient did not take antidiabetic medication. Adherence was excellent in all 
subjects: all 19 patients were 100% adherent.  
Rifampicin reduces plasma concentrations of moxifloxacin
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Pharmacokinetics of moxifloxacin and rifampicin and safety
The geometric mean for the ratio AUCphase 1/AUCphase 2 of moxifloxacin was 0.69, 
and the lower and upper 90% confidence intervals of the ratio were 0.65 and 0.74 
respectively. Similar figures were shown for moxifloxacin Cmax (table 1). Moxifloxacin 
Cmin showed a stronger decrease (ratio 0.38) when co-administered with rifampicin 
and isoniazid. As a result, bioequivalence for the combination of rifampicin, isoniazid 
and moxifloxacin when compared to moxifloxacin alone cannot be concluded. 
Moxifloxacin exposure decreased in all but one subject (figure 2). Moxifloxacin tmax 
was prolonged when combined with rifampicin and isoniazid (p=0.003; figure 2). 
A relatively small inter individual variability in pharmacokinetic parameters for 
moxifloxacin was observed, which was described elsewhere [25].
The AUC24h for moxifloxacin without rifampicin (in phase 2) did not correlate with 
the relative difference between the two phases (ratio of AUCphase 2 / AUCphase 1) 
(Pearson correlation coefficient 0.195, p=0.423).
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Table 1  Steady-state pharmacokinetic results for moxifloxacin (n=19).
PK parametera Geometric mean (range) Geometric
 
Phase 1b Phase 2c
 mean ratio
   (period 1/ period 2)
   and 90% CId
AUC0-24h (h mg/L) 33.3 (25.1-55.5) 48.2 (37.2-60.5)  0.69 (0.65-0.74)
Cmax (mg/L) 3.2 (2.5-4.5) 4.7 (3.4-6.0) 0.68 (0.64-0.73)
Cmin (mg/L) 0.38 (0.18-0.78) 0.78 (0.51-1.1) 0.38 (0.31- 0.48)
tmax (h) 2.5 (0.5-6.0)e 1.00 (0.5-3.0)f 0.003f
CL/F (L/h) 12.0 (7.2-16.0) 8.3(6.6-10.8) 1.45 (1.35-1.54)
Vd/F (L) 123 (83-187) 119 (8.4-179) 1.04 (0.98-1.09)
t½ (h) 7.1 (5.0-9.6) 9.9 (7.4-14.0) 0.72 (0.68-0.75)
a PK: pharmacokinetic, AUC0-24h: area under the concentration-time curve, Cmax: highest  observed 
plasma concentration, Cmin: trough concentration at 24h after intake of study  medication, tmax: time  
at which Cmax occurs, CL/F: total clearance, Vd/F: volume of distribution, t1/2: elimination half-life,  
F: bioavailability. b Combination of 400 mg moxifloxacin once daily, 600 mg isoniazid and 450 mg 
rifampicin three times weekly. c Moxifloxacin 400 mg once daily. d CI: confidence interval.  
e Median and range. f Wilcoxon signed rank test.
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The geometric mean values (range) for AUC/MIC and Cmax/MIC for moxifl oxacin in 
phase 2 approached the desired values for fast growing bacilli (96.4 (74.4-121) and 
9.5 (6.8-12.1), respectively), in contrast to the values in phase 1 (66.7 (50.3-111) 
and 6.5 (4.9-9.1), p<0.01). When moxifl oxacin was given alone (phase 2), nine out 
of nineteen participants (47%) reached an AUC24h/MIC greater than 100 versus only 
one patient (5%) when moxifl oxacin was combined with rifampicin and isoniazid 
in phase 1. These results were similar concerning the Cmax/MIC ratio. The median 
(range) time of moxifl oxacin above the mutant prevention concentration (MPC) was 
5.5 h. (2.5-7.5) when given alone in phase 2, versus 2 h. (0-7.5) when combined with 
rifampicin and isoniazid (p<0.01).
The pharmacokinetic parameters of rifampicin and its main metabolite desacetyl-
rifampicin are shown in table 2. No signifi cant correlation was found between exposure 
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Figure 2
Mean (+ SD) moxifloxacin steady state plasma concentrations versus time (n=19).  
Open squares, 400 mg moxifloxacin once daily. Closed squares, combination of 400 mg 
moxifloxacin once daily and 450 mg rifampicin and 600 mg isoniazid thrice weekly.  
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to rifampicin (AUC) and the ratio of AUCphase 2 / AUCphase 1 for moxifloxacin (Pearson 
correlation coefficient 0.168, p=0.493). The one diabetic patient showed average 
exposure to rifampicin, although plasma rifampicin concentrations have been found 
to be reduced in type 2 diabetes [25]. Only grade I adverse events and no laboratory 
abnormalities were noticed. 
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Table 2  Pharmacokinetic results for rifampicin 450 mg thrice weekly and  
its main metabolite desacetylrifampicin (n=19).
PK parametera Geometric mean (range) 
AUC0-24h (h mg/L) 35.7 (10.4-55.4)
Cmax (mg/L) 6.9 (2.4-11.5)
Cmin (mg/L) 0.34 (0.23-0.87) 
tmax  (h) 2.5 (1.5-6.0)b
CL/F (L/h) 12.7 (8.1-45.6)
Vd/F (L) 36.2 (23.9-91.8)
t½ (h) 2.0 (1.4-3.1)
Desacetylrifampicin c
AUC0-24h (h mg/L) 4.5 (0.0-7.1)b 
Cmax  (mg/L) 0.92 (0.0-1.5)b
Cmin (mg/L) 0.23 (0.0-0.39)b
tmax  (h) 4.0 (0.0-6.0)b
t½ (h) 1.94 (0.0-3.1)b 
Ratio desacetylrifampicin/ rifampicin
AUC0-24h (h mg/L) 0.13 (0.0-0.26)b
Cmax  (mg/L) 0.12 (0.0-0.21)b
Data are for study phase 1, in which patients received a combination of 400 mg moxifloxacin 
 administered once daily and 600 mg of isoniazid and 450 mg of rifampicin administered three times 
weekly. a PK: pharmacokinetics, AUC0-24h: area under the concentration-time curve, Cmax: highest  
observed plasma concentration, Cmin: trough concentration at 24h after intake of study  medication, 
tmax: time at which Cmax occurs, CL/F: total clearance, Vd/F: volume of distribution, t1/2: elimination  
half-life,  F: bioavailability. b Median and range. c Desacetylrifampicin was not found in four subjects.
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Discussion
To our knowledge, these are the first pharmacokinetic data of moxifloxacin 
in tuberculosis patients. The study demonstrates that steady state plasma 
 concentrations of moxifloxacin are significantly reduced when combined with 
rifampicin and isoniazid. 
The interaction is expected to result from an increase in phase II metabolism caused 
by rifampicin, as moxifloxacin does not undergo phase I oxidative metabolism 
[13]. No interference of isoniazid in the metabolism of moxifloxacin is anticipated, 
since isoniazid is only known to affect cytochrome P450 mediated metabolism [26]. 
Rifampicin is known as a very strong inducer of CYP-P450 iso-enzymes. It is probably 
less well known that this drug also induces phase II metabolism. More specifically, 
rifampicin induces uridine diphoshate glucuronosyltransferase (UGT) and sulpho-
transferase, thereby reducing plasma concentrations of rofecoxib, mycophenolate 
mofetil, lamotrigine, zidovudine and propafenone [13, 27-33]. A similar mechanism 
may be involved in the interaction with moxifloxacin, as this drug undergoes phase 
II biotransformation and will be excreted as a sulpho-compound or as a glucuronide 
via the kidneys (2.5% and 14%, respectively) and the faeces (34% and 14%, 
respectively) [34]. Recently, it was found in healthy volunteers that rifampicin mainly 
induces the sulphation pathway of moxifloxacin [35]. Of note, the difference in tmax 
between phases could be suggestive for a role of P-glycoprotein. The expression of 
P-glycoprotein in intestinal cells is induced by rifampicin and moxifloxacin could be a 
substrate of this protein [36]. However, induced sulphation or glucuronidation could 
also cause this difference. 
The AUC0-24h and Cmax of moxifloxacin showed a mean decrease of 31 and 32% 
respectively. This reduction in plasma concentrations can be characterized as modest 
and similar reductions in AUC (27%) and tmax were found in a similar study in healthy 
subjects [35]. Strikingly, Cmax was found to be unaffected by rifampicin in this study. 
In the current study, the reduction of moxifloxacin plasma concentrations occurred 
near-uniformly in all but one of the study subjects. Daily instead of intermittent dosed 
rifampicin could possibly amplify the extent of this interaction. For gram-negative, 
fast-growing bacteria, the greatest bactericidal effect and a decreased probability 
of resistance development to fluoroquinolones occurs at AUC24h/MIC and Cmax/MIC 
ratios above 100-125 or more and above 10 or more, respectively [17,18,23], in which 
AUC and Cmax values refer to total (protein bound plus unbound)  concentrations 
[18-22]. For M. tuberculosis, a slowly duplicating organism with the capacity for 
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dormancy, the pharmacodynamic parameters for optimal fluoroquinolone activity 
against are less well defined [21]. 
Recently, the activity of moxifloxacin against M. tuberculosis has been found to be 
best described by the ratio between AUC and MIC indeed [17,20]. Nuermberger 
showed that even the potent quinolone moxifloxacin, when used in TB treatment, 
does not reach the ideal pharmacodynamic values for activity against gram-negative 
bacilli [21].  Apart from this, a mutant prevention concentration (MPC) has been 
defined [24], above which plasma concentrations should be maintained to prevent 
the emergence of resistance. It has been demonstrated that only a few quinolones 
(among which moxifloxacin) achieve brief periods of concentrations above the mutant 
prevention concentration (MPC) [24]. In line with this, previous research using an 
aerosol model concluded that a moxifloxacin dose of 800 mg/day instead of 400 
mg/day is likely to achieve excellent M. tuberculosis microbial kill and suppress drug 
resistance [37]. It should be acknowledged that the clinical relevance of all these 
pharmacodynamic parameters in the setting of multidrug TB treatment is yet unclear. 
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Figure 3
Steady state area under the curve (AUC0-24h) of moxifloxacin alone once daily (phase 2) and 
when combined with rifampicine and isoniazid, thrice daily (phase 1, n=19)
Moxifloxacin Moxifloxacin,
isoniazid and rifampicin
A
re
a 
un
de
r 
th
e 
cu
rv
e 
(h
 m
g/
L)
Ruslami.1070-Proefschrift.indd   74 28-09-2009   06:40:45
75
Presumably, the same interaction between rifampicin and moxifloxacin is occurring 
in the murine model of tuberculosis treatment, and even so, the substitution of 
moxifloxacin for isoniazid markedly improves the activity of treatment. Therefore, it 
should be concluded that the clinical relevance of the interaction between rifampicin 
and moxifloxacin is unknown at this time, and this applies to the administration of 
this drug combination to shorten TB treatment duration as well as for other clinical 
situations in which this combination is used.   
On the basis of the current study, we would propose that follow-up pharmacoki-
netic studies are performed to assess whether a dose increase to 600 mg or 800 
mg moxifloxacin compensates for the decrease in plasma levels caused by (daily) 
co-administration of rifampicin.  In addition, a pharmacokinetic interaction study 
between moxifloxacin and rifapentine, another rifamycin, is warranted, considering 
that clinical trials with this combination are underway. Finally, additional research 
should be performed to explore the activity and tolerability of higher doses of 
moxifloxacin, even in the absence of rifampicin. 
This study is limited by the design of the study, which did not allow discrimination 
between an effect on the moxifloxacin metabolism of rifampicin or isoniazid. Besides, 
the MIC and MPC values of M. tuberculosis for moxifloxacin were not determined, 
but based on previous publications. Therefore, pharmacodynamic ratios were 
partly derived. Furthermore, this study was not designed to assess the impact of 
moxifloxacin on the pharmacokinetics of rifampicin. Such an effect is not expected, 
since moxifloxacin does not induce any metabolism. 
Concluding, we showed a 30% decrease in exposure to moxifloxacin when 
combined with intermittently administered rifampicin and isoniazid in Indonesian TB 
patients. This finding is in agreement with data from healthy volunteers [35], but 
the clinical relevance of this interaction has yet to be elucidated. A higher dose of 
moxifloxacin may possibly overcome the effect of rifampicin on the pharmacokinetics 
of moxifloxacin. Additional studies are warranted to assess the pharmacokinetics, 
dynamics and tolerability of a higher dose of moxifloxacin when combined with 
rifampicin or other rifamycin derivatives. 
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Abstract 
We performed a literature review on the effect of diabetes (DM) on epidemiology, 
clinical presentation and treatment of tuberculosis (TB). Using public databases it 
can be estimated that 10% [95%CI 7.3-13.6%] of new TB-cases in ten countries with 
the highest TB burden will be attributable to DM in 2025, a relative increase of 31.5% 
compared to 2003. Diabetes is associated with a higher age and body weight among 
TB-patients, but probably not with a specific clinical presentation of TB. With regard 
to treatment, rifampicin hampers glycemic control by increasing the metabolism of 
most oral antidiabetic drugs, while DM may reduce plasma rifampicin concentrations 
and increase TB treatment failure rates. In conclusion, it is clear that the global 
epidemic of DM has implications for control and treatment of TB. Prospective studies 
are needed to improve prevention, early detection and treatment of concomitant DM 
and TB, especially in developing countries.
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Introduction
The association between tuberculosis (TB) and diabetes mellitus (DM) was well 
known in the past, but somewhat forgotten in the second half of the 20th century with 
the advent of widely available treatment for both diseases. Now, with the current 
global growth of diabetes, the link between the two diseases is re-emerging. The 
epidemic growth of DM especially occurs in developing countries, where TB is highly 
endemic. As a result, DM and TB will increasingly present together, and this calls for 
renewed interest in this topic. 
Several questions can be asked. First, what is the effect of DM on the TB epidemic, 
and what projections can be made in light of the global emergence of DM? Second, 
what is the effect of DM on the clinical presentation of TB? Finally, what is known 
about combined treatment of DM and TB? In this overview, we will discuss these 
various aspects of the interaction between DM and TB. 
Search strategy and selection criteria
Data for this review were identified by searches of PubMed combining “Tuberculosis” 
and “Diabetes Mellitus” as free text and MeSH terms, combined with other terms 
including “cohort”, “risk factors”, “odds ratio”, “case control”, “cohort study”, 
“therapy”, “treatment”, “antituberculous”. 
We systematically checked full text papers referenced in retrieved articles. We also 
obtained data made available by public databases: (http://www.who.int/tb/
publications/global_report/2008 for TB database and http://www.eatlas.idf.org/
prevalence for prevalence of DM) to calculate the current proportion of TB patients 
attributable to DM in different countries, and make predictions about the future. 
Effect of diabetes mellitus on the tuberculosis epidemic
Diabetes as a risk factor for tuberculosis
Studies from different parts of the world have shown that 5-30% of TB patients 
present with concomitant DM [1-6] and available evidence indicates that DM acts as 
risk factor for development of TB. Data from the 1930s have shown that patients with 
DM had a three to four-fold increased risk of developing TB [7, 8]. More recent studies 
have confirmed this association [3, 6, 9-14]. In addition, a meta-analysis has been 
performed in 2008, using 13 observational studies. This meta-analysis assessed that 
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people with DM had a 3.11 times higher risk of getting TB (95% CI 2.27 – 4.26) 
compared to people without DM [15]. Furthermore, from this meta-analysis it 
appeared that young diabetic patients have a higher risk of TB, and that the relative 
risk is also higher in countries with a higher incidence of TB [15]. This means that a 
similar prevalence (%) of DM may contribute more to the TB epidemic in developing 
countries. 
HIV is by far the strongest risk factor for TB, but DM may be equally or more important 
in countries with a low HIV-prevalence. For example in India, a recent study estimated 
that DM accounts for 14.8% of pulmonary TB cases, while HIV accounts for 3.4% of 
cases [16] and in a recent study in California, 11% of TB among Hispanics was 
attributed to DM, and 17% to HIV [1]. Possible interactions between HIV and DM and 
their risk on TB remain to be determined. 
Only few studies specified whether diabetic TB patients had type 1 or type 2 DM. 
Type 2 DM is more prevalent, but type 1 DM is associated with a higher risk of TB. 
Studies from Ethiopia, Tanzania and Chile showed that type 1 DM patients had a 
three to five fold higher risk of developing TB than type 2 DM patients [2, 17, 18]. 
Data showed that long duration of illness and poor glucose control increase the risk 
of TB [17, 19].
Type 2 DM among TB patients is often unrecognized. A study in Tanzania found that 
among 34 diabetic TB patients, 73% of DM was newly diagnosed [9]. Also in a recent 
study from Indonesia, among 94 diabetic TB-patients, 61% of DM was newly 
diagnosed [2].
Contribution of diabetes to the tuberculosis epidemic
Socio-economic and life style changes in the developing countries lead to an 
increase of DM, especially type 2 DM. Table 1 shows the contribution of DM to TB in 
ten countries with the highest number of new TB cases. Based on the prevalence of 
DM [21], the incidence of TB [22], and the relative risk to develop TB associated with 
DM [15], it can be estimated that almost half a million, or 7.6% (95% CI 5.5-10.4%) of 
TB-cases in 2003 were due to DM in these 10 countries. The total number of people 
with DM worldwide is projected to rise from 171 million in 2000 to 366 million in 2030 
[23], and similar to the situation now, an estimated 80% of diabetic patients in 2030 
will live in TB endemic countries [22, 23]. As to TB, it is predicted that the incidence 
of TB in most parts of the world will stabilize or come down in the coming decades 
[22], but due to a rising prevalence of DM, the relative contribution of DM will increase. 
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Assuming similar population growth and change in TB incidence across different 
countries over time, the estimated proportion of TB attributable to DM in 2025 will be 
10.0% (95% CI 7.3-13.6%), a relative increase of 31.5% compared to 2003 (see 
legend Table 1 for calculations). The top-three countries for TB (India, China and 
Indonesia) will witness the largest effect of rising prevalence rates for DM (Table 1). 
In ten countries with the highest numbers of DM cases [23], the proportion of new TB 
cases attributable to DM was 8.8% (95% CI 6.4-12.1%) in 2003, and is predicted to 
be 12.0% (95% CI 8.8-16.5%) in 2025, a relative increase of 36.1%. 
In summary, both type 1 and type 2 DM are associated with an increased risk of TB 
and among TB patients type 2 DM is often undiagnosed. Given its worldwide 
prevalence, DM may contribute significantly to the TB problem, especially in areas 
with a low HIV-prevalence and the problem will increase in the near future. 
In these 10 countries with the highest global burden of TB, a total number of 462,256 
out of 6,115,890 TB cases (7.6%) in 2003 were attributable to DM, based on TB-incidence 
rates [22], country-specific prevalence rates of DM [21], and a relative risk to develop 
TB associated with DM of 3.11 [95%CI 2.27-4.26] [15]. Taking population size and 
country-specific increases in prevalence of DM between 2003 – 2005 into account, an 
estimated 10% of TB cases [95%CI 7.3-13.6%] in 2025 will be attributable to DM. Using 
similar calculations, an estimated 12% of TB cases [95%CI 8.8-16.5%] in 10 countries 
with the highest number of DM cases in 2025 will be attributable to DM.    
Effect of diabetes mellitus on the clinical presentation 
of tuberculosis 
Several researchers have addressed the question whether DM affects the clinical 
presentation of TB. Their findings are reviewed below. 
First, DM does not seem to be associated with so-called ‘primary tuberculosis’, nor 
with ‘reactivation tuberculosis’ [3]. When DNA-fingerprints of M. tuberculosis isolates 
from DM and non-DM patients were compared, DM was equally found among 
clustered cases (representing ‘primary tuberculosis’) and unique DNA-fingerprint 
patterns (representing ‘reactivation tuberculosis’). 
Second, in terms of gender, no difference has been found between diabetic and 
non-diabetic patients [3, 5, 14, 20, 24]. Third, DM does not appear to affect the clinical 
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manifestation of TB. Several studies showed a similar occurrence and duration of 
symptoms between diabetic and non-diabetic TB-patients [3, 5, 20, 24]. More sputum 
smear-negative cases were found among 92 hospitalized diabetic TB-patients 
compared to 92 age- and sex-matched non diabetic TB patients in Turkey (19.2 vs. 
0.7%, p<0.01) [25], but in contrast, more smear-positive cases were found among 
401 TB patients with self-reported DM, than among 1040 non-diabetic patients in a 
recent retrospective study in Texas (OR 1.8; 95% CI 1.3-2.4) [24]. Fourth, studies 
about the effects of DM on the radiological appearance of TB have met with conflicting 
results, as summarized in Table 2 [4, 26-36]. Finally, extrapulmonary involvement was 
less common in diabetic TB-patients in Malaysia [36] and Turkey [25], while no 
association was found between DM and extrapulmonary TB in Guinea [14]. 
Diabetic TB-patients are usually 10-20 years older than those without DM as type 2 
DM is associated with higher age [5, 8, 14, 36]. In addition, compared to non-DM 
patients, TB patients with DM usually have a higher body weight before start of 
treatment, and even more after treatment. In a recent study from West Africa, 23% of 
TB-DM patients were obese (BMI > 30 kg/m2), compared with 3% of non-diabetic 
patients (OR: 10.1; 95% CI 3.1-21.2) [14]. In a study from Indonesia, 53% of TB 
patients with DM were above 50 kg of weight before treatment started, compared to 
only 16.5% of non-diabetic patients (p<0.01) [20]. These differences in body weight 
may have implications for TB treatment.
In conclusion, based on the available literature, it remains uncertain whether DM 
affects clinical presentation of TB. No difference in terms of gender, however diabetic 
TB-patients are associated with higher age and body weight. Differences in patient 
selection and case-definitions used for DM may explain some of the discrepancy 
between different studies. Almost all of the above-mentioned studies lack detail 
regarding the diagnosis, possible complications and regulation of DM. 
Combined treatment of diabetes mellitus and tuberculosis 
Treatment of diabetes in diabetic tuberculosis patients
Many antidiabetic drugs are currently available. The most important ones are 
classified as insulin secretogogue (sulphonylureas and metiglinides), biguanide 
(metformin), thiazolidinediones (TZD) and insulin. Among them, sulphonylureas and 
TZDs are metabolized by cytochrome (CYP) P450 enzymes in the liver. 
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Rifampicin is a very potent inducer of these enzymes [37-39]. Plasma levels of several 
antidiabetic drugs are significantly lower when co-administered with rifampicin (table 3) 
[40-51]. Isoniazid is an inhibitor (rather than an inducer) of some the enzymes that 
are induced by rifampicin, most notably CYP2C9 which is relevant to the metabolism 
of sulphonylureas. However, the inductive effect of rifampicin generally outweighs 
the inhibitory effect of isoniazid on the same enzyme, so that the overall effect of 
isoniazid plus rifampicin probably is a decrease in the concentrations of other drugs 
[37]. Nothing is known about the effect of rifampicin and INH on metabolism of 
insulin, but it is unlikely to be significant as insulin is mostly degraded in the liver by 
hydrolysis of disulfide connections between the A and B chains through the action 
of IDE (insulin degrading enzyme) [52]. It is unlikely that the other first-line TB drugs 
like pyrazinamide and ethambutol interact with any antidiabetic drugs, but 
fluoroquinolones, especially gatifloxacin, are associated with hyper- and hypo-
glycaemia [53]. Based on the above, blood glucose levels should be monitored after 
start and discontinuation of rifampicin in patients using oral antidiabetic drugs. 
Full induction of drug-metabolizing enzymes is reached in about one week after 
Review on tuberculosis and diabetes
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Table 3  Effect of rifampicin on the exposure to anti diabetic drugs.
Antidiabetic drug  Change in exposure  Enzyme Reference
   (AUC1) induction
Insulin  no effect anticipated  no studies
    published
Sulphonylureas  Tolbutamide strong decrease  40, 41
 Glibenclamide  -39% CYP2C9 42
 (Glyburide) 
 Gliclazide -70% CYP2C9 43
 Glimepiride -34% CYP2C9 44
 Glipizide -22% CYP2C9 42
Biguanides Metformin no effect anticipated  no studies
    published
Meglitinide analogues Repaglinide -57%, -31%, -50% CYP3A4, CYP2C8 45-47
 Nateglinide -24% CYP2C9, CYP3A4 48
Thiazolidinediones Rosiglitazone -54%, -65% CYP2C8 49, 50
 Pioglitazone -54% CYP2C8 51
1 AUC : area under the concentration-time curve.
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starting rifampicin treatment and the induction dissipates in roughly two weeks after 
discontinuing rifampicin [39].
Metformin, which is not metabolized by rifampicin, might be a good alternative. 
Metformin has become a first choice drug for type 2 DM [54] as it has several 
mechanisms to control hyperglycaemia and does not lead to hypoglycaemia [55]. 
Metformin is relatively cheap, widely available and associated with less weight 
increase compared to other oral antidiabetic drugs. The disadvantage of metformin 
when it is combined with antituberculous drugs is that almost 30% of patients could 
experience gastrointestinal side effects [55], possibly leading to non-adherence and 
poor treatment outcome. 
In conclusion, rifampicin hampers glycemic control, calling for the use of higher 
doses of sulphonylureas and TZDs. This may not be effective, and other hypoglycemic 
drugs should be considered. As lack of resources in less-developed settings often 
precludes the use of insulin, metformin may be a good antidiabetic drug during 
TB-treatment, but this has not been investigated.  
Treatment and outcome of tuberculosis in diabetic tuberculosis patients
TB patients with DM should receive standard TB treatment, consisting of four different 
antituberculous drugs for two months (rifampicin, isoniazid, pyrazinamide and 
ethambutol), followed by two drugs (rifampicin and isoniazid) for another four months. 
Rifampicin is the cornerstone for TB treatment. Its action is concentration-dependent 
and the recommended dose of rifampicin is 10 mg/kg body weight [56] which might 
be at lower end of the dose-response curve. Higher daily dose are probably more 
effective and may reduce treatment duration [57]. In practice most guidelines advise 
450 mg/day for patients below 50 kg and 600 mg/day for patients above 50 kg. 
Considering that diabetic patients are usually heavier and gain more weight during TB 
treatment, adjustment of drug dose, especially in the later phase of treatment, seems 
highly relevant for diabetic patients. No further adjustment is needed; antidiabetic 
drugs do not affect the concentrations of antituberculous drugs [37].
An important question is whether DM affects TB treatment outcome. In the era before 
insulin therapy, many patients with type 1 DM in the western world appeared doomed 
to die from pulmonary TB [7]. With the introduction of insulin in 1922, this picture 
changed, although the risk of developing TB remained high, especially in lean and 
poorly controlled DM patients [8]. Once diagnosed, TB often ran a rapid and 
progressive course in DM patients. Among 2010 DM patients treated between 1930 
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and 1953, 53% died and the majority within one year [58]. Unfortunately, early studies 
did not compare outcome with non-diabetic patients. Following the introduction of 
the first antituberculous drugs, streptomycin (1945), para-aminosalicylic acid (PAS; 
1949) and isoniazid (INH; 1952), the prognosis of DM patients with TB improved 
dramatically [19, 58].
More recently, a number of studies have re-examined the effect of DM on outcome of 
TB treatment. In a study in Malaysia, 27% of diabetic versus 38% of non-diabetic TB 
patients had a negative sputum-smear at six months, but overall treatment success 
was similar (73% versus 61%) [36]. In a study in Saudi Arabia, two-months microscopic 
sputum conversion was 83% among diabetic TB patients, and 91% among 
non-diabetic patients, but in multivariate regression, this difference was not significant 
and three-month rates were similar [5]. In a retrospective study involving 5049 TB 
patients along the Texan-Mexican border, patients with self-reported DM (19.9%) 
remained sputum smear-positive significantly longer during the first two months of 
treatment [24]. However, no 6-month results were reported for this study, and none of 
the above studies has reported sputum culture results. This may be relevant: in a 
cohort of 634 Indonesian TB patients, diabetic patients had a significantly higher rate 
of positive sputum cultures at six months (adjusted OR: 7.65, P=0.004) [20]. Finally, 
in a recent report from Taiwan, one-year mortality was higher among TB patients with 
DM than among those without (17.6% vs 7.7%; adjusted odds ratio 5.5, 95% CI 2.3 
– 13.4) [59].
If DM indeed has a negative effect on TB treatment, what could be the possible 
mechanism(s)? Non-adherence to TB treatment and drug-resistance of M. 
tuberculosis are the most important risk factors for treatment failure and TB relapse. 
Adherence to TB treatment among DM patients seems similar or better than among 
non-diabetic TB patients [6, 36]. With regard to drug-resistance, studies have 
reported a higher rate of drug resistance among diabetic TB-patients [25, 60, 61], 
while others have found the opposite [3, 5, 62]. It is unclear why diabetic TB-patients 
might have a higher risk of becoming infected with a drug-resistant strain. Another 
possible explanation may be that diabetic TB-patients have an impaired cellular 
immunity interfering with effective eradication of mycobacteria. However, studies 
have met with conflicting results [63, 64].
A final possibility mechanism may lie in lower plasma concentrations of anti TB drugs 
which have been associated with treatment failure [65-67]. DM is one of the indications 
for plasma concentration monitoring of TB drugs in those countries where such 
facilities are available [68]. One pharmacokinetic study in Indonesian TB-DM patients 
Review on tuberculosis and diabetes
6
Ruslami.1070-Proefschrift.indd   93 28-09-2009   06:41:03
94
found that exposure to rifampicin (AUC0-6h) was 50% lower in heavier TB patients 
with DM compared to patients without DM [69]. Additional studies should be 
conducted to confirm this finding, disentangle the effects of body weight and 
hyperglycemia, and examine pharmacokinetics of other TB drugs in DM.  
Public health implications 
Given the fact that the global epidemic of DM especially takes place in the developing 
countries where most of TB patients reside, the role of DM as a risk factor for TB and 
the worse treatment outcome in TB patients with DM, screening of patients with DM 
for TB and vice-versa may have significant health implications, as has been advocated 
by others [70]. But to our knowledge, the impact of such interventions has not been 
examined. Active screening and treatment of latent TB among DM patients, as 
advocated in some guidelines, might contribute to sustainable TB control [71]. 
However, in most endemic countries such policy is not implemented or evaluated. 
Implementing the ‘DOTS’ (‘directly observed treatment short course’) framework 
might help to halt and reverse the incidence of infectious disease such as TB by 
2015 (millennium development goals 6).
Conclusions 
The association of DM and TB is epidemiologically important in light of the expanding 
epidemic of type 2 DM in TB-endemic settings. Therefore, screening of TB patients 
for the presence of DM and vice-versa will have implications for control and treatment 
of both diseases in developing countries. There are no data on the effectiveness and 
costs of screening DM patients for (active and latent) TB, and TB patients for the 
presence of DM on a large scale. Also, DM, TB and HIV might be a deadly threesome, 
but this has not been studied. 
DM is associated with higher age and body weight, but data regarding the effect of 
DM on clinical presentation are conflicting. With regard to treatment, rifampicin 
increases metabolism of most oral anti diabetic drugs, complicating glycemic control 
during TB treatment. The tolerability and effectiveness of metformin for glucose 
control is unknown when combined with TB drugs. At the same time, lower plasma 
rifampicin concentrations and lower cure rates have been found in diabetic TB 
patients. However, these findings need further confirmation, and other questions 
remain to be answered. In addition, long-term follow-up data of combined treatment 
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using standard (six-month) regimens is lacking. Such follow-up studies might show 
a need for controlled studies exploring longer TB treatment or altered drug regimens. 
Weaknesses in the current scientific literature, which is mostly cross-sectional and 
retrospective, add to our lack of good data. We therefore call for more interest and 
well-designed studies, which will help to improve prevention and treatment of 
concomitant DM and TB, especially in developing countries. 
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Exposure to rifampicin is strongly reduced           
in tuberculosis patients with type 2 diabetes
Clin Infect Dis 2006;43:848-54
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Abstract
Background 
Type 2 diabetes (DM) is a strong risk factor for tuberculosis (TB), and is associated 
with a slower response to TB treatment and a higher mortality. As lower concentra-
tions of antituberculosis drugs might be a contributing factor, we compared the phar-
macokinetics of rifampicin in tuberculosis patients with and without diabetes.
Methods 
Seventeen adult Indonesian TB patients with type 2 diabetes (TB-DM) and 17 age 
and gender matched TB patients without diabetes were included during the 
continuation phase of TB treatment, using rifampicin 450 mg (10 mg/kg) and 600 mg 
isoniazid three times weekly. Steady-state plasma concentrations of rifampicin and 
its metabolite desacetylrifampicin were assessed at 0, 2, 4 and 6h after drug intake. 
Results 
Geometric means (95% CI) of rifampicin exposure (AUC0-6h) were 12.3 mg·h/L 
(8.0-24.2) in TB-DM patients, and 25.9 mg·h/L (21.4- 40.17) in TB patients (p=0.003). 
Similar differences were found for the Cmax of rifampicin. No significant differences in 
tmax values of rifampicin were observed. The AUC0-6h of desacetylrifampicin was 
also much lower in TB-DM versus TB patients (geometric means 0.60 versus 3.2 
mg·h/L, p =0.001). Linear regression analysis revealed that higher body weight 
(p<0.001), the presence of DM (p=0.06) and the plasma glucose concentration 
(p=0.016) were correlated with exposure to rifampicin. 
Conclusion 
Exposure (AUC0-6h) to rifampicin was 53% lower in Indonesian tuberculosis patients 
with diabetes compared to patients without diabetes. Tuberculosis patients with 
diabetes and a higher body weight may need a higher dose of rifampicin. 
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Introduction
Worldwide the prevalence of type 2 diabetes is increasing, especially in developing 
countries, where tuberculosis (TB) is highly endemic. More specifically, it is estimated 
that in 20 years from now, 75% of the patients with type 2 diabetes (DM) will live in 
countries which harbor the majority of tuberculosis cases [1]. As a result, a growing 
number of tuberculosis patients will have diabetes. Recent studies from Saudi Arabia 
[2], Russia [3], and from our own group in Indonesia [4] show that between 10 and 
30% of tuberculosis patients may suffer from diabetes at this time. This is important, 
as diabetes seems to be associated with a less favourable response to tuberculosis 
treatment [5,6]. Indeed, in a large Indonesian cohort of TB patients, the presence of 
diabetes was associated with significantly lower sputum conversion rates after eight 
weeks of treatment (Alisjahbana et al, submitted for publication).
Altered pharmacokinetics of antituberculosis drugs might explain the adverse effect 
of diabetes on the response to tuberculosis treatment. It has been shown that 
diabetes patients have lower plasma concentrations of certain drugs [7,8]. If this 
also applies to antituberculosis drugs, this might explain the slower response to 
tuberculosis treatment in diabetes patients. Lower plasma concentrations of antitu-
berculosis drugs have been associated with clinical failure and acquired drug 
resistance [9-11]. For rifampicin, a key drug in tuberculosis treatment, available 
evidence suggests that its efficacy is dependent on exposure to the drug or to the 
maximum drug concentrations achieved [12]. 
Recent studies including ours, have reported low plasma concentrations of TB drugs 
in patients [13-16] but so far no studies have systematically examined the pharma-
cokinetics of tuberculosis drugs in patients with diabetes. Therefore in the present 
study, we compared plasma concentrations of rifampicin in tuberculosis patients 
with and without type 2 diabetes.
Methods 
Study design and recruitment of subjects
We conducted a prospective pharmacokinetic study in the urban outpatient 
tuberculosis clinic Perkumpulan Pemberantasan Tuberculosis Indonesia (PPTI) in 
Jakarta, Indonesia. Within the context of a larger study evaluating the effect of 
diabetes on the immune response in tuberculosis, tuberculosis patients with type 2 
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diabetes (TB-DM) were included, and age and gender matched TB patients without 
diabetes (TB) were selected as controls. 
Tuberculosis diagnosis was based on clinical symptoms and chest X-ray examination, 
confirmed by microscopic detection of acid-fast bacilli and culture of Mycobacterium 
tuberculosis.  Treatment consisted of a standard regimen of daily rifampicin, isoniazid, 
pyrazinamid, and ethambutol for two months, and rifampicin and isoniazid thrice 
weekly for another four months  (2HRZE/ 4H3R3), according to the Indonesian 
National Tuberculosis Program (NTP). All patients took identical TB drugs from a 
national manufacturer. Isoniazid and rifampicin were formulated in separate tablets. 
Bioequivalence of the rifampicin tablets to an international reference standard has 
been established before [17]. All patients were included after at least two weeks of 
tuberculosis treatment in the continuation phase. The Indonesian NTP prescribes 
450 mg rifampicin (10 mg/kg, considering the low body weight of Indonesian people) 
and 600 mg isoniazid three times a week during the continuation phase.
Capillary and venous blood glucose was measured in all patients before start of 
tuberculosis treatment. Newly established diabetes was diagnosed according to 
WHO criteria [18], i.e. if fasting blood glucose was ≥ 7.0 mmol/L, capillary blood 
glucose was ≥ 6.1 mmol/L or random plasma glucose was ≥ 11.1 mmol/L, measured 
at two different time points. A diagnosis of diabetes was also accepted if patients 
had established diabetes and were using antidiabetic agents. At time of blood 
sampling for measurement of rifampicin pharmacokinetics, diabetes was confirmed, 
as hyperglycemia may disappear during tuberculosis treatment [19]. This confirmation 
showed that capillary fasting blood glucose concentrations were ≥ 6.1 mmol/L in all 
patients and fasting blood glucose from plasma was ≥ 7.0 mmol/L in all but one 
subject whose diabetes was very strictly controlled (Table 1). In accordance with 
national guidelines, tuberculosis patients with type 2 diabetes were treated with oral 
antidiabetic drugs after 2-4 weeks of tuberculosis treatment. Study subjects had to 
be at least 18 years of age, and were not allowed to use any drug that is known to 
affect the pharmacokinetics of rifampicin. Patients were excluded if they were 
pregnant or lactating, had gastro-intestinal problems, e.g. diarrhea or vomiting on 
the days preceding the pharmacokinetic assessment, were HIV positive, or if they 
had elevated creatinine (>1.25 times above the upper limit of normal) or alanine 
transaminase levels (>2 times the upper limit of normal). The study protocol of the 
main diabetes-immune response study was approved by the local institutional review 
board. Written informed consent for the pharmacokinetic substudy was obtained 
from all subjects. 
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Pharmacokinetic assessment
From 11 p.m. on the day preceding the study day until four hours after drug intake 
on the study day, patients refrained from the intake of any food or any drugs, other 
than the study medication. Considering that the patients did not take food, they also 
did not take their antidiabetic drugs in this period. 
 On the day of pharmacokinetic assessment the patients took 450 mg of rifampicin 
and 600 mg of isoniazid with 230 ml of still water. Serial venous blood samples were 
collected just prior to, and 2, 4 and 6 hours after witnessed drug intake in a fasted 
state. Plasma was immediately separated and frozen at –20°C, transferred to –80°C 
within 60h, until transport on dry ice to the Netherlands for bio-analysis. The stability 
of rifampicin and its metabolite desacetylrifampicin under all these conditions has 
been validated before. 
Bioanalysis
Total rifampicin concentrations and the concentrations of its main metabolite 
desacetylrifampicin were analyzed by a validated high performance liquid chromato-
graphy (HPLC) method with UV detection. Two hundred microliters of acetonitrile and 
10 µL ascorbic acid solution were added to 200 µL of plasma sample. The mixture 
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Table 1  Patient characteristics.
  TB-DM TB p-value
Male sex (%) 9 / 17 (53%) 11 / 17 (65%) 0.49θ
Age (yr) 50 (28-60) 48 (27-59) 0.85δ
Weight (kg) 55.6 (36.6-75.2) 46.2 (33.6-70.8) 0.01
Male 55.6 (45-75.2) 50.0 (33.6-55.2) 0.03δ
Female 55.4 (36.6-65.2) 40.4 (36.2-70.8) 0.15δ
Body mass index (kg/m2) 23.9 (16.5-27.7) 18.9 (13.8-33.0) 0.007δ
Male 20.9 (16.5-26.6) 19.1 (13.8-21.0) 0.015δ
Female 24.8 (18.8-27.7) 18.7 (15.6-33.0) 0.19δ
Fasting blood glucose (mmol/L) 9.3 (6.3-12.3) 5.2 (4.4-5.6) <0.001δ
HbA1c (%) 9.85 (0-13) 5.6 (0-7) 0.014δ
Rifampicin dose (mg/kg body weight) 8.1 (6.0-12.3) 9.7 (6.4-13.4) 0.008δ
Data are presented as median (range). θ Pearson Chi-square test. δ Independent t-test.
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was vortexed for 20 s and centrifuged for 5 min. Then 400 µl of 10 mM potassium 
dihydrogen phosphate was added and the mixture was vortexed and centrifuged 
again. Two hundred microliters of the clear supernatant were injected in the HPLC 
apparatus. Chromatographic analysis was performed on an Omnispher 5 C18 
column  (250 by 4.6 mm, Varian, Middelburg, the Netherlands) protected with a 
Chromguard RP guard column (10 by 3 mm, Varian, Middelburg, the Netherlands). 
The mobile phase consisted of 10 mM potassium dihydrogen phosphate (pH 4.5) 
and acetonitrile (62:38 % v/v). The flow rate was set at 1 ml/min and the wavelength 
for UV detection was 334 nm. Rifampicin and desacetylrifampicin retention times 
were 7.8 and 3.6 min., respectively. The lower limits of quantitation for rifampicin and 
desacetylrifampicin were 0.28 and 0.15 mg/L respectively. Accuracy was 99.8%, 
100.4%, and 100.4% for the rifampicin standard concentrations of 2.9 mg/L, 9.5 
mg/L and 23.7 mg/L respectively. The accuracy of the desacetylrifampicin standard 
concentrations of 0.09 mg/L, 2.25 mg/L and 27.0 mg/L was 103.9%, 102.4% and 
102.6% respectively. Intraday precision and between-day precision (in %, coefficient 
of variation) ranged from 0.7% to 1.1% and from 0.1% to 0.6% for rifampicin, and 
from 0.9% to 2.9% and from 0.5 to 3.6% for desacetylrifampicin, respectively. 
Pharmacokinetic analysis
Pharmacokinetic parameters of rifampicin and desacetylrifampicin were calculated 
using noncompartmental methods. The area under the plasma concentration time 
curve from time zero until 6 hours post dose (AUC0-6h) was assessed using the linear 
trapezoidal rule. The highest observed plasma concentration was defined as Cmax 
and the corresponding sampling time as tmax. Cmax and tmax were determined directly 
from the plasma concentration-time data. Pharmacokinetic parameters were 
calculated by using the WinNonlin software package (version 4.1; Pharsight 
Corporation, Mountain View, California). The relative exposure of metabolite 
desacetylrifampicin compared to rifampicin was expressed as the ratio of the 
metabolite and the parent drug.
Data and statistical analysis 
Differences in AUC0-6h and Cmax values in TB patients versus TB-DM patients were 
tested with an independent-samples t-test on the ln transformed pharmacokinetic 
data. Pearson Chi-square test was used to determine the difference in proportions of 
patients reaching a reference peak plasma concentration of 8 mg/L for rifampicin 
[20,21]. Values for tmax were not transformed and were compared using Wilcoxon 
rank sum test. Univariate analyses were performed in the separate groups (TB and 
TB-DM) to assess the effect of gender, age, body weight and fasting plasma glucose. 
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A multivariate linear regression analysis with forced entry was performed to assess 
the variation in rifampicin pharmacokinetics (AUC0-6h and Cmax) attributable to the 
presence of diabetes and other variables that emerged from the univariate analyses. 
All statistical evaluations were performed with SPSS for Windows, version 12.0.1 
(SPSS Inc., Chicago, IL, USA). P values less than 0.05 were considered statistically 
significant in all analyses.
Results
Patients
Thirty-six patients with pulmonary tuberculosis were recruited for the study, of whom 
two patients were excluded from further analysis. Rifampicin concentrations in one 
patient could not be analyzed due to interference from endogenous substances. The 
analysis of the second patient revealed a trough plasma rifampicin concentration of 
2.8 mg/L before witnessed drug intake, suggesting that the patient had already taken 
the drug before arrival at the clinic. The remaining 34 patients presented with a 2- to 
6-month history of cough (100%), shortness of breath (85%), fever (91%), night 
sweats (68%), and weight loss (85%). All patients showed chest X-ray abnormalities, 
and sputum microscopy and M. tuberculosis culture were positive in all. Characteris-
tics of the patients are presented in table 1. Twelve of 17 (71%) tuberculosis patients 
with type 2 diabetes (TB-DM) used oral antidiabetic treatment at the time of plasma 
rifampicin measurement. Glibenclamide was mostly used, only one patient used 
glipizid. No patient was treated with metformin or insulin. 
Two patients used captopril for the treatment of hypertension. These co-medications 
are not known to affect the pharmacokinetics of anti-TB drugs. As expected, body 
weight and body mass index (BMI) were significantly higher in the TB-DM group 
(Table 1). As a result, the rifampicin dosage per kg of body weight was lower for the 
patients in the TB-DM group. 
Pharmacokinetics of rifampicin and desacetylrifampicin
Marked interindividual variability was observed in the exposure to rifampicin (range 
AUC0-6h; 5.5-71.6 mg·h/L). Tuberculosis patients with DM had significantly lower 
rifampicin plasma concentrations than TB patients without DM (Table 2). The mean 
exposure to rifampicin (AUC0-6h) in TB-DM patients was 53% lower than the exposure 
in TB patients (Figure 1). Similar differences were found for Cmax, and a strong 
correlation was observed between AUC0-6h and Cmax in both TB and TB-DM patients 
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(Pearson correlation coefficient 0.983, and 0.987; p<0.01). The percentage of 
patients who reached a reference value of at least 8 mg/L for rifampicin was 
significantly lower in TB-DM patients compared to TB patients. Although the median 
rifampicin tmax values differed between TB-DM and TB patients, this difference did 
not reach statistical significance at all. With regard to desacetylrifampicin, the 
AUC0-6h and Cmax of desacetylrifampicin were significantly lower in the TB-DM group, 
while tmax was not different. The geometric mean (95% CI) of the desacetylrifampicin/ 
rifampicin AUC0-6h ratio was 0.13 (0.11-0.15) in the TB-group, and 0.09 (0.06-0.11) 
in the TB-DM group (p=0.009).  
Univariate analyses
In the TB-DM group, no statistically significant difference was found in exposure 
between male and female patients (AUC0-6h 18.8 vs. 13.0 mg·h/L respectively; NS). 
In the TB-group, male patients had lower rifampicin exposure than females (mean 
AUC0-6h 24.4 vs. 42.5 mg·h/L; p=0.048). Age did not show a significant correlation 
with rifampicin pharmacokinetics. Body weight inversely correlated with rifampicin 
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Table 2  Pharmacokinetic parameters of rifampicin and desacetylrifampicin in 
tuberculosis patients with type 2 diabetes (n=17) and patients without 
type 2 diabetes (n=17). 
.
Parameter# TB-DM TB Ratio TB-DM/TB p-value
Rifampicin*     
AUC0-6h (mg⋅h/L) 12.3 (8.0-24.2) 25.9 (21.4– 40.2) 0.47 (0.31-0.77) 0.003ς
Cmax (mg/L) 3.49 (2.4- 6.3) 6.74 (5.6-10.1) 0.52 (0.34-0.80) 0.004ς
> 8mg/L (%) 1 / 17 (5.9%) 8 / 17 (47.0%)  0.007θ
tmax (h; median, range)    4 (2-6) 2 (2-4)  0.52ψ
Desacetylrifampicin    
AUC0-6h (mg⋅h/L) 0.60 (0.76-2.06) 3.2 (2.7-6.0) 0.27 (0.17-0.62) 0.001ς
Cmax (mg/L) 0.24 (0.26 –0.65) 0.87 (0.72-1.60) 0.40 (0.09-0.82) 0.023ς
tmax (h; median, range) 4 (4-6) 4 (4-6)  0.524ψ
Data are represented as geometric mean (95% CI), unless stated otherwise. # AUC0-6: the area  
under the plasma concentration-time curve from time 0 until 6 hours post-dose, Cmax: the maximum 
observed plasma concentration, tmax: the time to Cmax * 450 mg (10 mg/kg), in the continuation  
phase of tuberculosis treatment. ς Independent t-test on ln transformed data. θ Pearson Chi-square 
test. ψ Wilcoxon rank sum test.
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exposure, both in the TB-DM group (Pearson correlation coefficient -0.462, p=0.062), 
and in the TB group (-0.468, p=0.058; Figure 2). The parallel lines in figure 2 
demonstrate an equal effect of body weight on exposure in both groups. In addition, 
the difference between the dashed (TB) and solid (TB-DM) lines illustrates a clear 
effect of the presence of diabetes on the exposure to rifampicin. Fasting plasma 
glucose showed an inverse correlation with AUC0-6h (Pearson correlation coefficient 
–0.476, p=0.004) in the group as a whole. 
Multivariate analysis
The assumptions for multivariate linear regression were met, including the absence 
of multicollinearity, independence of the outcome value and linearity of the model. 
The effect of the independent variables body weight and diabetes on the dependent 
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Figure 1  Mean plasma concentration time profiles of rifampicin in  
17 tuberculosis (TB) and 17 tuberculosis patients with diabetes 
(TB-DM), with standard deviations.
The open circles represent the tuberculosis patients without diabetes and the closed squares 
represent the tuberculosis patients with diabetes. * P value of comparison between groups  
< 0.05
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variable ln AUC0-6h were assessed in Model 1 (Table 3). The absolute difference in ln 
AUC0-6h between TB and TB-DM patients was 0.745. Every additional kg of body 
weight decreased ln AUC0-6h by 0.035. The weight difference between TB and TB-DM 
patients was approximately 9.5 kg. The weight corrected portion in the absolute 
difference for the presence of type 2 diabetes was 0.425, corresponding with 57% of 
the difference in exposure to rifampicin between groups. 
A second regression analysis was performed in which fasting blood glucose was 
assessed as independent variable for ln AUC0-6h. The presence of diabetes and 
fasting blood glucose cannot be assessed in one model simultaneously, as these 
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Figure 2  Natural logarithm (ln) of the Area under the Curve (AUC0-6h) of 
rifampicin versus body weight.
The dashed regression line represents the tuberculosis patients without diabetes and the 
solid regression line represents the tuberculosis patients with diabetes. 
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variables are highly correlated. Multivariate regression analysis revealed that fasting 
blood glucose was significantly associated with rifampicin AUC0-6h (Table 3) and 
Cmax (data not shown). Every extra mmol of fasting blood glucose/L resulted in a 
decrease of ln AUC0-6h of 0.114. The mean difference of approximately 4 mmol/L in 
fasting plasma glucose between TB and TB-DM patients corresponds with 61% of 
the difference in exposure to rifampicin. Fasting blood glucose and diabetes status 
show equal effects on the dependent variable ln AUC0-6h. 
Thus, body weight and diabetes and hyperglycemia are strongly and inversely 
associated with rifampicin AUC0-6h and Cmax. 
Discussion 
In this study, we showed that exposure (AUC0-6h) to rifampicin was 53% lower in 
Indonesian tuberculosis patients with diabetes, compared to tuberculosis patients 
without diabetes. Similarly, Cmax of rifampicin was above the target concentration of 
8 mg/L in only one out of seventeen (6%) tuberculosis patients with diabetes, 
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Table 3  Regression analysis of independent associations of various  
variables with exposure to rifampicin (AUC0-6h).
Model Regression parameter B* (SE) p-value
1A Intercept  4.889 (0.544) <0.001
 Body weight - 0.035 (0.011) 0.004
 Type 2 diabetes - 0.425 (0.219) 0.062
2B Intercept  5.423 (0.517) <0.001
 Body weight - 0.034 (0.011) 0.004
 Fasting plasma glucose at PK assessmentζ - 0.114 (0.045) 0.016
A Adjusted R2 = 0.424   
B Adjusted R2 = 0.466 
* B: the regression coefficient for determining the regression equation, SE: standard error.  
Adjusted R2: reflects the effect size, i.e. 42.2% of the variation in ln AUC0-6h  is explained by  
the model. ζ PK assessment: pharmacokinetic assessment
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compared to eight of seventeen (47%) patients without diabetes. A higher body 
weight and the presence of diabetes contributed to lower rifampicin exposure. In 
addition, more profound hyperglycemia was associated with lower plasma rifampicin 
concentrations. 
The magnitude of the difference in AUC0-6h and Cmax of rifampicin between TB-DM 
patients and TB patients was much larger than anticipated and is likely to be clinically 
relevant. A 50% lower exposure to a key tuberculosis drug such as rifampicin may 
cause clinical failures and favor the emergence of resistance. In fact, the findings of 
this study suggest that the unfavorable response of patients with type 2 diabetes to 
tuberculosis drugs [5,6] may at least partially be explained by differences in pharma-
cokinetics. If these findings are confirmed, higher fixed dosages of rifampicin may be 
warranted for patients with diabetes and a higher body weight. If available, physicians 
may consider assessing plasma concentrations of rifampicin in diabetes patients in 
order to individualize dosing. In this case we would advise to use multiple time point 
sampling.   
Several mechanisms have been postulated for altered pharmacokinetics in diabetes 
patients. The absorption, distribution, metabolism and excretion of drugs could all 
be changed in diabetes [8]. 
With regard to absorption, gastro-intestinal problems are common in diabetes 
patients. In this study, diarrhea and vomiting were excluded beforehand. Gastroparesis 
(delayed gastric emptying) could decrease the rate of absorption, as reflected in an 
increase in tmax and a decrease in rifampicin Cmax. However, this study did not show 
any marked difference in tmax between the two study groups, suggesting that delayed 
absorption was not responsible for a lower Cmax in TB-DM patients. It should be 
acknowledged that the number of sampling points might have been too small to 
detect a change in tmax. Furthermore, it is unlikely that gastroparesis is associated 
with reduced absorption of rifampicin, since this drug is not subject to saturable 
first-pass metabolism after multiple doses and does not have an absorption window 
in the gastro-intestinal tract [22,23].
The low exposure to rifampicin in TB-DM patients may possibly be explained by the 
highly pH-dependent solubility and absorption of rifampicin [23,24]. Diabetes- 
associated hyperglycemia, strongly related to rifampicin exposure in this study, can 
reduce secretion of gastric hydrochloric acid resulting in a higher gastric pH [7,25], 
which in turn has been associated with a decrease in rifampicin absorption [23]. This 
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hypothesis needs confirmation as no gastric pH was measured in our study and others 
have not found an effect of antacids on the pharmacokinetics of rifampicin [26].
With regard to metabolism and excretion, our results suggest that metabolism of 
rifampicin to the desacetyl-metabolite was reduced or excretion of this metabolite 
was increased in TB-DM patients, at least in the first 6 hours after administration. 
These findings do not explain the low exposure to rifampicin in TB-DM patients. 
On the contrary, decreased metabolism in the hepatocytes of diabetes patients 
might be explained by the expression of advanced glycosylation end products (AGE) 
in the liver [27], impairing the normal function of for example basement membranes 
of cells [28].
Linear regression analysis showed an unexpectedly strong effect of body weight on 
the exposure to rifampicin. These results emphasize that rifampicin should be 
carefully dosed on the basis of body weight as recommended by the WHO and 
others [20]. Apparently, uniform dosing of rifampicin for all Indonesian patients (‘one 
dose fits all’) is inadequate. As was clearly shown, the fact that tuberculosis patients 
with diabetes had a higher body weight, can only partially explain the differences in 
rifampicin pharmacokinetics.
This study was limited by the small sample size, and by the limited number of time 
points for pharmacokinetic assessment. In addition, this study only assessed the 
pharmacokinetics of rifampicin in the continuation phase of treatment. Furthermore, 
this study focused on pharmacokinetics and did not assess the outcome of 
tuberculosis treatment. 
In summary, we showed that exposure to rifampicin was strongly reduced in 
tuberculosis patients with type 2 diabetes. Tuberculosis patients with concomitant 
diabetes and a higher body weight may possibly need a higher dose of rifampicin. 
Screening for diabetes at tuberculosis diagnosis could be worthwhile, and physicians 
may consider pharmacokinetic assessment of rifampicin in this patient group (if 
available). Further studies are warranted to assess the influence of diabetes, as well 
as the possible benefit of active treatment of diabetes on the pharmacokinetics of TB 
drugs and the outcome of tuberculosis treatment.
Exposure to rifampicin reduced in type 2 diabetes
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Abstract 
Background 
Altered pharmacokinetics of TB drugs may contribute to the increased risk of 
tuberculosis (TB) treatment failure in diabetic patients. We previously found that 
rifampicin exposure was two-fold lower in diabetic compared to non-diabetic 
TB-patients during the continuation phase of treatment. We now examined the 
influence of diabetes on pharmacokinetics of TB drugs in the intensive phase of TB 
treatment, and evaluated the effect of glycemic control.
Methods
Eighteen diabetic and 18 gender- and body weight- matched non-diabetic TB-patients 
were included in an Indonesian setting. Intensive pharmacokinetic sampling was 
performed for rifampicin, pyrazinamide and ethambutol at steady state. Rifampicin 
bioavailability was determined by comparing rifampicin exposure after oral and 
intravenous administration. Pharmacokinetic assessments were repeated in ten 
diabetic TB-patients after glycemic control.
Results 
No differences in AUC0-24h, Cmax, Tmax, and t½ of rifampicin, pyrazinamide and 
ethambutol were found between diabetic and non-diabetic TB-patients in the 
intensive phase of TB treatment. For rifampicin, oral bioavailability and metabolism 
were similar in diabetic and non-diabetic patients. Pharmacokinetic parameters of 
TB drugs were not correlated with blood glucose level or glucose control. 
Conclusions
Diabetes does not alter the pharmacokinetics of TB drugs during the intensive phase 
of TB treatment. Reduced exposure to rifampicin in diabetic patients in the 
continuation phase may be due to an increased body weight and possible differences 
in hepatic induction. Further research is needed to determine the cause of increased 
TB treatment failure in diabetic patients.
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Introduction 
            
Diabetes mellitus (DM) is a well-known risk factor for tuberculosis (TB) [1-3], with 
prevalence rates among TB patients ranging from 10 – 30% [3-5]. There is a rapid 
increase in the global prevalence of DM, especially in the developing countries where 
TB is highly endemic. By the year of 2030, it is estimated that 80% of DM patients will 
live in the high-burden countries for TB [6]. As a result, the number of TB patients 
with DM will further increase [7]. 
Diabetes exerts a negative effect on TB treatment, especially among patients with 
poor glycemic control, with more treatment failure and more relapse [1, 2, 4, 8]. One 
of the possible underlying mechanisms could be altered pharmacokinetics of anti TB 
drugs. Lower plasma concentrations of TB drugs have been associated with clinical 
failure and acquired drug resistance [9, 10]. Our previous study showed that the 
mean exposure (AUC0-6h) to rifampicin as well the mean peak plasma concentration 
(Cmax) of rifampicin were two-fold lower in Indonesian TB-patients with DM compared 
to those without DM [11]. In multivariate analyses, a higher body weight (p<0.001), 
the presence of DM (p=0.06) and higher blood glucose levels (p=0.016) contributed 
to lower rifampicin plasma concentrations. These results suggested that heavier 
diabetic TB-patients may need to be treated with a higher dose of rifampicin, and 
that glycemic control may increase drug concentrations. 
In our previous study TB-patients with and without DM were not matched for weight 
[12, 13], only rifampicin was measured, and limited sampling points were used to 
assess the pharmacokinetics of this drug. We have therefore performed an in-depth 
follow-up study, in which TB-patients with and without DM were matched for weight 
to be able to disentangle the effects of DM and weight on plasma concentrations. 
Furthermore, rifampicin as well as pyrazinamide and ethambutol were studied and 
intensive pharmacokinetic sampling was performed. The first objective of the study 
was to compare the pharmacokinetics of rifampicin, pyrazinamide and ethambutol 
between weight-matched diabetic and non-diabetic TB patients. The second 
objective was to elaborate the possible mechanism of the alteration of pharmacoki-
netics of rifampicin, and the third was to evaluate the effect of glycemic control on 
the pharmacokinetics of TB drugs in diabetic TB-patients. 
Pharmacokinetics of anti-tuberculosis drugs in diabetic patients
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Methods 
Study Subjects
Diabetic TB-patients, who started with or were in the first two weeks of the intensive 
phase of TB treatment (arm 1) and non-diabetic TB-patients who were matched for 
gender and body weight (not more than 5 kg difference) as controls (arm 2) were 
recruited from an outpatient TB clinic in Bandung, Indonesia. The diagnosis of 
pulmonary TB was based on clinical symptoms, chest X-ray examination, sputum 
microscopy and M. tuberculosis culture. DM was diagnosed based on WHO criteria 
[14]. In addition, patients were included if they had previously been diagnosed with 
DM and had poor glucose control at the time of recruitment, either with or without 
use of anti diabetic drugs. Patients who were pregnant, below 18 or above 60 years 
of age, taking any drug that is known to affect the pharmacokinetics of TB drugs and 
those with diarrhea, vomiting or abnormal liver or kidney function were excluded. HIV 
status was assessed anonymously at the end of the study and patients with positive 
results were excluded from further analysis because HIV infection may affect the 
pharmacokinetics of TB drugs. 
Study design 
A prospective, two-arm, three-period pharmacokinetic study was conducted. 
All study subjects received standard TB treatment consisting of rifampicin 450 mg 
(corresponding to 10 mg/kg in Indonesian patients, who have a low body weight), 
isoniazid 300 mg, pyrazinamide 1500 mg and ethambutol 750 mg daily for two 
months, followed by isoniazid 600 mg and rifampicin thrice weekly for four months, 
according to the Indonesian National Tuberculosis program. All patients received TB 
drugs from the same manufacturer, formulated in separate tablets. Bioequivalence of 
the rifampicin tablets and an international reference standard has been established 
before [15]. Adherence to TB drugs was monitored by pill-count and physician 
assessment methods every time patients attended for follow-up [16].
A first pharmacokinetic (PK) assessment was performed two weeks after starting TB 
treatment, at steady-state (see figure 1). All TB drugs including rifampicin were given 
orally (study objective 1). A second PK assessment was performed the following day 
with the same dose of rifampicin administered intravenously, to enable an adequate 
discrimination between possible effects of DM on absorption, metabolism or 
elimination of rifampicin (study objective 2). For intravenous infusion, 450 mg 
rifampicin (Rifadin - Bayer) was diluted in 250 ml of normal saline (NaCl 0.9%) and 
administered over a period of 90 min (rate of infusion: 5 mg/min) [17].
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In accordance with national guidelines, TB-patients with DM were then treated with 
hypoglycaemic agents starting after 2-4 weeks of TB treatment. For ten selected 
patients, short-acting insulin (Humulin 300 unit - Novo Nordisk) was used aiming at 
normal blood glucose levels within two to three weeks. Patients were educated about 
injecting insulin, recognizing hypoglycemia and monitoring of blood glucose at 
home. They were provided with a glucometer, and the study physician made dose 
adjustments if necessary. A third PK assessment was performed after normal blood 
glucose was achieved (see figure 1). In this PK assessment all TB drugs were given 
orally (study objective 3). After the third PK assessment, glucose control was 
continued with oral anti diabetic drugs. 
Pharmacokinetics of anti-tuberculosis drugs in diabetic patients
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Figure 1  Study design.
DM: diabetes mellitus, TB: tuberculosis. R: rifampicin 450 mg daily; Z: pyrazinamide 1500 mg  
daily; E: ethambutol 750 mg daily. p.o: per os; i.v: intravenous. PK: Pharmacokinetic  assessement. 
PK  I took place two weeks after starting TB treatment, all TB drugs were administered per os, PK II 
was performed the day after PK I, rifampicin 450 mg was administered intravenously by continuous 
infusion for 90 min. PK III was performed in 10 diabetic TB-patients 3 weeks after normal blood 
glucose level was achieved. Glycemic control was used insulin injection s.c (subcutaneous) with 
adjusted dose in order to normalize blood glucose within 2-3 weeks; all TB drugs were administered 
per os.
DM
Non-DM
Blood Glucose control (insulin s.c.)
2 weeks 2-3 weeks 3 weeks
Normal
Blood Glucose
Start
TB treatment
PK III: R, Z, E (p.o)PK I: R, Z, E (p.o)
PK II: R (iv)
PK I: R, Z, E (p.o)
PK II: R (iv)
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Based on the first objective and data from the previous study [18], it was calculated 
that a minimum number of 34 (17 in each arm) patients was required to be able to 
demonstrate a difference of at least 25% in the rifampicin exposure between diabetic 
and non-diabetic TB-patients by using the independent samples t-test with a 
significance level (α) of 5% and a power (1-β) of 80%. Informed consent was obtained 
from all subjects and the study was approved by the Independent Ethics Committee, 
Faculty of Medicine, University of Padjadjaran, Bandung, Indonesia.
Pharmacokinetic assessment and bioanalysis
Patients refrained from the intake of any food or drugs from 11 pm on the day 
preceding the PK 1 and 3 assessments until four hours after the intake of study 
medication. They took all TB drugs with 230ml of still water. Serial venous blood 
samples were collected just prior to, and ½, 1, 1½, 2, 2½, 3, 4, 6, 8, and 12 hours 
after witnessed drug intake. Plasma was immediately separated and frozen at -20°C, 
transferred to -80°C within 72h and transported on dry ice to The Netherlands for 
bioanalysis. The stability of rifampicin, its metabolite desacetylrifampicin, 
pyrazinamide and ethambutol under all these conditions have been validated before. 
The plasma concentrations of rifampicin, desacetylrifampicin, pyrazinamide and 
ethambutol were assessed with validated high-performance liquid chromatographic 
(HPLC) assays with the methods as described before [18]. 
Pharmacokinetic analysis
A non-compartmental analysis with WinNonLin version 4.1 (Pharsight Corp., Mountain 
View, California) was performed to compute the pharmacokinetic parameters of 
rifampicin, desacetylrifampicin, pyrazinamide and ethambutol. 
The maximum concentration of drug in plasma (Cmax) and the time to this maximum 
concentration (Tmax) were determined directly from the plasma concentration-time 
data. The terminal, log-linear period (log C versus t) was defined by the last data 
points (N > 3). The absolute value of the slope (-β/2.303, where β is the first-order 
elimination rate constant) was calculated by least-squares linear regression analysis. 
Half life (t½) was calculated from the expression 0.693/β. If the concentration at 12h 
post dose (C12) was quantifiable, the concentration at 24 h (C24) was estimated 
using the equation C24 = C12 * e-β(t24-t12). The area under the concentration-time curve 
from 0 to 24h post dose (AUC0-24h) was assessed using the linear-log trapezoidal 
rule from 0 up to the last concentration. Apparent clearance (CL/F, where F is bioavail-
ability) was calculated by dividing dose by AUC0-24h, and apparent volume of 
distribution (V/F) by dividing CL/F by β. The relative exposure of the metabolite 
Chapter 8
Ruslami.1070-Proefschrift.indd   124 28-09-2009   06:41:24
125
desacetylrifampicin compared to rifampicin was expressed as the ratio of the 
metabolite and the parent drug. Oral bioavailability (F) of rifampicin was calculated 
by dividing the oral AUC0-24h (PK assessment 1) by the intravenous AUC0-24h (PK 
assessment 2). 
Statistical analysis
Pharmacokinetic parameters were log-transformed before statistical analysis. 
Differences in AUC0-24h, Cmax, t½, CL/F and V/F in diabetic versus non-diabetic 
TB-patients (study objective 1) were tested with the independent-samples t-test, and 
a geometric mean ratio plus 95% confidence interval was calculated for every 
comparison. Values for Tmax were not transformed and were compared using 
Wilcoxon rank-sum test. Proportions of diabetic and non-diabetic patients with 
plasma concentrations of TB drugs above reference values were compared using 
the chi-square test. Reference plasma concentrations used were > 8 mg/L for 
rifampicin, > 20 mg/L for pyrazinamide and > 2 mg/L for ethambutol [19]. The 
independent-samples t-test was used to examine the difference in oral bioavailability 
of rifampicin between diabetic versus non-diabetic TB-patients (study objective 2), 
while the paired t-test was used to assess the within-subject effect of glucose control 
on the pharmacokinetics of TB drugs (study objective 3) and Wilcoxon signed-rank 
test was used to compare the Tmax values. All statistical evaluations were performed 
with SPSS for Windows, version 16.0.1 (SPSS Inc., Chicago, IL, USA). P values less 
than 0.05 were considered statistically significant in all analyses.
Results 
Patient’s baseline characteristics
Thirty-six pulmonary TB patients were included in this study. Patient characteristics 
were similar in the two arms, except for age; diabetic patients were older than 
non-diabetic patients (table 1). As patients were matched for body weight there was 
no difference in distribution of patients based on body weight, BMI or drug dose per 
kilogram between both arms. None of diabetic TB-patients used anti diabetic drugs at 
the time of the pharmacokinetic assessments. As would be expected diabetic patients 
had higher blood glucose values (table 1). None of the patients were HIV (+). 
Before and during all pharmacokinetic assessments, no patient had diarrhea or 
vomiting that might have affected the pharmacokinetic profiles that were recorded. 
No co-medication was recorded during the pharmacokinetic assessments. 
Pharmacokinetics of anti-tuberculosis drugs in diabetic patients
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Pharmacokinetics of TB drugs in diabetic and non-diabetic TB-patients
For comparison of pharmacokinetic parameters of TB drugs between diabetic and 
non-diabetic TB-patients (study objective 1), data were available for 17, 18 and 17 
pairs of patients for rifampicin, pyrazinamide and ethambutol respectively. There was 
no difference in exposure to rifampicin, pyrazinamide nor ethambutol between 
diabetic and non-diabetic TB-patients (table 2, figure 2). Other pharmacokinetic 
parameters of these three drugs were similar between the two groups (Table 2 and 3). 
An alternative test for analysis of the data, i.e. the paired t-test on the pharma cokinetic 
parameters of the pairs of matched patients, did not reveal a difference either. 
The proportion of patients reaching the reference values of rifampicin, pyrazinamide 
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Table 1 Patient characteristics before start of treatment.
  TB-DM TB p-value
  (n=18) (n=18)
Gender (%)
male 7 (39) 8 (44) 1.000 a
Age (year)
mean (SD)  47 (8)  35 (10) 0.001 b
Body weight (kg)
mean (SD) 47.3 (7.0) 47.3 (7.2) 0.849 b
BMI (kg/m2)
mean (SD) 20.3 (3.5) 19.6 (3.0) 0.490 b
Drug dose (mg/kg BW)
rifampicin 9.7 (1.6) 9.6 (1.6) 0.817 b
ethambutol 16.2 (2.7) 16.1 (2.6) 0.856 b
pyrazinamide 32.5 (5.5) 32.2 (5.2) 0.855 b
Blood Glucose (mmol/L)
fasting 16.6 (3.3) 5.6 (1.6) 0.000 b
HbA1c (%)
mean (SD) 11.1 (2.2)  
Clinical manifestation (%)
cough 18 (100) 18 (100) 1.000 a
hemoptysis  8 (44) 4 (22)  0.289 a
shortness of breath 15 (83) 17 (94) 0.603 a
fever 15 (83) 14 (79) 1.000 a
loss weight 16 (89) 13 (72) 0.402 a
sputum-smear (+) 16 (89) 18 (100) 0.486 a
m. tuberculosis culture (+) 16 (89) 18 (100) 0.486 a  
a Pearson Chi-square test. b Independent t-test .
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and ethambutol showed no significant differences between both arms (table 2 and 3). 
There were no significant correlations between rifampicin AUC0-24h (Pearson 
correlation coefficient -0.026, p=0.884) as well rifampicin Cmax (correlation coefficient 
0.094, p=0.598) and fasting blood glucose levels, and the same applied for 
pyrazinamide and ethambutol. Age, which was higher in diabetic patients, did not 
display a significant correlation with rifampicin AUC0-24h and rifampicin Cmax, nor 
Pharmacokinetics of anti-tuberculosis drugs in diabetic patients
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Table 2  Pharmacokinetic parameters of rifampicin and desacetylrifampicin in 
tuberculosis patients with type 2 diabetes (n=17) and patients without 
type 2 diabetes (n=17). 
.
Parametera TB-DM TB Ratio of p-value
    TB-DM to TB
Rifampicinb (n=17 per group) 
AUC0-24h (mg·h/L) 49.0 [40.9 – 58.7] 50.6 [42.9 – 59.8] 0.97 [0.77 – 1.23] 0.815 c
Cmax (mg/L) 10.5[9.0 – 12.3] 9.6 [8.4 – 11.0] 1.09 [0.90 – 1.31] 0.364 c
Cmax  > 8mg/L (%) 9/16 [56.3] 8/16 [50]  1.000 d
Tmax (h;median, range) 2 [0.5 – 4] 2.5 [1 – 4]  0.282 e
t½ (h) 2.1 [1.8 – 2.4] 2.2 [1.9 – 2.5] 0.94 [0.78 – 1.12] 0.644 c
CL/F (L/h) 9.2 [7.7 – 11.0] 8.9 [7.5 – 10.5] 1.04 [0.83 – 1.31] 0.814 c
V/F (L) 27.4 [23.7 – 31.6] 27.6 [23.6 – 32.4] 0.98 [0.80 – 1.19] 0.889 c
F (%) 69 74  0.413 c
Desacetylrifampicinb (n=9 per group)
AUC0-24h (mg·h/L) 5.7 [3.9 – 8.4] 8.3 [5.6 – 12.1] 0.69 [0.42 – 1.15] 0.142 c
Cmax (mg/L) 1.1 [0.85 – 1.5] 1.4 [1.1 – 2.0] 0.78 [0.53 – 1.15] 0.196 c
Tmax (h;median, range) 3.0 [2.0 – 4.0] 4.0 [1.5 – 4.0]  0.808 e
t½ (h) 2.3 [1.9 – 2.8] 2.4 [2.1 – 2.8] 0.94 [0.76 – 1.17] 0.574 c
Ratio desacetyrifampicin/rifampicin
AUC0-24h  0.11 [0.09 – 0.13] 0.13 [0.10 – 0.17] 0.83 [0.62 – 1.12] 0.205 c
Cmax  0.12 [0.10 – 0.15] 0.16 [0.12 – 0.19] 0.80 [0.61 – 1.05] 0.097 c
Data are presented as geometric mean plus 95% CI, unless stated otherwise.
a AUC0-24h : the area under the concentration-time curve of the drug in plasma from 0 to 24 h post-
dose, Cmax : the maximum concentration of drug in plasma, Tmax : time to maximum concentration  
of drug in plasma, CL/F : total clearance, V/F : apparent volume of distribution, F : bio-availability.  
b 450 mg (10 mg/kg) in the intensive phase of TB treatment. c Independent t-test on log transformed 
data. d Pearson Chi-square test. e Wilcoxon rank sum test.
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with pharmacokinetics of pyrazinamide and ethambutol (data not shown). Male 
gender was associated with a lower rifampicin AUC0-24h (p=0.037) and Cmax 
(p=0.057), but this did not confound a possible relationship between DM and 
rifampicin exposure (data not shown). No association was found between gender 
and pharmacokinetics of pyrazinamide and ethambutol. 
Absorption, metabolism and elimination of anti-tuberculosis drugs 
Comparison of pharmacokinetic assessments following oral and intravenous 
 administration of rifampicin showed that oral bioavailability was similar in both groups 
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Table 3  Pharmacokinetic parameters of pyrazinamide and ethambutol in 
 diabetic and non-diabetic tuberculosis patients.
Parametera TB-DM TB Ratio of p-value
    TB-DM to TB
Pyrazinamide b (n=18 per group) 
AUC0-24h (mg·h/L) 409 [369 – 455] 468 [422 – 519] 0.88 [0.76 – 1.01] 0.066 c
Cmax (mg/L) 45.5 [41.6 – 49.3] 47.0 [44.1 – 50.1] 0.96 [0.87 – 1.07] 0.470 c
Cmax  > 20mg/L (%) 18/18 (100) 18/18 (100)  1.000 d
Tmax (h;median, range) 1.0 (0.5 – 4.0) 1.5 [0.5 – 6.0)  0.606 e
t½ (h) 6.2 [5.5 – 6.9] 7.1 [6.1 – 8.2] 0.87 [0.73 – 1.05] 0.139 c
CL/F (L/h) 3.7 [3.3 – 4.1] 3.2 [2.9 – 3.6] 1.14 [0.99 – 1.31] 0.067 c
V/F (L) 32.5 [30.8 – 34.3] 32.6 [29.7 – 35.7] 1.00 [0.90 – 1.11] 0.974 c
Ethambutol f (n=17 per group)
AUC0-24h (mg·h/L) 13.8 [12.0 – 15.9] 13.5 [12.0 – 15.1] 1.02 [0.86 – 1.22] 0.775c
Cmax (mg/L) 2.2 [1.8 – 2.7] 1.95 [1.6 – 2.4] 1.12 [0.86 – 1.47] 0.393c
Cmax  > 2mg/L (%) 10/17 (58.8) 8/17 (47.1)  0.366d
Tmax (h;median, range) 3 (1.0 – 4.0) 3 (1.0 – 6.0)  0.930e
t½ (h) 5.5 [5.0 – 6.1] 5.0 [4.5 – 5.6] 1.1 [0.95 – 1.26] 0.193c
CL/F (L/h) 54.3 [47.2 – 62.7] 55.7 [49.8 – 62.4] 0.98 [0.82 – 1.36] 0.778c
V/F (L) 431 [361 – 515] 405 [340 – 483] 1.07 [0.84 – 1.36] 0.592c
Data are presented as geometric mean plus 95% CI, unless stated otherwise.
a AUC0-24h : the area under the concentration-time curve of the drug in plasma from 0 to 24 h post-
dose, Cmax: the maximum concentration of drug in plasma, Tmax : time to maximum concentration  
of drug in plasma, CL/F : total clearance, V/F: apparent volume of distribution. b 1500 mg (30 mg/
kg) in the intensive phase of TB treatment. c Independent t-test on log transformed data. d Pearson 
 Chi-square test. e Wilcoxon rank sum test. f 750 mg (15 mg/kg) in the intensive phase of TB treatment.
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Figure 2  Mean steady-state plasma concentration - time profiles of 
 antituberculous drugs.
Mean steady-state plasma concentration-time profiles of a) rifampicin (n=17),  
b) pyrazinamide (n=18) and c) ethambutol (n=17) in tuberculosis (TB) patients with (  ) and 
without (  )  diabetes (DM).
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(table 2). There was also no delayed absorption in diabetic TB patients as shown by 
a similar Tmax among diabetic and non-diabetic TB patients (table 2). Rifampicin 
clearance in both groups was also similar (table 2). Due to interferences in the 
plasma samples, desacetylrifampicin could not be measured accurately in all 
samples; nine data pairs were available for statistical analysis. The mean values for 
AUC0-24h or Cmax of desacetylrifampicin did not differ between two groups, but the 
numbers may be too small to find a significant difference. In addition, the desacetyl-
rifampicin/rifampicin ratio for AUC0-24h and Cmax were similar in both groups (table 2). 
Like rifampicin, pyrazinamide and ethambutol showed no differences in absorption, 
metabolism and clearance between TB patients with and without DM (table 3).
Effect of blood glucose control on pharmacokinetics of tuberculosis drugs
Ten patients received subcutaneous insulin to achieve and maintain normal blood 
glucose levels. After 5-6 weeks they had a decrease in fasting blood glucose levels 
(16.3 to 7.9 mmol/L, p=0.000) and HbA1c (10.6 to 7.1 %, p=0.001) and a significant 
(11%) weight gain. Repeated pharmacokinetic assessment did not show a significant 
increase in drug exposure. The ratio of AUC0-24h after/before glycemic control was 
1.15 for rifampicin, 0.94 for pyrazinamide and 0.87 for ethambutol (NS). None of the 
other pharmacokinetic parameters was significantly different after blood glucose 
control (data not shown).
Discussion
This study showed that there were no differences in pharmacokinetics of rifampicin, 
pyrazinamide and ethambutol in the intensive phase of TB treatment between 
Indonesian TB-patients with and without DM who were matched for gender and body 
weight. Exposure to TB drugs as well their maximal concentration were not correlated 
with blood glucose level or glucose control, and oral bioavailability, absorption, 
metabolism and clearance of rifampicin, pyrazinamide and ethambutol were similar 
in both groups. 
The results of this study are different from our previous pharmacokinetic study of 
rifampicin in diabetic TB-patients [11]. In that study we found that diabetic patients, 
especially those with poor glucose control, had a strongly reduced exposure to 
rifampicin. What factors can explain the contrasting results of the present and 
previous study? It is unlikely that the study setting plays a significant role. Patients in 
the present study came from a different clinic, but they have shown to be clinically, 
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ethnically and genetically homogenous [20]. The severity of DM is not an explanation 
either, as the fasting blood glucose level and HbA1c were higher in the present study 
(15.6 vs. 9.3 mmol/L and 11.2 vs. 9.85 % respectively). None of the diabetic patients 
in the current study versus 71% in the previous study took antidiabetic drugs before 
the pharmacokinetic assessment [11], but there is no evidence that antidiabetic 
drugs affect the pharmacokinetics of antituberculous drugs [21].
The difference was also not due to more intensive sampling in the present study; 
limited time point analysis (AUC0-6h) from the present data led to similar results (data 
not shown). The two studies used the drugs from the same manufacturer, and 
samples were processed, transferred and analyzed with the same validated methods. 
The pharmacokinetic data of TB drugs from non-diabetic TB-patients in this study 
were very similar to the data from patients (taking a similar dose of rifampicin) in a 
previous study in the same setting [18]. Therefore, from all the possible explanations 
we feel that only two may have had a significant role: matching for differences in 
body weight and timing of sampling (intensive versus continuation phase of 
TB-treatment). 
Body weight is likely to have affected the results. In the previous study diabetic 
TB-patients had a 20% higher body weight than non-diabetic TB-patients, and a 
higher body weight results in a more than dose-proportional decrease in the mean 
AUC0-24h, consistent with the non-linear pharmacokinetics of rifampicin [22, 23]. The 
higher body weight in diabetic patients in the previous study may have explained 
their lower rifampicin exposure, although regression analysis showed that DM and 
blood glucose level had an independent effect on plasma rifampicin exposure [11]. 
To exclude possible confounding by body weight, in the present study we matched 
patients for body weight (and gender).
Timing of pharmacokinetic sampling may also have affected the results, because the 
current study was performed in the intensive phase and the previous study in the 
continuation phase of treatment, with rifampicin taken thrice weekly without 
pyrazinamide and ethambutol. Our studies in Indonesian patients have shown lower 
plasma rifampicin concentrations during the continuation phase [11, 24] than the 
intensive phase of treatment [18, 25]. On the one hand this seems counterintuitive 
because higher induction of liver cytochromes with daily use of rifampicin [22, 26] 
and co-administration of pyrazinamide [27, 28] will lower rifampicin concentrations in 
the intensive phase. On the other hand, a higher body weight might decrease 
rifampicin concentrations during the continuation phase. 
Pharmacokinetics of anti-tuberculosis drugs in diabetic patients
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The current and previous studies suggest that DM does not alter the pharma-
cokinetics of TB drugs during the intensive phase of TB treatment, but possibly 
reduces rifampicin exposure during the continuation phase. This is supported by the 
fact that DM was strongly associated with positive sputum culture after continuation 
phase, but not after the intensive phase of TB treatment [8]. 
We hypothesize that the differential effect of DM on the pharmacokinetics of TB 
drugs during the intensive and continuation phase of treatment is due to differences 
in rifampicin induction. In the intensive phase, with daily administration of rifampicin, 
the activity of liver enzymes and transport pumps would be controlled completely by 
the very strong rifampicin induction [26]. No drug or disease state would be able to 
overcome this. In contrast, thrice weekly dosing in the continuation phase may be 
associated with less induction on liver enzymes and transport mechanism, and the 
possible effect of DM might become manifest. Clearly this issue needs further 
investigation. 
To summarize, we have examined the effect of DM on the pharmacokinetics of TB 
drugs in Indonesian diabetic TB-patients in the intensive phase of TB treatment. Our 
data suggest that DM per se is not associated with altered pharmacokinetics of TB 
drugs in the intensive phase. It is likely that a higher body weight in diabetic 
TB-patients and especially in the continuation phase plays a role in the alteration of 
pharmacokinetics of TB drugs that might lead to a negative effect of TB treatment. 
Further study is needed to confirm these findings and to examine concentration-
effect relationship (pharmacodynamics) of TB treatment. Also, more research is 
needed to examine why DM puts TB patients at risk for treatment failure, and if 
diabetic TB-patients should receive prolonged or dose-adjusted TB treatment.
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Introduction
History of tuberculosis treatment
It took four decades to find the current regimen for TB treatment. In 1944 streptomycin 
(SM) and para-aminosalicylic acid (PAS) were identified as the first anti TB drugs [1]. 
This was followed by the discovery of isoniazid (INH) in 1952, which, added to SM and 
PAS (“triple therapy”) led to cure in 90-95% of patients. However, treatment at that time 
had to be taken for 24 months [2]. From 1960, ethambutol was used instead of PAS due 
to its better tolerability and ability to shorten the treatment to 18 months. By the year 
1970, rifampicin was introduced; the addition of this strong antimicrobial shortened the 
duration of treatment to nine months. Pyrazinamide (PZA) in the 1980s allowed a further 
reduction of treatment to six months, with studies showing more than 95% cure. Since 
the first randomized clinical trial evaluating streptomycin as a single drug (one of the first 
randomized clinical trials in medical history) [1], many randomized controlled clinical 
trials have been conducted to establish the effectiveness of “short-course” treatment 
using these agents. As such, short-course regimens have become the standard of care 
throughout the world. But since the 80’s, this standard has not changed [3]. 
Basic requirements in tuberculosis treatment and the role of clinical 
pharmacology 
Despite the progressive reduction of duration of the treatment from 24 to 6 months with 
relatively high cure rates (90-95%), there are several problems associated with current TB 
treatment. This is because several basic requirements have to be met for successful 
treatment. First, anti-TB drugs must be given in combination to prevent the development 
or selection of drug-resistant mycobacteria. Second, drugs have to given for at least 
6 months, to prevent relapses after treatment is stopped. Third, patient compliance must 
be monitored to ensure proper administration and intake of the drugs. These requirements 
are more difficult to meet especially in developing countries and in the context of HIV [3]. 
In TB treatment, like in most drug therapies, the drug concentration is a connecting link 
between drug dose and treatment response. Non-adherence, suboptimal dosing of 
TB drugs and pharmacokinetic variability increase the risk of suboptimal drug 
 concentrations; this may cause treatment failure, continuous disease transmission 
and the emergence of drug resistance. Conversely, improving the pharmacokinetics of 
anti-TB drugs may result in a better outcome of the treatment of TB.
TB treatment is more challenging and less successful in certain patient groups, 
including children, pregnant women, malnourished patients, or patients with HIV- 
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infection, renal problems, liver disease, diabetes mellitus (DM), or other concurrent 
illnesses. For instance, the combined treatment of patients with TB and HIV 
co-infection, involves a high pill count which is associated with adherence problems, 
overlapping toxicity, drug interactions, and the risk of immune reconstitution syndrome 
[4]. It is important to realize that the pharmacokinetic and pharmacodynamic 
 characteristics of TB-drugs may be different in specific patient groups as listed above. 
For such patients, absorption, metabolism or excretion of TB-drugs may be altered. 
In addition, with varying degrees of immune dysfunction, the drug concentrations 
needed for effective containment or killing of mycobacteria in these patient groups 
may be higher; while drug concentrations associated with side effects or drug-toxicity 
may be lower. 
Tuberculosis in Indonesia
Indonesia is a country with the third highest caseload of TB worldwide. However 
most pharmacokinetic studies have been done in Europe, America and Africa. 
In fact, to date there are hardly any pharmacokinetic data on TB-treatment in healthy 
Indonesian subjects, end even less for tuberculosis patients. A number of challenges 
related to TB-treatment are very relevant for Indonesia, including adherence and 
drug resistance. In addition, Indonesia is facing a very rapid growing HIV-epidemic 
in Asia, and a steady increase in the prevalence of diabetes mellitus [5], which in 
absolute numbers so far is currently much more common than HIV-infection.
This thesis focuses on pharmacokinetic and other aspects of TB treatment in Indonesia. 
Its findings can help to improve TB treatment in Indonesia and elsewhere. 
Summary of research findings
This thesis consists of three parts: adherence; optimization of TB treatment from a 
pharmacokinetic point of view; and studies in a specific group of patients with 
diabetes mellitus. 
In chapter 2 we evaluated a step-wise method to find the most valid and feasible 
method to detect non-adherence to TB treatment in an Indonesian setting. As a first 
step adherence was measured with several available methods, assessing the validity 
of each single method with MEMS (medication event monitoring system) as the gold 
standard. As a second step, the feasibility of each method was judged by physicians 
in the field. Finally, the most valid and feasible methods were combined to reveal the 
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best combination to detect non-adherence. We found that in an Indonesian setting, 
a combination of self-report and physician assessment could identify all non-adherent 
patients.
The second part focuses on optimization of TB treatment from a pharmacokinetic point 
of view. Besides non-adherence, suboptimal drug concentrations may also lead to 
treatment failure and emergence of drug resistance. From a pharmacokinetic viewpoint, 
optimization of TB treatment can be achieved by increasing the dose of available TB 
drugs and/or by using newer (more potent) drugs. Rifampicin, the key drug in TB 
treatment, has concentration- and exposure-dependent killing characteristics. Available 
data suggest that the currently applied 10 mg/kg dose of rifampicin may be too low for 
adequate treatment of TB, and that increasing the dose may allow shortening of the 
treatment duration. In chapter 3 we investigated the effect of increasing the dose of 
rifampicin in terms of pharmacokinetics and tolerability in a randomized clinical trial. 
Indonesian pulmonary TB patients were randomized to a standard (450 mg, 10 mg/kg) 
or higher (600 mg) dose of rifampicin as well as receiving other TB drugs. The two-hour 
peak plasma concentration of rifampicin was significantly higher in the 600 mg group. 
No differences were noted in terms of tolerability. 
In chapter 4, these findings were confirmed in a double-blind randomized clinical 
trial involving 50 newly diagnosed TB patients who again were randomized to receive 
a standard (450 mg) or higher (600 mg) dose of rifampicin besides other TB drugs. 
Full pharmacokinetic curves for rifampicin, pyrazinamide and ethambutol were 
obtained after six weeks of TB treatment (at the steady-state condition). Increasing 
the rifampicin dose from 450 mg (10 mg/kg in Asian patients) to 600 mg (13 mg/kg) 
caused a more than proportional mean 65% increase in rifampicin AUC0-24h and a 
49% increase in rifampicin peak plasma concentration (Cmax). Almost all (96%) 
patients who received a higher dose of rifampicin achieved the desired level of 
rifampicin Cmax (> 8 mg/L). The increase in rifampicin dose did not affect the phar-
macokinetics of pyrazinamide and ethambutol. No significant differences were found 
in the incidence of adverse events, although nausea and vomiting occurred slightly 
more often in the higher dose group than the standard dose group. Grade 1 and 2 
hepatotoxicity was more common in the higher dose group, but no patient developed 
severe hepatotoxicity. 
Besides optimizing the use of available drugs like rifampicin, newer drugs might help 
to improve treatment outcome and shortening treatment duration. Moxifloxacin is a 
primary candidate due to its very strong bactericidal activity and good tolerability [6]. 
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Rifampicin, a strong inducer of metabolism and transport mechanisms of many 
drugs, also induces the phase II metabolic enzymes that are involved in the 
bio transformation of moxifloxacin. In chapter 5 we investigated the interaction 
between moxifloxacin and rifampicin. Nineteen TB patients received 400 mg 
moxifloxacin for five days in addition to rifampicin and INH during the last month of 
their TB treatment, and moxifloxacin alone for five days one month after TB treatment. 
A full pharmacokinetic curve revealed that rifampicin reduces the exposure (AUC0-24h) 
and the peak plasma concentration (Cmax) of moxifloxacin by 30%. 
The third part of this thesis focuses on a specific patient-group, patients with diabetes 
mellitus (DM). Socio-economic and life style changes in developing countries lead to 
an increase of DM, especially type 2 DM. DM is a well-known risk factor for developing 
TB. People with DM are three times as likely to develop active TB compared to those 
without DM [7]. Chapter 6 is a review of the current knowledge about TB and diabetes, 
assessing the implications of the global increase of diabetes for tuberculosis control 
and patient care. The epidemic growth of DM has occurred especially in developing 
countries, where TB is highly endemic. In 2025, it is estimated that 10% of new 
TB-cases in the 10 countries with the highest TB burden will be attributable to DM, a 
relative increase of 31.5% compared to 2003. With regard to treatment, rifampicin 
hampers glycemic control by increasing the metabolism of oral antidiabetic drugs 
(i.e. sulphonylureas), while diabetic patients experience higher treatment failure rates, 
possibly due to lower plasma rifampicin concentrations. A better understanding of the 
association between these two diseases will help improve prevention, early detection 
and treatment of concomitant DM and TB, especially in developing countries.
As stated, DM is associated with poorer treatment outcome. One of the possible 
mechanisms may lie in the alteration of plasma concentration of anti-TB drugs. 
In chapter 7 we compared plasma concentrations of rifampicin in TB patients with 
and without DM in the continuation phase of TB treatment. The Cmax and exposure 
(AUC0-6h) to rifampicin was 50% lower in TB-DM patients compared to patients 
without DM. The exposure to rifampicin was inversely and independently correlated 
with the greater body weight, the presence of DM and the plasma glucose 
concentration. 
In chapter 8 questions underlying the previous study were addressed in more detail. 
More elaborative pharmacokinetic measurements were performed in 18 diabetic and 
18 non-diabetic TB-patients who were matched for gender and body weight to 
exclude possible bias caused by these factors (body weight in the previous study 
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was 20% higher in diabetic patients). Intensive pharmacokinetic sampling was 
performed for rifampicin and other anti-TB drugs (pyrazinamide and ethambutol) at 
steady state. Possible differences in absorption, metabolism, excretion and effect of 
glycemic control were elaborated. After matching for body weight, there were no 
differences in AUC0-24h, Cmax, Tmax, and half-life of rifampicin, pyrazinamide and 
ethambutol between diabetic and non-diabetic TB-patients. For rifampicin, oral 
bioavailability and metabolism were similar in diabetic and non-diabetic patients. No 
correlation was found between the pharmacokinetic parameters of anti-TB drugs and 
blood glucose level or glycemic control. 
General Discussion
The questions addressed, research findings as well as recommendations for future 
research and policy included in this thesis are summarized in the table below.                            
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Table 1  Research findings and recommendations
Questions Findings Recommendations
•  What is the best (valid + 
feasible) method to detect 
non-adherence to TB 
treatment?
•  Presentation of a systematic 
approach to evaluate 
adherence methods
•  Patients’ self-report 
combined with physician 
assessment
•  Larger study with longer 
follow-up to verify patients’ 
adherence to TB treatment
Non-adherence
Higher dose of rifampicin
•  What is the effect of 
increasing the daily dose 
of rifampicin from 450 to 
600 mg?
•  More than dose-
proportional increase of 
AUC0-24h and Cmax of 
rifampicin 
•  No effect on 
pharmacokinetics of other 
TB drugs (pyrazinamide and 
ethambutol)
•  No additional serious 
adverse events
•  Phase I/ II studies to 
evaluate the highest dose 
of rifampicin that is still safe 
and tolerable 
•  Phase III studies to evaluate   
the effect of higher dose 
rifampicin on treatment 
outcome and safety/
tolerability.
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Table 1  Continued
Questions Findings Recommendations
Moxifloxacin
Diabetes Mellitus
AUC = area under the curve, Cmax = maximum plasma concentration.
•  What is the effect 
of rifampicin on the 
pharmacokinetics of 
moxifloxacin?
•  30% reduction of plasma 
moxifloxacin AUC and Cmax 
•  First descriptive 
pharmacokinetic data of 
moxifloxacin in TB patients
•  Clinical studies evaluating a 
higher dose of moxifloxacin 
•  Pharmacokinetic studies 
to assess the interaction 
between moxifloxacin and 
other TB drugs 
•  Pharmacokinetic studies 
to assess the interaction 
between moxifloxacin and 
higher dose of rifampicin
•  What is the implication of 
the global increase of DM 
for TB control and patient 
care?
•  Are there any differences in 
absorption, metabolism or 
excretion of rifampicin and 
other TB drugs in diabetic 
patients?
•  Is there an effect of glucose 
control on pharmacokinetics 
of TB drugs?
•  In 2025, 10% of TB cases 
will be attributable to DM
•  Glucose control using 
sulphonylureas is difficult in 
patients taking rifampicin. 
•  53% lower plasma 
rifampicin AUC in TB-DM 
patients than in TB-
patients in the continuation 
phase of TB treatment;                      
no difference in PK in 
intensive phase in TB-DM 
and TB patients with similar 
body weight 
•  Hyperglycemia associated 
with lower plasma rifampicin 
in the continuation but not 
in the intensive phase of 
TB-treatment.
•  Cost-effectiveness studies 
of screening for DM in TB 
patients and vice versa. 
•  Evaluation of 
pharmacokinetics, 
tolerability and effectiveness 
of metformin for glucose 
control when combined  
with TB drugs
•  Studies to explore the 
explanation of poor 
treatment outcome in TB-
DM patients
•  Pharmacokinetic studies 
comparing the intensive  
and continuation phase of 
TB treatment.
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a. Adherence to TB treatment
As mentioned above, due to its length and complexity, TB treatment may be 
complicated by non-adherence. The World Health Organization (WHO) has introduced 
the concept of ‘directly observed treatment short course’ (DOTS), which has been 
implemented worldwide for almost 15 years [8]. However, randomized controlled 
trials provide no assurance that DOT, compared with self-administration of treatment, 
has any quantitatively important effect on cure or treatment completion in people 
receiving TB treatment [9]. Besides, few studies have assessed the ability of standard 
DOTS regimens to result in lasting cure for patients treated under routine programmatic 
conditions [10]. Therefore, detecting the patients who are non-adherent to TB 
treatment is necessary, and it is even more important in the setting where direct 
supervision of drug intake is not feasible. Considering that every single method has 
its own disadvantages, which may be specific for a particular setting, we have applied 
and recommend a systematic, step-wise approach to select a combination of valid 
and locally feasible methods to detect non-adherence to TB treatment.
b. Higher dose of rifampicin.
In two different phase II studies, we examined the effect of increasing the rifampicin 
dose from 10 mg/kg to 13 mg/kg daily. A higher dose of rifampicin resulted in a more 
favorable rifampicin peak plasma concentration (Cmax) and exposure to rifampicin 
(AUC0-24h) without any additional serious adverse events. Moreover, a higher dose of 
rifampicin did not affect the pharmacokinetics of other anti-TB drugs (see Table 1). 
This calls for follow-up phase II studies to evaluate the pharmacokinetics and safety/
tolerability of an even higher (15- or 20-mg/kg) dose of rifampin combined with other 
TB drugs. The results of such studies are important before advancing to large phase 
III studies to substantiate the effect of higher dose of rifampicin on treatment 
outcome. 
Rifampicin might be the favorable drug for shortening TB treatment, since it is widely 
available at low costs, and since it has been used for many years so that physicians 
all over the world are familiar with its adverse events. If increasing the dose of 
rifampicin is proven to be effective and safe, it could be implemented quickly for the 
benefit for many patients. 
From these studies it appears that increasing the rifampicin dose results in a more than 
dose-proportional increase of AUC0-24h (65% increase) and Cmax (49% increase) of 
rifampicin (see Table 1). How can this be explained? Certainly, a role exists for the 
non-linear pharmacokinetics of rifampicin, which seems to be attributable to a saturation 
Summary and general discussion  I  Ringkasan I  Samenvatting
9
Ruslami.1070-Proefschrift.indd   145 28-09-2009   06:41:35
146
of the excretory capacity of the hepato-biliary system for rifampicin [11-13]. Moreover, 
the interaction between the overloaded excretory capacity of the hepato-biliary system 
and the reasorption of liver-excreted rifampicin through the enteric tract (entero-hepatic 
circulation) might result in more sustained blood concentrations [14, 15]. 
With the same daily dose of rifampicin (10 mg/kg), the rifampicin peak plasma 
concentrations (Cmax) at steady state are somewhat higher in Indonesian HIV-negative 
TB patients compared to seronegative patients in other settings. The rifampicin Cmax 
in a steady state in Indonesian patients was 10.5 mg/L [16], while patients in 
Botswana [17] and in South Africa [18] showed a much lower rifampicin Cmax (6.0 
mg/L in Botswana and 5.9 mg/L in South Africa]. There are two dominant explanations 
for this difference. First the saturation of the liver’s excretory capacity in Indonesian 
patients is reached faster/earlier; second there is a genetic or functional difference in 
the expression of p-glycoprotein or another transporter that affects the absorption or 
intestinal/hepatic first pass metabolism of the drug [19]. If this is true, the optimal 
dose of rifampicin may be different for Asian patients compared to patients in other 
settings. Studies are ongoing in Africa to examine the safety, tolerability, pharmaco-
kinetics and early bactericidal activity of standard TB-treatment with higher doses of 
rifampicin (900 mg and 1200 mg, i.e. 15 and 20 mg/kg) [20], this may be too high for 
Indonesian patients. As a high dose might be a concern in terms of the occurrence 
of dose-related adverse-events, there is a need for studies to evaluate the pharma-
cokinetics and safety of different doses of rifampicin above 600 mg/day in Indonesian, 
or in fact in Asian patients, irrespective of the outcome of studies on high-dose 
rifampicin in African patients (see Table 1).
c. Newer drug: Moxifloxacin
Moxifloxacin is considered to be the most potent newer drug for TB, which shortens 
the duration treatment. The effect of rifampicin on the pharmacokinetics of 
moxifloxacin was investigated in patients who were in the continuation phase of TB 
treatment. The combination of standard dose rifampicin and moxifloxacin 400 mg 
resulted in a mean 30% decrease of exposure (AUC) and peak plasma concentration 
of moxifloxacin (see Table 1). Moxifloxacin, which is used at a daily dose of 400 mg, 
has concentration-dependent killing activity. A reduction of moxifloxacin concentra-
tions through combined use of rifampicin might lead to suboptimal therapy and the 
emergence of mycobacterial drug resistance. Tuberculosis resistant to fluoroquino-
lones is a matter of growing concern, compounded further by the use of fluoroqui-
noles for treatment of community-acquired pneumonia [21, 22]. As a result, one 
could postulate that a higher dose of moxifloxacin might be more potent and have a 
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lower risk of drug resistance development, when this drug is combined with rifampicin. 
On the other hand, higher doses of moxifloxacin might lead to more drug-related 
toxicity. In addition, little information is available about the interaction of moxifloxacin 
with other anti TB drugs. On a theoretical base, pyrazinamide might compete with 
renal excretion of moxifloxacin as was shown for gatifloxacin, another new 
 fluoroquinolone [23]. Therefore, there is a need for studies evaluating higher doses 
of moxifloxacin (600 mg/day and more) for TB treatment, and for pharmacokinetic 
studies of moxifloxacin in combination with rifampicin and other TB-drugs (see Table 1). 
Regarding the inductive effect of rifampicin, it appears to be maximal at a daily dose 
of 300 mg [24]. Therefore, the reduction of moxifloxacin concentrations is probably 
similar with higher doses of rifampicin. However, if a higher dose of rifampicin proves 
to be safe and effective, it should also be evaluated in combination with moxifloxacin 
in terms of pharmacokinetics and toxicity.
Currently, moxifloxacin remains an expensive drug. In terms of safety and efficacy, 
more studies are needed to define how long moxifloxacin should be given. In one 
randomized-control trial in TB patients, moxifloxacin 400mg daily for eight weeks was 
more effective and equally safe compared to ethambutol [25]. A concomitant 
disadvantage of moxifloxacin is that prolonged treatment will lead to quinolone-
resistance of microorganisms other than Mycobacterium tuberculosis (e.g. Salmonella 
typhi and Pneumococcus).
d. Specific-patients group: Diabetes mellitus
Diabetes mellitus (DM) is a risk factor for developing TB and it is associated with a 
poor treatment outcome. Due to the global increase of DM, especially in the 
developing countries where TB is endemic, we calculated that in 2025, 10% of TB 
cases would be attributable to DM, a 30% increase from 2003 (see Table 1). Ideally, 
DM patients should be screened for TB and vice versa, but this may not be realistic 
in every setting. Studies investigating the feasibility and cost-effectiveness of the 
screening are therefore needed. 
In terms of diabetes treatment, glucose control using sulphonylureas is difficult in 
patients who are taking rifampicin, as rifampicin increases the metabolism of 
sulphonyl ureas. Rifampicin does not affect the metabolism of insulin, however insulin 
is not always available, and more difficult to administer and requiring closer 
monitoring. Metformin, which on a theoretical base is not metabolized by rifampicin, 
might be a good alternative. Metformin has become a first choice drug for type 2 DM 
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[26]; it is relatively cheap, widely available and associated with more limited weight 
gain compared to other oral antidiabetic drugs. The disadvantage of metformin when 
it is combined with anti-TB drugs is that almost 30% of patients could experience 
gastrointestinal side effects [27], possibly leading to non-adherence and poor 
treatment outcome. Studies regarding tolerability and efficacy of metformin when 
combined with anti-TB drugs should therefore be performed.
Different studies have shown that diabetes has a negative effect on TB treatment 
outcome [28, 29]. Currently, the underlying mechanisms for the effect of diabetes 
remain unknown, but altered pharmacokinetics may be one possible explanation. 
Therefore we examined whether the concentrations of rifampicin are lower in diabetic 
patients. As a possible explanation, we also explored possible alterations in drug 
absorption, metabolism, and excretion. Finally, we examined whether glucose control 
affects the pharmacokinetics of anti-TB drugs. Exposure (AUC) to rifampicin as well 
as rifampicin Cmax, was strongly reduced in TB-DM patients in the continuation 
phase of TB treatment in which rifampicin and isoniazid are given intermittently, but 
not in the intensive phase (in which drugs are administered on a daily basis) after 
matching for body weight (see Table 1). Hyperglycemia associated with lower 
Plasma rifampicin concentrations in the continuation but not in the intensive phase 
of TB-treatment. We hypothesize that this difference is due to differences in rifampicin 
induction. In the intensive phase, with the daily administration of rifampicin, the 
activity of liver enzymes and transport pumps would be controlled completely by the 
very strong rifampicin induction [24]. In addition, higher body weight in diabetic-TB 
patients especially in the continuation phase plays a role in the alteration of pharma-
cokinetics of TB drugs. We can conclude that studies comparing the pharma-
cokinetics of TB drugs between the intensive phase and continuation phase of TB 
treatment are needed to explain this unexpected finding. In addition, more studies 
are needed to understand the poor treatment outcome in TB-DM patients (Table 1).
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Future/other relevant issues
Pharmacodynamics of TB drugs
Regarding the pharmacodynamics of TB drugs, available data show that microbial 
killing of rifampicin correlates with the area under the concentration-time curve 
(AUC)-to-MIC ratio [30, 31]. The suppression of resistance is associated with the free 
peak concentration (Cmax)-to-MIC ratio [31]. This implies that higher doses of 
rifampicin would optimize its effect as long as the patients could tolerate them. Little 
is known about the pharmacodynamics of other first line TB drugs (isoniazid, 
pyrazinamide and ethambuthol). 
With regard to the association between plasma drug concentration and the outcome 
of TB treatment, available data are still limited. Lower plasma rifampicin  concentrations 
have been associated with delayed sputum conversion, treatment failure, relapse and 
drug resistance [32, 33]. But recent studies were not able to demonstrate a relation 
between the rifampicin plasma concentration with the culture conversion of the sputum 
[34] and the risk of TB recurrence [35], although both may have been underpowered. 
A recent study among Thai TB patients could not demonstrate the pharmacokinetic-
pharmacodynamic (PK-PD) relationship between the rifampicin AUC and putative 
biomarkers of sterilizing activity but this PK-PD relationship was observed for isoniazid 
[36, 37]. More studies on pharmacodynamics of the first line TB drugs are needed, 
and PK-PD modeling is also relevant to be able to develop more new TB drugs.
Drug resistance
Optimization of patient care in TB includes more than just shortening the duration of 
treatment. Multidrug-resistant (MDR; resistance to at least rifampicin and isoniazid) 
and extensively drug-resistant (XDR; MDR plus resistance to any fluoroquinolone 
and at least one of three injectable second-line drugs) TB pose a serious threat to 
global control of TB. MDR and XDR-TB usually develop in the presence of effective 
mono- or duo-therapy or partially suppressed drug concentrations that enable 
replication of bacteria, the formation of mutants, and overgrowth of wild-type strains 
by mutants (selective pressure) [38]. Globally, the proportion of MDR-TB in new TB 
cases ranges from 0% to 22% and in re-treatment cases from 0% to 86%  [38]. In the 
two countries with the highest TB burden, China and India, 8% and 5% of TB cases 
are estimated to have MDR-TB, which will probably not respond to standard treatment. 
In countries of Eastern Europe as many as one in five cases may be MDR-TB. The 
treatment of XDR-TB is even more challenging, as multiple second-line drugs may be 
ineffective [39]. New classes of anti-TB drugs are needed to combat these problems. 
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Unfortunately, the current pipeline is inadequate to respond to the pressing need 
[38]. Several obstacles hamper the rapid development of new anti-TB drugs including 
large, long-term investment, and limited opportunities for profit [40]. 
HIV and TB
Another challenge for the control of TB is the global HIV epidemic. In 2007, 15% of 
TB cases were accompanied by HIV infection [41]. HIV is the strongest risk factor for 
TB. With regard to treatment, combined treatment of TB and HIV is associated with 
three major complications [4]. First, induction of the cytochrome P-450 and 
 P-glycoprotein by rifampicin results in reduced plasma concentration of NNRTIs 
(nonnucloside reverse-transcriptase inhibitors) and in particular PIs (protease 
inhibitors) [19]. This potentially reduces the effectiveness of those ARVs and 
contributes to the development of drug resistant HIV-virus. Second, the high pill load 
and overlapping toxicity of anti-TB drugs and ARV can potentially lead to a 
 discontinuation of treatment and an increase the risk of non-adherence. Third, 
patients may develop immunopathological reactions, known as the immune 
 reconstitution inflammatory syndrome (IRIS). Here suppression of HIV replication 
from antiretroviral (ARV) therapy allows for immune recovery; an increase of CD4+ 
cell count and the restoration of the pathogen-specific immune responses over time 
[42]. In some patients, this restoration of immunity may result in immunopathological 
reactions and clinical deterioration. IRIS associated with TB can occur as ‘paradoxical’ 
IRIS in which there is a paradoxical worsening or recurrence of TB manifestation 
shortly after ARV treatment. ‘Unmasking’ IRIS occurs when HIV patients who have 
unrecognized TB develop clinical manifestations of TB after ARV treatment is 
commenced [43]. Managing these complexities is challenging especially in resource-
limited settings where the majority of TB-HIV cases occur. 
Latent TB
The last issue is treatment of latent TB infection (LTBI). This is both a challenge and 
an opportunity. Up to one third of the world’s population is estimated to be infected 
with M. tuberculosis [44]. Approximately 5-10% of those with LTBI will develop TB 
disease at some point in their life, sometimes decades after becoming infected. This 
risk is much higher among HIV-infected patients [45]. Eradication of TB is the ultimate 
goal but this cannot be achieved without treating the “reservoir” of latent infection. 
Therefore, in the long run, treatment of LTBI is the key to control TB [46]. The two 
fundamental objectives of preventive therapy for LTBI are – from the point of view of 
the individual patient - the prevention of morbidity and mortality associated with active 
TB, and – from a public health point of view - the prevention of disease transmission 
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and progression, and related costs. At present, treatment of LTBI is only given routinely 
in low-endemic settings. In high-endemic settings, the effectiveness of treating LTBI 
has been questioned where detection and treatment of active tuberculosis remains 
the dominant priority. Treatment of latent tuberculosis is considered ineffective in such 
settings, because of the high risk of re-infection through widespread transmission. 
But this is a paradigm, which should be critically reviewed. First, as stated above, TB 
control without addressing the reservoir of LTBI is impossible. Second, in many 
endemic settings, the majority of transmissions may still occur within the household. 
In Indonesia, our preliminary data support this hypothesis (Bachti Alisjahbana and 
Merrin Rutherford, personal communication). Therefore, household screening of 
high-risk groups with the use of interferon-gamma release assays (IGRA) and 
subsequent prophylactic treatment might be feasible in this setting. Research to find 
the best regimen in terms of safety and completion for patients both HIV (-) and 
HIV (+), including the potential of newer drugs, are urgently needed.
With all the problems, especially the problem raised by MDR- and XDR-TB, where the 
treatment becomes more difficult, a prophylactic vaccine against TB seems the 
ultimate solution [47]. 
Academic collaboration
This thesis is a result of an academic collaboration, a collaboration between clinicians, 
pharmacists, pharmacologists and experts in mycobacteriology. It is also a product 
of an international collaboration. In Indonesia, the infrastructure to conduct clinical 
pharmacological research is not yet established, especially for patients. The National 
TB Program is among a few government programs that acknowledge the needs of 
academic collaboration on operational research to boost their performance. However 
in general, clinical research on TB, or other urgent infectious disease problems, is 
not yet optimal. This is not due to the lack of human resources. It is the partnership 
among professionals from different disciplines and different countries that could 
empower Indonesian academicians to conduct relevant research of international 
quality, but with local (Indonesian) capacity and ownership. This thesis is a product 
of such a collaboration, on an equal basis and with a strong emphasis on local 
capacity building. As part of this thesis, phase 2 clinical trials and pharmacokinetic 
studies were conducted involving tuberculosis patients. This is unique not only to 
Indonesia, but also to most of the developing countries. Besides our group, there are 
few groups that are doing pharmacokinetic studies in patients in developing countries 
themselves, they are in Africa and in India. Hopefully, the research and capacity 
building leading to the completion of this thesis can contribute to the development of 
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a centre of excellence for TB research in Indonesia, which is able to compete 
internationally, provide the strong evidence and tools necessary for effective control 
of TB. 
To achieve these goals, more Indonesian researchers need to have better chances. 
Only a few Indonesian researchers have the opportunity to conduct research in 
international collaborations. Moreover, even fewer researchers are able to continue 
afterwards as post-docs. There is hardly any long-term career perspective in research 
for biomedical professionals in Indonesia. Financially this is not very promising, and 
often the institutional infrastructures and support are lacking. In my PhD program, I 
feel fortunate to have the support because it has been embedded in a better infra-
structure, which is needed to conduct proper research projects. If the infrastructure 
has appropriate support and funding, long-term research positions, possibilities 
of additional training overseas, and building of (laboratory) capacities can be 
established locally in an Indonesian institution.  
The studies in this thesis were conducted within an Indonesian-Dutch-Tanzanian 
research network PRIOR, which stands for ‘Poverty Related Infection Oriented 
Research’, which is supported by the Netherlands Foundation for Advancement of 
Tropical Research (NWO-WOTRO) and others. We are grateful for the support, but 
unfortunately, the sustainability of the work later on is dependent on the fund raising 
efforts of the post-docs, which may need time and experience. Hopefully, in the 
coming years there will be more options for additional support for research activities, 
so that we can continue to generate the ‘evidence’ needed for better patient 
management and TB control.
Concluding remarks
This thesis is the continuation of the work conducted by my Indonesian colleagues 
Bachti Alisjahbana, Edhyana Sahiratmadja and Ida Parwati. They have performed 
patient-oriented research focused on patient care, the immune response in TB 
infection, and the Mycobacterium tuberculosis. In this thesis we examined the 
outcome of TB treatment from a clinical pharmacological point of view. Methods to 
identify non-adherence to TB treatment have been evaluated, a number of pharma-
cokinetic studies have been conducted to provide important data necessary for 
developing more effective or shorter treatment regimens, and better management of 
tuberculosis in patients with diabetes.
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There is much remaining to be done. Further studies are needed to face the challenge 
to improve the outcome of TB treatment. Other patient groups like children, 
HIV-patients, patients with TB-meningitis and patients with drug resistant TB should 
be included in such studies, and more attention should be given to management of 
latent TB, if we really want to eradicate TB in due time. 
I am grateful that I was able to engage in TB-research in the last five years, and I 
hope to be able to contribute to future studies and to further strenghening the 
research capacities in Bandung and the collaboration with professionals of other 
institutes from Indonesia as well as from other countries. Hopefully this team-effort 
will continue to increase our understanding of TB and help to develop or to improve 
tools to fight the problems of TB in Indonesia and beyond.
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Pendahuluan
Sejarah pengobatan tuberkulosis 
Diperlukan waktu setidaknya 4 dekade untuk sampai ke pengobatan tuberkulosis 
(TB) seperti saat ini. Pada tahun 1944 streptomisin (SM) dan para-amino-salisilat 
(PAS) pertama kali diidentifikasi sebagai obat anti TB Menyusul kemudian pada 
tahun 1952 isoniazid (INH) ditemukan. Kombinasi INH dan SM serta PAS (disebut 
triple therapy) mampu menyembuhkan 90-95% penderita. Akan tetapi pengobatan 
TB ini memakan waktu yang lama, yaitu 24 bulan [2]. Sejak tahun 1960 etambutol 
menggantikan posisi PAS karena obat ini lebih dapat diterima oleh pasien dan 
mampu mengurangi lama pengobatan menjadi 18 bulan. Pada tahun 1970 rifampisin 
ditemukan; penambahan antimikroba yang poten ini mampu memperpendek lama 
pengobatan menjadi 9 bulan. Munculnya pirazinamid pada tahun 1980an makin 
memperpendek pengobatan menjadi hanya 6 bulan dengan tingkat kesembuhan 
95%. Sejak uji klinik pertama dilakukan untuk mengevaluasi efek streptomisin 
sebagai obat tunggal (merupakan uji klinik pertama dalam sejarah kedokteran [1]), 
banyak uji klinik telah dilakukan dalam upaya menentukan kemanjuran pengobatan 
jangka pendek (short-course treatment) yang menggunakan obat-obatan tersebut. 
Akhirnya pengobatan TB jangka pendek ini menjadi standar pengobatan di seluruh 
dunia. Namun sejak tahun 80an, standar ini tidak berubah [3].
Persyaratan dasar dalam pengobatan tuberkulosis serta peranan 
farmakologi klinik
Walaupun lama pengobatan berhasil diperpendek dari 24 menjadi 6 bulan dengan 
tingkat kesembuhan yang cukup tinggi (90-95%), masih terdapat beberapa masalah 
sehubungan dengan pengobatan TB saat ini. Hal ini disebabkan karena adanya 
beberapa persyaratan dasar yang harus dipenuhi untuk tercapainya keberhasilan 
pengobatan. Pertama, obat anti TB hendaklah diberikan dalam bentuk kombinasi 
beberapa macam obat untuk menghindari berkembangnya mikobakteria yang 
resisten terhadap obat anti TB. Kedua, obat-obatan tersebut harus dimakan selama 
paling tidak 6 bulan, untuk mencegah kekambuhan setelah obat dihentikan. Ketiga, 
kepatuhan minum obat harus dimonitor untuk meyakinkan bahwa pasien meminum 
obat dengan tepat.  Persyaratan ini sulit dipenuhi terutama di Negara-negara 
berkembang dan dengan adanya HIV [3].
Pada pengobatan TB, seperti hampir pada pengobatan pada umumnya, kadar obat 
dalam darah merupakan penghubung antara jumlah obat yang diminum dan respon 
pengobatan yang didapat. Ketidak-patuhan minum obat, dosis obat yang tidak 
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optimal, dan variabilitas farmakokinetik meningkatkan risiko tidak optimalnya kadar 
obat dalam darah. Kadar obat yang sub-optimal dapat menyebabkan kegagalan 
pengobatan, terus terjadinya penularan penyakit, dan berkembangnya resistensi 
obat. Sebaliknya, perbaikan profil farmakokinetik obat anti TB diharapkan akan 
memberikan hasil pengobatan TB yang lebih baik.
Pengobatan TB lebih sulit dan lebih banyak gagal pada kelompok pasien tertentu, 
seperti pada pasien anak-anak, wanita hamil, pasien dengan gizi buruk, pasien 
dengan HIV, gangguan ginjal dan hati, diabetes mellitus (DM), atau dengan kondisi 
lainnya. Sebagai contoh pada pasien dengan HIV dan ko-infeksi TB, banyaknya 
jumlah obat yang harus diminum akan sangat berhubungan dengan meningkatnya 
ketidak-patuhan minum obat,  kejadian efek samping dan toksisitas, interaksi obat, 
dan risiko terjadinya immune reconstitution syndrome (IRS) [4]. Adalah penting 
untuk disadari bahwa karakteristik farmakokinetik dan farmakodinamik obat anti TB 
mungkin berbeda pada kelompok pasien tersebut di atas. Untuk pasien dengan 
kondisi-kondisi tersebut mungkin terdapat gangguan pada absorpsi, metabolisme 
atau ekskresi obat. Dismaping itu, dengan bervariasinya tingkat gangguan sistim 
imunitas, kadar obat yang dibutuhkan untuk membunuh mikobakteria pada kelompok 
pasien ini mungkin lebih tinggi. Sebaliknya pada pada pasien yang mengalami efek 
samping atau toksisitas, mungkin memerlukan kadar obat yang lebih rendah.
Tuberkulosis di Indonesia
Indonesia merupakan negara ketiga terbanyak di dunia dengan kasus TB. Sampai 
saat ini hampir semua studi farmakokinetik dilakukan di Eropa, Amerika dan Afrika. 
Harus diakui bahwa sampai saat ini sangat sedikit data mengenai farmakokinetik 
obat TB pada subyek orang Indonesia yang sehat, dan bahkan lebih sedikit lagi 
pada penderita TB. Banyak masalah yang berhubungan dengan pengobatan TB 
sangat relevan untuk pasien TB di Indonesia, termasuk masalah kepatuhan minum 
obat dan resistensi obat. Selain itu, Indonesia menghadapi masalah  dengan sangat 
cepatnya perkembangan kasus HIV dan peningkatan prevalesi diabetes mellitus [5]. 
Saat ini jumlah kasus DM sangat jauh lebih banyak dari jumlah kasus HIV.
Fokus tesis ini adalah mengenai farmakokinetik dan aspek pengobatan TB di 
Indonesia khususnya pada penderita DM. Penulis berharap hasil penelitian dalam 
tesis ini dapat membantu meningkatkan pengobatan TB di Indonesia dan di tempat 
lain. 
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Ringkasan hasil penelitian
Tesis ini terdiri dari 3 bagian: kepatuhan minum obat; optimalisasi pengobatan TB 
dari sudut pandang farmakokinetik; dan studi pada kelompok pasien tertentu, yaitu 
pada pasien dengan DM. 
Pada bab 2 kami mengevaluasi secara bertahap penentuan metode yang paling valid 
dan memungkinkan untuk mendeteksi ketidak-patuhan minum obat pada penderita 
TB di Indonesia. Pada tahap pertama, tingkat kepatuhan pasien diukur dengan 
beberapa metode yang tersedia dan validitas masing-masing metode tersebut 
dinilai dengan menggunakan MEMS (medication event monitoring system) sebagai 
baku emas. Tahap kedua adalah menilai tingkat kemungkinan (feasibility) tiap-tiap 
metode yang dilakukan oleh dokter lapangan. Pada tahap terakhir, beberapa metode 
dengan validitas dan fisibilitas yang tinggi digabung dan dilihat kombinasi mana 
yang paling baik dalam mendeteksi ketidak-patuhan minum obat. Hasil penelitian 
memperlihatkan bahwa untuk Indonesia, kombinasi penilaian diri oleh pasien 
terhadap diri sendiri dan penilaian pasien lapangan dapat mengidentifikasi semua 
pasien yang tidak patuh minum obat. 
Bagian kedua dari tesis ini fokus kepada optimalisasi pengobatan TB dari sudut 
pandang farmakokinetik. Disamping ketidak-patuhan minum obat, kadar obat 
yang sub-optimal juga dapat menyebabkan kegagalan terapi dan berkembangnya 
resistensi obat. Dari sudut pandang farmakokinetik, pengobatan TB dapat lebih 
dioptimalkan dengan meningkatkan dosis obat yang saat ini tersedia dan/atau dengan 
menggunakan obat baru yang lebih kuat. Rifampisin, obat kunci pada pengobatan 
TB, mempunyai karakteristik concentration- and exposure-dependent killing, semakin 
tinggi konsentrasi atau paparan suatu obat dalam darah, akan semakin kuat 
daya bunuhnya terhadap mikobakterium. Data yang ada memperlihatkan bahwa 
dosis rifampisin yang dipakai saat ini, 10 mg/kg BB agaknya terlalu rendah untuk 
pengobatan TB yang adekuat, dan bahwa penigkatan dosis rifampisin mungkin 
dapat membantu memperpendek lama pengobatan. Pada bab 3 kami meneliti efek 
peningkatan dosis rifampisin dalam konteks farmakokinetik dan tolerabilitas pasien 
dengan melakukan uji klinik acak terbuka (open randomized clinical trial). Penderita 
TB dipilih secara acak untuk menerima rifampisin dosis standar (450 mg, 10 mg/
kg) atau dosis lebih tinggi (600 mg) disamping obat TB lainnya. Pada penelitian ini 
didapatkan bahwa kadar maksimal rifampisin pada 2 jam sesudah minum obat lebih 
tinggi secara bermakna pada kelompok pasien yang mendapat rifampisin 600 mg, 
tanpa adanya perbedaan dalam tolerabilitas. 
Summary and general discussion  I  Ringkasan I  Samenvatting
9
Ruslami.1070-Proefschrift.indd   163 28-09-2009   06:41:45
164
Pada bab 4 temuan ini dikonfirmasi dengan melakukan ujii klinik acak tersamar 
ganda (double-blind randomized clinical trial) yang melibatkan 50 penderita TB 
paru yang baru didiagnosis. Subyek penelitian dipilih secara acak  untuk menerima 
rifampisin dosis standar (450 mg) atau dosis lebih tinggi (600 mg) disamping obat 
TB lainnya. Kurva farmakokinetik rifampisin, pirazinamid dan etambutol ditentukan 
setelah penderita makan obat TB setidaknya 6 minggu (pada kondisi steady-state). 
Peningkatan dosis rifampisin dari 450 mg (10 mg/kg pada pasien Asia) menjadi 600 
mg (13 mg/kg) menyebabkan peningkatan paparan terhadap rifampisin (AUC0-24h) 
sebesar 65%, lebih dari proposi peningkatan dosis (33%). Demikian juga dengan 
kadar maksimal rifampisin dalam darah, terdapat peningkatan sebesar 49%. Hampir 
semua subyek (96%) yang mendapat rifampisin dosis lebih tinggi mencapai kadar 
maksimal dalam darah yang diharapkan (> 8 mg/L). Peningkatan dosis rifampisin 
ini tidak mempengaruhi farmakokinetik obat TB lainnya (pirazinamid dan etambutol). 
Tidak didapatkan perbedaan yang bermakna dalam kejadian efek samping, 
walaupun nausea dan vomitus lebih sering pada kelompok yang mendapatkan dosis 
lebih tinggi. Hepatotoksisitas grade 1 dan 2 lebih banyak ditemukan pada kelompok 
pasien yang mendapat dosis lebih tinggi, akan tetapi tidak ada yang berkembang 
ke tahap yang lebih berat. 
Disamping mengoptimalkan pemakaian obat yang tersedia seperti rifampisin, obat 
yang lebih baru juga diharapkan dapat meningkatkan hasil akhir pengobatan TB 
dan memperpendek lama pengobatan. Moksifloksasin merupakan calon utama 
karena akitifitas bakterisidal yang tinggi dengan tingkat tolerabilitas yang baik [6]. 
Rifampisin merupakan induktor yang kuat terhadap metabolisme dan mekanisme 
transpor banyak obat lainnya, juga menginduksi enzim metabolisme fase II yang 
terlibat dalam biotransformasi moksiflokasin. Pada bab 5 kami meneliti interaksi 
antara moksiflokasin dan rifampisin. Sembilan belas penderita TB yang dalam 
satu bulan terakhir pengobatan TB (sedang minum INH dan rifampisin) mendapat 
moksifloksasin 400 mg selama hari 5 hari, dan satu bulan sesudah selesai 
pengobatan TB, mereka kembali minum moksiflokasin 400 mg selama 5 hari.  Kurva 
farmakokinetik memperlihatkan bahwa rifampisin menyebabkan penurunan paparan 
(AUC0-24h) terhadap moksifloksin maaupun kadar maksimal moksiflokasin sebesar 
30%. 
Bagian ketiga dari tesis ini fokus pada kelompok pasien tertentu, yaitu pada 
pasien TB dengan diabetes mellitus (DM). Perubahan sosio-ekonomi dan gaya 
hidup di negara-negara berkembang menyebabkan makin meningkatnya kasus 
DM, terutama DM tipe 2. Diabetes diketahui merupakan salah satu risiko untuk 
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terjadinya TB. Penderita dengan DM mempunyai resiko 3 kali lebih besar untuk 
menderita TB dibanding mereka yang tidak menderita DM [7]. Bab 6 merupakan 
review tentang bagaimana pemahaman terhadap TB dan DM saat ini, serta menilai 
implikasi peningkatan global DM terhadap kontrol TB dan pengelolaan pasien. 
Pertumbuhan DM  secara epidemik terjadi terutama di negara-negara  berkembang 
yang juga merupakan daerah endemis TB.  Pada tahun 2025, diperkirakan 10% 
dari kasus TB baru di 10 negara dengan kasus TB terbanyak “disumbangkan” oleh 
DM, terjadi peningkatan relatif sebesar 31.5% jika dibandingkan pada tahun 2003. 
Sehubungan dengan pengobatan, rifampisin mengganggu pengontrolan gula darah 
karena rifampisin menginduksi metabolism obat anti diabetik oral (seperti sulfonil 
urea). Di lain pihak, pasien dengan DM biasanya lebih sering mengalami kegagalan 
dalam pengobatan TB, yang kemungkinan disebabkan rendahnya kadar rifampisin 
dalam darah. Pemahaman yang lebih baik terhadap hubungan dua penyakit ini 
akan membantu meningkatkan pencegahan, deteksi dini, dan pengobatan TB yang 
disertai DM, terutama di negara-negara berkembang. 
Seperti yang sudah disebutkan sebelumnya, DM berhubungan dengan hasil 
pengobatan TB yang lebih buruk. Salah satu kemungkinan penyebabnya adalah 
adanya gangguan kadar obat anti TB dalam darah pada penderita DM. Pada bab 7 
kami membandingkan kadar rifampisin plasma pada penderita TB dengan dan tanpa 
DM, pada fase intermiten pengobatan TB. Kadar maksimal rifampisin dalam darah 
(Cmax) dan paparan  (AUC0-6h) rifampisin pada penderita TB dengan DM 50% lebih 
rendah dibanding pada penderita TB tanpa DM. Paparan rifampisin berhubungan 
terbalik  secara indipenden dengan berat badan pasien, status DM dan tingginya 
kadar gula darah pasien. 
Pada bab 8 beberapa temuan yang dari penelitian sebelumnya dieksplorasi secara 
lebih terperinci. Dilakukan pengukuran profil farmakokinetik yang lebih elaboratif 
terhadap 18 pasang penderita TB dengan dan tanpa DM yang sesuai gender 
dan berat badan, hal ini adalah untuk menhindari bias yang mungkin terjadi yang 
disebabkan oleh faktor ini (pada penelitian sebelumnya penderita TB-DM mempunyai 
berat badan 20% lebih berat dibanding mereka yang tidak menderita DM). Dilakukan 
pengukuran profil farmakokinetik obat TB (rifampisin, pirazinamid dan etambutol) 
pada kondisi stabil (steady-state). Dielaborasi apakah terdapat perbedaan pada 
absorpsi, metabolism dan ekskresi obat, juga efek pengontrolan glukosa darah 
terhadap farmakokinetik obat TB. Setelah dilakukan penyesuaian tehadap gender 
dan berat badan pada kedua kelompok pasien, tidak ditemukan adanya perbedaan 
pada paparaan (AUC0-24h), kadar maksimal dalam darah (Cmax), waktu mencapai 
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kadar maksimal dalam darah (Tmax), and dan waktu paruh (t½) ketiga obat TB 
tersebut antara kelompok pasien yang dengan dan tanpa DM. Juga tidak terdapat 
perbedaan bioavailabilitas dan metabolism rifampisin pada kedua kelompok pasien. 
Tidak ditemukan hubungan antara parameter farmakokinetik obat TB dengan kadar 
gula darah maupun pengontrolan gula darah. 
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Introductie
De geschiedenis van de tuberculose behandeling
Het heeft vier decennia geduurd om het huidige regime voor TB behandeling te vinden. 
In 1944 zijn streptomycine (SM) en para-aminosalicylic acid (PAS) geïdentificeerd 
als eerste geneesmiddelen tegen TB [1]. Dit werd gevolgd door de ontdekking van 
isoniazide (INH) in 1952, dat toegevoegd aan SM en PAS (Triple therapie) leidde tot 
genezing bij 90-95% van de patiënten. Echter, op dat moment duurde de behandeling 
24 maanden [2]. Vanaf 1960 werd ethambutol gebruikt in plaats van PAS vanwege 
de betere verdraagbaarheid en de mogelijkheid om de behandeling te verkorten 
tot 18 maanden. In 1970 werd rifampicine geïntroduceerd; de toevoeging van dit 
krachtige antimicrobiële middel verkortte de duur van de behandeling tot negen 
maanden. Pyrazinamide (PZA) zorgde in de jaren 80 voor een verdere verkorting van 
de behandeling tot zes maanden, met onderzoeken die meer dan 95% genezing lieten 
zien. Sinds het eerste gerandomiseerde klinisch onderzoek met streptomycine als 
enige geneesmiddel (een van de eerste gerandomiseerde klinische onderzoeken in de 
medische geschiedenis) [1], zijn veel gerandomiseerde klinische studies uitgevoerd 
om de effectiviteit van “kortdurende” behandeling met deze middelen aan te tonen. 
Als zodanig zijn de kortdurende regimes standaard behandeling geworden in de hele 
wereld. Sinds de jaren 80 is deze standaard behandeling niet aangepast [3]. 
Cruciale voorwaarden bij tuberculose behandeling en de rol van de 
klinische farmacologie
Ondanks de geleidelijke inkorting van de duur van de behandeling van 24 tot 6 maanden 
met daarbij een relatief hoge genezingskans (90-95% in onderzoeksverband), zijn er 
verschillende problemen die samenhangen met de huidige TB behandeling. Er moet 
namelijk aan een aantal cruciale voorwaarden worden voldaan voor een succesvolle 
behandeling. Ten eerste moeten anti-TB-geneesmiddelen in combinatie worden 
gegeven om ontwikkeling of selectie van geneesmiddelresistente mycobacteriën 
te voorkomen. Ten tweede moeten de geneesmiddelen tenminste gedurende 6 
maanden worden gegeven omdat anders terugval na het stoppen van de behandeling 
kan optreden. Ten derde moet de therapietrouw van de patiënten gecontroleerd 
worden om goede toediening en inname van de middelen te garanderen. Vooral in 
ontwikkelingslanden en met HIV als begeleidende ziekte kan aan deze voorwaarden 
moeilijker voldaan worden [3].
Bij TB behandeling, net als bij de meeste geneesmiddelbehandelingen, is de 
concentratie van het middel in het bloed de verbindende schakel tussen de dosering 
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van het geneesmiddel en de respons op de behandeling. Niet innemen (non-
compliance of therapie-ontrouw), suboptimale dosering van TB geneesmiddelen 
en farmacokinetische variabiliteit verhogen het risico op suboptimale concentraties 
van het geneesmiddel. Dit kan leiden tot falen van de behandeling, voortdurende 
overdracht van de ziekte en het ontstaan van resistentie tegen de geneesmiddelen. 
Omgekeerd kan de ontwikkeling van nieuwe behandelcombinaties met een 
verbeterde farmacokinetiek van de anti-TB geneesmiddelen resulteren in een beter 
resultaat van de behandeling van tuberculose.
Behandeling van TB is moeilijker en minder succesvol in bepaalde patiëntengroepen, 
waaronder kinderen, zwangere vrouwen, ondervoede patiënten en patiënten met een 
HIV-infectie, nierproblemen, lever- en vaatziekten, diabetes mellitus (DM), of andere 
gelijktijdig optredende ziekten. De behandeling van patiënten met tuberculose 
en HIV co-infectie houdt in dat een groot aantal pillen moet worden ingenomen. 
Dat wordt geassocieerd met therapietrouwproblemen, overlappende toxiciteit, 
geneesmiddelinteracties, en het risico op immuunreconstitutiesyndroom [4]. Het 
is belangrijk om te beseffen dat de farmacokinetische en farmacodynamische 
eigenschappen van TB-geneesmiddelen kunnen verschillen in specifieke patiënten-
groepen, zoals hierboven vermeld. In dergelijke patiënten kunnen absorptie, 
metabolisme of uitscheiding  van TB-geneesmiddelen anders zijn. Bovendien 
kan de concentratie van geneesmiddelen die nodig is voor effectieve inkapseling 
of het doden van mycobacteriën in deze patiëntengroepen met een verschillende 
mate van immuundeficiëntie hoger zijn, terwijl al bij een lagere concentratie van 
geneesmiddelen bijwerkingen of geneesmiddelentoxiciteit optreden.
Tuberculose in Indonesië
Indonesië staat op de derde plaats als het gaat om het aantal gevallen van tuberculose 
wereldwijd. Desondanks zijn de meeste farmacokinetische onderzoeken gedaan 
in Europa, Amerika en Afrika. Op dit moment zijn er nauwelijks farmacokinetische 
gegevens over de TB-geneesmiddelen bij gezonde Indonesische proefpersonen of 
tuberculose-patiënten. Een aantal problemen gerelateerd aan TB-behandeling zijn 
zeer relevant voor Indonesië, vooral therapietrouw en het voorkomen van resistentie 
tegen geneesmiddelen. Daarnaast wordt Indonesië geconfronteerd met een zeer 
snel groeiende HIV-epidemie in Azië, en een gestage toename van de prevalentie 
van diabetes mellitus [5], dat absoluut gezien momenteel veel meer voorkomt dan 
HIV-infectie. 
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Dit proefschrift richt zich op de farmacokinetische en andere aspecten van TB-
behandeling in Indonesië. De bevindingen kunnen helpen bij de verbetering van TB 
behandeling in Indonesië en elders.
Samenvatting van de onderzoeksresultaten
Dit proefschrift bestaat uit drie delen: therapietrouw; optimalisatie van TB 
behandeling vanuit farmacokinetisch oogpunt; en onderzoeken in een specifieke 
patiëntenpopulatie met diabetes mellitus als begeleidende ziekte naast TB. 
In hoofdstuk 2 hebben we stapsgewijs gezocht naar de meest betrouwbare en 
uitvoerbare methode voor het opsporen van therapie-ontrouw bij TB behandeling 
in de Indonesische setting. Als eerste stap werd therapietrouw gemeten met 
verschillende beschikbare methoden door elke afzonderlijke methode te vergelijken 
met MEMS (medicatie event monitoring-systeem) als de gouden standaard. Als 
tweede stap werd de haalbaarheid van elke methode beoordeeld door artsen in het 
veld. Tot slot werden de meest betrouwbare en haalbare methoden gecombineerd 
om tot de beste combinatiemethode te komen voor het opsporen van therapie-
ontrouw. Wij concludeerden dat in de Indonesische setting door een combinatie 
van zelfrapportage en de beoordeling van de arts alle therapie-ontrouwe patiënten 
geïdentificeerd konden worden.
Het tweede deel richt zich op optimalisatie van TB behandeling vanuit farmacokinetisch 
oogpunt. Naast therapie-ontrouw kunnen ook suboptimale geneesmiddelen-
concentraties leiden tot het falen van de behandeling en het optreden van resistentie 
tegen geneesmiddelen. Vanuit een farmacokinetisch oogpunt kan TB behandeling 
worden geoptimaliseerd door verhoging van de dosis van de beschikbare TB 
middelen en/of door nieuwere (meer potente) geneesmiddelen te gebruiken. 
De werkzaamheid van rifampicine, het belangrijkste geneesmiddel  in de TB 
behandeling, is concentratie- en blootstelling-afhankelijk. Beschikbare gegevens 
suggereren dat de momenteel gebruikte dosis van 10 mg/kg rifampicine te laag is 
voor een adequate behandeling van tuberculose, en dat door een verhoging van de 
dosis de behandelingsduur kan worden verkort. In hoofdstuk 3 onderzochten we 
het effect van het verhogen van de dosering van rifampicine op de farmacokinetiek 
en verdraagbaarheid met een gerandomiseerde klinische studie. Indonesische 
longtuberculose patiënten werden gerandomiseerd naar een behandeling met een 
standaard (450 mg, 10 mg/kg) of hogere (600 mg) dosis rifampicine; daarnaast werden 
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ook andere TB geneesmiddelen gebruikt. De rifampicine piek plasmaconcentratie 
(op 2 uur na doseren) was significant hoger in de 600 mg groep. Er werden geen 
verschillen gezien met betrekking tot verdraagbaarheid.
In hoofdstuk 4 zijn deze resultaten bevestigd in een dubbel-blind gerandomiseerd 
klinisch onderzoek bij 50 nieuw gediagnostiseerde TB patiënten die ook werden 
gerandomiseerd naar een standaard (450 mg) of hoge (600 mg) dosis rifampicine 
naast andere TB geneesmiddelen. Volledige farmacokinetische curves van 
rifampicine, pyrazinamide en ethambutol werden opgenomen na zes weken 
tuberculosebehandeling (op de steady-state). Het verhogen van de dosis rifampicine 
van 450 mg (10 mg/kg in Aziatische patiënten) tot 600 mg (13 mg/kg) veroorzaakte een 
meer dan proportionele gemiddelde stijging van 65% van de rifampicine blootstelling 
(AUC0-24h) en een toename van 49% van de rifampicine piek plasma concentratie 
(Cmax). Bij bijna alle (96%) patiënten werd na de hogere dosis van rifampicine het 
gewenste niveau van rifampicine Cmax (>8 mg/L) bereikt. De verhoging van de dosis 
rifampicine beïnvloedde de farmacokinetiek van pyrazinamide en ethambutol niet. 
Er werden geen significante verschillen gevonden in de incidentie van bijwerkingen, 
hoewel misselijkheid en braken iets vaker voorkwamen in de hogere dosis groep 
dan in de groep met de standaard dosis. Graad 1 en 2 hepatotoxiciteit kwam meer 
voor in de hogere dosis groep, maar geen enkele patiënt ontwikkelde ernstige 
levertoxiciteit. 
Naast het optimaliseren van het gebruik van de beschikbare middelen zoals 
rifampicine, kunnen nieuwe geneesmiddelen het behandelingsresultaat verbeteren 
en de behandelingsduur verkorten. Moxifloxacine is een belangrijke kandidaat door 
de zeer sterke bactericide werking en de goede verdraagbaarheid [6]. Rifampicine, 
een krachtige inducer van het metabolisme en van het transportmechanisme van 
veel geneesmiddelen, induceert ook de fase II enzymen die betrokken zijn bij de 
biotransformatie van moxifloxacine. In hoofdstuk 5 onderzochten we de interactie 
tussen moxifloxacine en rifampicine. Negentien TB patiënten kregen in de laatste 
maand van hun TB behandeling 400 mg moxifloxacin gedurende vijf dagen in 
aanvulling op rifampicine en isoniazide behandeling, en alleen moxifloxacin 
gedurende vijf dagen op een maand na de TB-behandeling. Analyse van de volledige 
farmacokinetische curves liet zien dat rifampicine de blootstelling (AUC0-24h) en de 
piek-plasmaconcentratie (Cmax) van moxifloxacin met 30% verlaagt.
Het derde deel van dit proefschrift richt zich op een specifieke groep patiënten: 
patiënten met diabetes mellitus (DM). Sociaal-economische en life style veranderingen 
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in ontwikkelingslanden leiden tot een stijging van DM, vooral type 2-DM. DM is een 
bekende risicofactor voor het ontwikkelen van tuberculose. Mensen met DM hebben 
een drie keer zo grote kans op de ontwikkeling van actieve tuberculose in vergelijking 
met mensen zonder DM [7]. Hoofdstuk 6 geeft een  overzicht van de huidige kennis 
over tuberculose en diabetes, met de nadruk op het inschatten van de gevolgen van 
de wereldwijde toename van diabetes voor tuberculose bestrijding en patiëntenzorg. 
De epidemische toename van DM wordt vooral gezien in ontwikkelingslanden, 
waar tuberculose sterk endemisch is. Er wordt geschat dat in 2025 10% van de 
nieuwe TBC-gevallen in de 10 landen waar TB het meest voorkomt kunnen worden 
toegeschreven aan DM. Dat is een relatieve toename van 31,5% ten opzichte van 
2003. Ook de gelijktijdige behandeling van beide ziektes kan tot problemen leiden. 
Rifampicine verstoort de controle van de suikerspiegel door een verhoging van het 
metabolisme van orale antidiabetes geneesmiddelen (bijvoorbeeld sulfonylureum-
derivaten), terwijl een hoog aantal diabetes patiënten faalt op TB behandeling, 
mogelijk als gevolg van lagere plasma rifampicine concentraties. Een beter begrip 
van de associatie tussen deze twee ziekten zal bijdragen tot een verbetering van 
preventie, vroegtijdige opsporing en gelijktijdige behandeling van DM en tuberculose, 
met name in ontwikkelingslanden.
Zoals al eerder aangegeven, is DM geassocieerd met een slechter behandelings-
resultaat van TB. Een van de mogelijke mechanismen kan de verandering van 
plasmaconcentraties van anti-TB geneesmiddelen zijn. In hoofdstuk 7 vergeleken 
we de plasmaconcentraties van rifampicine in TB patiënten met en zonder DM in de 
continueringsfase van de TB behandeling. De Cmax en blootstelling (AUC0-6h) aan 
rifampicine was 50% lager in TB-DM patiënten vergeleken met patiënten zonder DM. 
De blootstelling aan rifampicine was omgekeerd evenredig gecorreleerd aan een 
hoger gewicht, aanwezigheid van DM en de plasma glucoseconcentratie.
In hoofdstuk 8 zijn de vragen uit het vorige onderzoek in meer detail onderzocht. 
Uitgebreider farmacokinetische metingen zijn uitgevoerd in 18 TB-patiënten 
met diabetes en in 18 TB-patiënten zonder diabetes die werden gematched op 
geslacht en lichaamsgewicht om mogelijke bias van deze factoren uit te sluiten (het 
lichaamsgewicht van diabetes patiënten was 20% hoger in het vorige onderzoek). 
Intensieve farmacokinetische curves werden opgenomen van rifampicine en andere 
anti-TB geneesmiddelen (pyrazinamide en ethambutol) op steady-state. Mogelijke 
verschillen in absorptie, metabolisme, excretie en het effect van bloedsuikercontrole 
met insuline werden onderzocht. Na matching voor lichaamsgewicht waren er geen 
verschillen in AUC0-24h, Cmax, Tmax, en halfwaardetijd van rifampicine, pyrazinamide 
en ethambutol tussen TB-patiënten met en zonder diabetes. De orale biologische 
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beschikbaarheid en het metabolisme van rifampicine van TB-patiënten met en 
zonder diabetes waren vergelijkbaar. Er werd geen correlatie gevonden tussen 
de farmacokinetische parameters van anti-TB geneesmiddelen enerzijds en 
bloedglucosespiegels of bloedsuikercontrole anderzijds.
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